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Summary
This thesis summarizes the main findings of the research project lead from September 2010 until August
2013 in the laboratory of Safety Epigenetics in the Pre-Clinical Safety group (PCS) of the Novartis In-
stitutes for Biomedical Research (NIBR), and performed under the co-supervision of the professor Erik
Van Nimwegen (Computational & Systems Biology, Biozentrum) at Basel university.
The aim of this project was to develop and apply innovative bioinformatics methods to toxicogenomic
data generated mainly from IMI-MARCAR consortium in order to gain a better understanding of the
early gene regulatory processes underlying non-genotoxic carcinogenesis in the context of drug safety
assessment.
This thesis is organized as follows. In Chapter 2 we first introduce the problem of non-genotoxic
carcinogenesis in the context of drug safety assessment. We then briefly present the liver and dis-
cuss important mechanisms of hepatocarcinogenesis along with experimental models with a focus on
Phenobarbital-promoted liver tumor rodent model. We finally give an overview of toxicogenomic data
and bioinformatic approaches to model transcriptional regulatory networks. The main findings of the
thesis, that are arranged in two manuscripts, are then each covered in the central chapters of this thesis.
Chapter 3 shows how adapting existing probabilistic algorithm to comprehensive toxicogenomic data
from in vivo experiments leads to identification of key regulatory interactions underlying early stages of
drug-induced liver tumorigenesis. This manuscript has been published in Nucleic Acid Research journal
in January 2014. Chapter 4 describes a study where human relevance of rodent humanized model is
discussed in terms of gene expression data. This manuscript has been published in Toxicological Sciences
in April 2014. Of note only the material that was considered sensible for complete publication in peer
reviewed journals is reported in this thesis. The thesis concludes by a discussion on the major findings,
their implications for drug safety assessment, an outlook of where future work could be taken up and the
remaining open questions (Chapter 5).
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Chapter 1
Introduction
Non-genotoxic carcinogens (NGC) form a group of molecules that do not directly bind DNA (1) but that
produce perturbations in the gene expression and epigenetic state of cells (2; 3; 4) which facilitate tumor
formation, typically through the promotion of preexisting neoplastic cells into neoplasms (5; 6). The
molecular events underlying the NGC-induced transformation of normal hepatocytes to altered hepato-
cellular foci are still unclear and no acute early molecular markers for NGC are available for drugs under
development. The significant delay in drug development due to positive findings of drug-induced non-
genotoxic carcinogenesis together with the fact that many environmental pollutants, industrial chemicals,
and food contaminants are potential NGC that have not been adequately tested for carcinogenicity are
some of the reasons that motivate toxicologists to develop early biomarkers of NGC and improve early
safety assessment of such compounds.
According to regulatory expectations, drug safety is tested in both short term in vitro and long-term
in vivo studies in several experimental animals (rodent and non-rodent species) prior testing on human
(7). As the safety assessment in experimental animals has been very successful in predicting toxicity of
biologically active chemicals in humans (8), differences in species biochemistry or pathophysiology be-
tween human and rodents have raised doubts regarding the appropriateness of extrapolating some rodent
tumor findings to humans (9). A better understanding of NGC mode of action on cellular mechanism is
believed to help addressing the relevance of rodent assays to human risk assessment (10; 9) and help in
early prediction of NGC in drug development.
Toxicogenomics is a ten years old discipline that applies genomic science to toxicology. It allows to
investigate the molecular and cellular effects of chemicals in biological systems and thus complements
biochemical and phenotypic classic approaches leading to both drug toxicity and drug mode of action
identification. Furthermore toxicogenomic data are particularly suitable for early biomarkers as genomic
perturbations are often detectable prior to phenotypic symptoms.
In this dissertation we have adapted innovative bioinformatic approaches to toxicogenomic data from
comprehensive in vivo experiments in order 1) to identify key early regulatory interactions underlying liver
drug-induced non-genotoxic carcinogenesis and 2) to examine potential species-specificity (human-mice)
in receptor-dependent mechanisms underlying liver tissue molecular responses to NGC. The outcome of
this research provides with novel mechanism-based candidate biomarkers for NGC, and allows for a better
understanding of early mechanisms and pathways underlying drug-induced toxicity in rodents and their
relevance to human.
Chapter 2
Background
2.1 Safety assessment in drug in development
2.1.1 Preclinical safety assessment
The approximately 15-years long process of drug development comprises the assessment of the drug
efficacy, bioavailability and safety (11). Preclinical safety assessment is a crucial step that takes place
early on during the drug development process. It is intended to i) define the target organ toxicity of
the tested compound, ii) estimate a safety margin between the efficacious dose and the dose causing an
adverse effect, iii) predict drug toxicity in humans and iv) eventually identify a maximum recommended
safe starting dose (MRSD) (12) for the clinic as reviewed in (13). Importantly ≈30% of failures in the
development of drugs are related to toxicity and safety issues as reviewed elsewhere (11) making it a
serious impediment to development of new medicines. Drug safety is assessed in both short term in vitro
and long-term in vivo studies in several experimental animals (rodent and non-rodent species) before
testing on human as required by regulatory agencies (7).
2.1.2 Hepatotoxicity
One of the major safety issue in drug development is hepatotoxicity due to the facts that 1) the liver
has the greatest biotransformation capability for the processing of chemicals and thus is involved in the
metabolism of nearly all xenobiotics; and 2) that the liver is exposed to the largest amounts of chemicals
absorbed from the gastrointestinal tract (14). Consequently the liver is a primary target organ for most
chemicals irrespective of their mode of action (14). Importantly liver adapts to drug exposure in a way
that is not necessarily toxic. Indeed the three following types of morphologic alterations of the liver
can occur upon xenobiotic exposure depending on dose and duration (as reviewed in (15)): (i) adap-
tive alteration that consists of an exaggerated normal physiologic response; (ii) pharmacologic alteration,
that consists of an expected alteration in response to the desired action of the test compound; and (iii)
adverse alteration that consists of morphologic alterations that are generally undesired, progressive and
deleterious to the normal function of the cell(s) involved.
Hepatotoxicity can primarily result from 1) inhibition of mitochondrial function, 2) disruption of intra-
cellular calcium homeostasis, 3) activation of apoptosis, 4) oxidative stress (16), 5) inhibition of specific
enzymes and transporters, and 6) formation of reactive metabolites that cause direct toxicity or immuno-
genicity (17). Hepatic adaptive liver response upon chemical exposure often results in enhanced tissue
capacity to dispose of the chemical, via for example induction of phase I and II enzymes that catalyze bio-
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transformation of the inducing chemical. Adaptive response usually leads to changes in gene expression,
alteration of the metabolome and increase in liver size (18) that are reversible upon cessation of exposure,
preserve viability and are not considered toxic (14). Hepatocytes hypertrophy can also be observed that
reflects hyperplasia of organelles, mainly endoplasmic reticulum and peroxisomes as increase in functional
demand leads to organelle expansion and thus enhancing the capacity of the liver to respond to stress.
An adaptive effect can however become adverse if exposure exceeds a certain threshold (that can be
time or dose related) leading to disruption of equilibrium, compromised tissue viability and, in the worse
case, liver tumor (14). These are typically induced upon the prolonged creation of reactive oxygen species
(19; 20; 21), or covalent binding with cellular macromolecules (22). Of note biliary system, hepatic vas-
culature, Kupffer cells, or stellate cells (Ito cells) can also be targeted by tested compounds and involved
in adverse effects (15).
2.1.3 Carcinogenicity testing and non-genotoxic carcinogens
The most expensive, time- and animal-consuming test in preclinical safety aims to identify chemicals that
may pose potential human carcinogenic risk compared to the benefit for the therapeutic indication (23).
Carcinogenicity testing is required prior to registration of many new pharmaceutical agents intended for
chronic or intermittent use over 6 months of duration (24), and clinical considerations include the ex-
pected duration of treatment, the severity of the disease or disorder, the nature and size of the patient
population, and the availability of other therapies as reviewed in (25).
Carcinogenic compounds are classified either as genotoxic or non-genotoxic carcinogens (NGC) depend-
ing on whether their carcinogenicity resides or not in their ability to interact with DNA and induce
DNA mutation and repair responses. Genotoxic carcinogens induce structural DNA changes leading to
pro-carcinogenic mutations and can be organized according to their structural features such as alkenes,
aromatic amines and nitrosamines. Conversely NGC, initially designated as “epigenetic” carcinogens by
Weisburger and Williams (1981) (26), are non DNA-reactive compounds that produce epigenetic effects
on cells, that either indirectly result in DNA modification or facilitate development of preexisting neo-
plastic cells into neoplasms (27).
Genotoxic carcinogens are inexpensively identified in the early stage of drug development using in vitro
assays (28; 29). There is however currently no sufficiently accurate and well-validated short-term assay
to identify NGC and NGC identification largely relies on 2-year rodent bioassays which current protocol
involves exposing a large number of animals (50-70 male and female rats and mice per group) to varying
doses of the studied chemical with histopathological assessment of multiple organs and tissues in each of
the animals at the end of the 2-year exposure period as reviewed in (24; 25). Importantly, as this test
is time-consuming, labor-intensive long and costs millions of dollars per compound, it is often planned
late in the development process (30). The identification of early mechanisms-based biomarkers for NGC
would therefore allow for the design of more predictive tests that would eventually lead to significant
improvement in cancer risk assessment of compound in development.
As mentioned previously, the liver is the major target organ of chemically induced toxicity and the
most prevalent drug-induced tumor site in both male and female mice and rats according to the National
Toxicology Program (NTP) database and the Carcinogenic Potency Database (CPD) (25), and as such a
leading single cause for withdrawal of approved drugs from the U.S. market (15; 17). This thesis focuses
on NGC-induced liver tumorigenesis and the following sections briefly introduces liver physiology.
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2.2 Liver physiology
The liver is a vital organ that has a pivotal role in human body metabolic homeostasis. Liver functions
include but are not limited to i) glucostat activity i.e glucose release and production via glycogenolysis
and gluconeogenesis respectively (31), ii) bile acid formation, iii) filtering activity of the blood coming
from the digestive tract, iv) metabolic homeostasis of carbohydrates, amino acids, lipids and lipoproteins
and v) detoxification of numerous endo- and exogenous substances (32). Accordingly the liver is highly
responsive to environmental perturbations such as changes in portal blood composition (33).
Oxygenated blood from aorta enters the liver through the hepatic artery. Nutrients enriched blood
containing immune complexes and xenobiotics arrives from gastrointestinal tract, spleen and pancreas
and enters the liver via the portal vein; it then proceeds through the sinusoids (surrounded by a single
cell layer consisting of about 20 hepatocytes) and eventually drains into the central venule located at the
center of each lobule, the microscopic functional unit of the liver (34). Liver also produces bile that is
transported away to larger bile ducts via bile ductule (inverse flow direction as blood, see Figure 2.1).
Portal vein, hepatic artery, and bile ductule compose the portal triad (34).
Most liver functions are endorsed by the hepatocytes, that constitute the major cellular compartment of
the liver. Hepatocytes are aligned on plates of one cell thick as depicted in Figure 2.1 extending from
the portal triad in linear fashion to the central vein, with two basolateral domains facing the sinusoidal
space from which uptake of blood-borne contents takes place as reviewed in (14). Together with portal
triad and central veinule they form the microscopic functional unit of the liver tissue designated as the
hepatic lobule (32) (see Figure 2.1). Hepatocytes are connected via gap junctions formed by connexons
allowing fast cell-cell communication between adjacent hepatocytes (14).
Portal blood is progressively filtered by hepatocytes and a decreasing gradient of nutrient and oxygen is
created from periportal to perivenous regions. Pathologists commonly discern 3 zones (see Figure 2.1)
in liver lobule that follows the bloodstream: the periportal region perfused with blood rich in oxygen,
substrates and hormones (zone 1), the perivenous region, that receives blood with low oxygen content
(zone 3), and the zone in between (zone 2). Liver zonation is also reflected by differences in hepato-
cyte ultrastructure that correlate with different enzymatic activities and gene expression. Periportal
hepatocytes have larger and fewer mitochondria (32) and are specialized in oxidative energy metabolism,
amino acid catabolism, ureagenesis, gluconeogenesis, cholesterol synthesis and selected types of protective
metabolism as reviewed in (35). Conversely perivenous hepatocytes have more abundant endoplasmic
reticulum, express most CYP forms and perform preferentially glycolysis, glycogen synthesis from glu-
cose, liponeogenesis, glutamine formation, and xenobiotic metabolism (35).
Hepatocytes occupy almost 80% of the total liver volume and also perform the majority of liver functions;
10% of the liver volume (and 40% to the total number of liver cells) is occupied by sinusoidal endothelial
cells (SEC), Kupffer cells (resident liver macrophages), hepatic stellate cells (fat- and retinoids-storing
cells) and pit cells (large granular lymphocytes) generally being more numerous in the periportal region
(32; 36). As the majority of liver functions are carried by hepatocytes, these cells are also the main
targets of liver damaging agents.
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Figure 2.1: Basic architecture of the liver lobule. Oxygenated blood from aorta and nutrient
enriched blood from gastrointestinal tract enter the liver through the hepatic artery and portal vein
respectively. Portal blood then proceeds through the sinusoids, surrounded by a single hepatocyte layer,
until the central venule. Bile is transported away to larger bile ducts via bile ductule. Portal vein, hepatic
artery, and bile ductule compose the portal triad. Differences in hepatocyte ultrastructure that correlate
with different enzymatic activities and gene expression discern 3 zones in liver lobule that follows the
bloodstream: the zone 1 or periportal region, the zone 2 or midzonal region and the zone 3 or pericentral
region.
2.2.1 Liver proliferation
In normal adult liver, less than 5% hepatocytes undergo proliferation; this reflects a low rate of cell death
through apoptosis (37). The liver has however a substantial regenerative capacity that is reflected by
the complete recovery of the liver upon partial resection or severe injury. This phenomenon results from
rapid proliferation of all the existing mature cellular populations composing the intact organ to restore
organ mass (32) and does not necessarily depend on progenitor or stem cells (34). In this process the
regenerative response is tightly regulated to be proportional to the amount of liver removed and to result
in a liver size proportional to the body size (38).
The regulation of hepatocyte proliferation has been subjected to extensive investigations (see (39) for
review) and while the exact mechanisms responsible for the exit from the quiescent state and the re-entry
into the cell cycle remain unclear, sequential changes in gene expression, growth factor production, and
morphologic structure have been shown to take place during this process (34). Extracellular factors and
paracrine interactions with neighboring non-parenchymal liver cells such as Kupffer and Ito cells have
been moreover shown to be essential components of this machinery (39). Interestingly mitogenic response
upon liver injury has been shown to occur in different population of hepatocytes (originating from dif-
ferent zones) according to the type of stimuli i.e. type of chemical exposure, and reduction in liver mass
(39; 40; 41; 42).
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2.2.2 Liver polyploidy
Progressive nuclear polyploidization occurs widely in metabolically active tissues and is a characteristic
feature of mammalian hepatocytes that takes place during postnatal growth (43). About 70% of adult
hepatocytes in rodents and 40% in humans are tetraploid (44; 45; 46). Polyploidy in hepatocytes is
initiated in postnatal liver growth and can result from different mechanisms (Figure 2.2) that include
i) incomplete cytokinesis (leading to binuclear polyploid hepatocytes), ii) endoreplication, defined as
cycles of DNA replication in the absence of mitosis or iii) endomitosis where mitosis is interrupted
(47; 48; 49; 46; 50). Thus polyploid hepatocytes can be either mononuclear or binuclear. Sister chromatids
in polyploid cells are associated either with a single centromere or have distinct centromeres for all of
their chromosomes depending on whether their result from endocycling or from endomitosis (43; 51).
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Figure 2.2: Mechanisms leading to hepatocyte polyploidy| A. Schematic representation of different
cell cycle stages with genes that are differentially expressed upon PB treatment between day 1 and day 3
and involved in regulating these stages (see Chapter 4). B. Schematic representation of DNA content
along the different cell cycle stages. C. Polyploidy or polynucleidy can result from incomplete cytokinesis,
endocycle or endomitosis that are likely regulated by genes reviewed in Pandit et al, (2013) (52).
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The regulatory mechanisms underlying polyploidization are not completely clear, however regulation
of mitosis and cytokinesis have been identified as key processes. Insulin signaling and downstream reg-
ulation of the PI3K/Akt signaling pathway that controls cytoskeleton organization has been related to
cytokinesis failure (50; 53; 54). More recently E2F7 and E2F8 were shown to inhibit the completion of cell
division thus enhancing hepatocytes polyploidy and binucleation in liver development and regeneration,
whereas the canonical activator E2F1 was shown to counteract their activities (55; 56). A consequence of
the increase in cellular DNA content is an increase in cellular volume that was demonstrated in studies
with both human and mouse liver cells where the volume of hepatocytes was approximately twice with
doubling DNA content (57; 58; 59; 60).
As liver polyploidy is not necessary for the liver to fulfill its functions, the role of increase in ploidy
in the liver is not entirely clear. Some speculate that endoreplication occurs as a mean to increase the
availability of DNA copies and thus increase gene expression (43). As oxidative liver damage has been as-
sociated with a pronounced increase in the population of polyploid cells, and ligands of nuclear receptors
such as PB and TCPOBOP have been shown to cause liver polyploidisation (39; 61; 62), polyploidisation
was proposed as a mean to increase resistance to genotoxic damage and apoptosis (63).
While hepatocyte polyploidy generally occurs in cells that are terminally differentiated (43), liver tumor
lesions such as hepatocarcinoma, hepatoadenoma and early liver lesions (see Section 2.3 for terminol-
ogy of liver tumors) are characterised by lower polyploid fraction compared to an age-matched normal
liver in both humans and carcinogen-induced rodent models (64; 44; 65; 66; 67). While some propose
that selective proliferation of mononucleated 2n hepatocytes could be one of the early events of the liver
transformation process and thus proposing polyploidization as a tumor-suppressor function, others argue
that polyploidization being linked to chromosomal instability might promote tumor development (68).
2.3 Liver tumorigenesis and Hepatocarcinoma (HCC)
As mentioned earlier, observed neoplastic lesions following long-term exposure to both genotoxic and
non-genotoxic chemicals are predominantly liver tumors arising from hepatocytes (69) and are therefore
a key area in drug safety. Hepatocytes-derived liver tumors can start as hepatocellular adenoma (HCA)
that are benign liver tumors composed of non invasive multilayered differentiated hepatic plates (70).
HCA are usually well demarcated as they show prominent compression of the surrounding tissues (71).
HCA can in rare cases transform into hepatocellular carcinoma (HCC) (also named hepatoma), the most
frequent malignant liver cancer (72). HCC can be well differentiated lesions or undifferentiated cells, have
undefined borders and are diffusively infiltrative cancer.
Development of hepatocellular carcinoma (HCC) is a complex and long process that involves hepato-
cyte transformation in neoplastic cells, inhibition of apoptosis, stimulated angiogenesis, reprogramming
of energy metabolism, evasion to immune destruction and invasion in surrounding tissues via tissue remod-
eling; these are key features of HCC that are mostly shared among any cancers, as extensively reviewed
in (73). In the case of human HCC, these features are often the consequence of chronic inflammation
(as a result of liver cirrhosis and chronic hepatitis) and subsequent liver fibrosis (74; 75) that is the
fifth cause of cancer death worldwide. Dramatic changes in gene expression accompany all mechanisms
associated with HCC development, from the transformation of normal hepatocyte into neoplastic cells
to the establishment of a tumor-prone environment (76). Importantly as liver tumors have been well
described and characterized, the underlying gene regulatory mechanisms bridging the long-term effect
of chronic inflammation or drug exposure to the hallmarks of cancer in HCC remain largely unknown.
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In the following we review some key aspects that significantly influence liver tumor development with a
focus on gene expression and transcription factors, key regulators of gene expression.
2.3.1 Gene regulatory mechanisms in HCC development
2.3.1.1 Gene expression regulation
Gene expression regulation is a complex cellular process that is summarized in Figure 2.3. Data and pa-
pers generated by the Encyclopedia of DNA Elements (ENCODE) consortium in September 2012 largely
contribute to the current knowledge of functional elements in the human genome sequence (77; 78; 79; 80)
and point towards a higher complexity of gene regulation than was previously believed.
Gene expression is first regulated at transcriptional level (step 1 in Figure 2.3). Transcriptional reg-
ulation is a key and complex mechanism that depends on the presence of a specific combination of
transcription factors (TFs) and co-factors in both the promoter regions of genes and in regulatory sites
located more distant from the genes (leading to DNA looping and long-range interactions (81)), that alto-
gether facilitate RNA Polymerase II recruitment and binding to upstream gene promoters and eventually
determine the onset and rate of RNA synthesis (see (82) for review on transcriptional regulation); RNA
Polymerase II is indeed responsible for transcribing protein-coding genes and miRNA. While numerous
proteins such as chormatin remodellers, polymerase and helicase are involved in regulating transcription,
DNA binding TFs play central role in this mechanism as they bind to specific DNA sequences of promoter
and distal regions (80; 83; 84) also designated as transcription factor binding sites (TFBS) (79; 85; 86; 87);
the specific combination of TFs contained in the regulatory regions then eventually determines which spe-
cific subset of genes is expressed under which condition. This mechanism is particularly crucial for the
cell to fulfill its function in appropriate time and condition as it allows complex and precise patterns
of the expression of the 40,000 genes contained in human genome with the ≈ 1,900 human TFs (88)
thus enabling the cell to respond to intrinsic and extrinsic cues such as drug-induced response in case of
hepatocytes. Importantly the TFs DNA binding rate (step 8 in Figure 2.3) also depends on 1) nuclear
concentration in TFs and co-factors (step 7 in Figure 2.3), and 2) the local cell-dependent chromatin
context (79; 80; 89; 90) such as histone modifications, nucleosome positioning and DNA methylation;
DNA methylation indeed defines feature of mammalian cellular identity (91) and is itself influenced by
DNA-binding factors, especially in Low Methylated Regions (LMRs) where the presence of DNA-binding
factors and their binding is necessary and sufficient to determine the low methylation status of these re-
gions (92). As a consequence, DNA methylation pattern highly correlates with global occupancy patterns
of major sequence-specific regulatory factors (93).
RNA post-processing, that includes RNA splicing (94) and polyadenylation, and subcellular localiza-
tion (78) are additional regulatory mechanisms of gene expression, that depend on a complex machinery
of RNA binding proteins and interactions with several RNA molecules (miRNAs and lncRNA) that even-
tually determine mRNA stability and degradation (steps 2 and 3 in Figure 2.3). Importantly DNA
methylation and GC architecture have also been shown to regulate RNA splicing (95; 96).
mRNA is eventually destined to migrate to cytoplasm where protein translation can start (step 3 and 4 in
Figure 2.3). Post-translational modifications then determines protein activation and localization (steps
5 and 6 in Figure 2.3). If the protein encodes a TF, nuclear translocation and interaction with co-factors
(steps 7 and 8 in Figure 2.3) eventually lead to gene expression. Importantly all of the regulatory steps
described in Figure 2.3 can be disrupted in cancer leading to aberrant protein expression and disrupted
cell functions.
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Figure 2.3: Gene expression regulation| A) Gene expression regulation encompasses several levels
from gene transcription to DNA binding. B) Overview of 8 steps of gene expression regulation.
2.3.1.2 Genetic mutations in HCC development: genotoxic carcinogens MOA
Accumulation of genetic mutations is a widely accepted cellular process that initiates the slow trans-
formation of a normal cell into neoplastic cells, especially mutations in oncogenes and tumor-suppressor
genes (73; 97) and the carcinogenicity of genotoxic compounds resides in their ability to interact with
DNA and induce DNA mutation. Genetic mutations can affect 1) regulatory regions, leading to aberrant
transcriptional rate, 2) intron-exon boundary regions, leading to aberrant splicing, or 3) exonic regions,
leading to change in protein conformation that can affect protein stability and protein interaction with
partners and DNA that can then impact cancer development. Recent progresses and easier access to
DNA-sequencing technologies allowed for establishment of exhaustive list of genetic mutations in HCC
(98; 99; 100).
2.3.1.3 Epigenetic changes in HCC development: non-genotoxic carcinogens MOA
With the advent of genome-scale methylome and histone marks characterization, epigenetic disruptions
emerged as an additional fundamental basis for cancer initiation and progression that contribute to stabi-
lization of pre-existing genetic mutations and/or activation/silencing of oncogenes and tumor-suppressor
genes via changes in chromatin status of their regulatory regions (97; 101). Epigenetic modifications
are not restricted to chromatin status modifications and encompass disruption in any of the regulatory
steps mentioned in Figure 2.3 including TFs and cofactors changes in activity, and disruption in splic-
ing machinery. NGC carcinogenicity resides in their ability to stabilize pre-neoplastic mutated cells and
promote their growth via such epigenetic changes. As reviewed earlier, while genotoxic compound are
easily identified early on during process of drug development, NGC class of compound poses major issues
for preclinical toxicity testing as their mode of action is more complex (longer time-scale of disease and
requirement of interaction between different cellular compartments). There is therefore a great need for
increasing understanding of underlying regulatory mechanisms.
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2.3.1.4 Transcription factors in liver non-genotoxic carcinogenesis
TFs are considered as key intrinsic regulators of mechanisms underlying epigenetic reprogramming as-
sociated with cancer development (102). As reviewed in (103) activation or aberrant expression of TFs
frequently represents the last step in a number of signaling pathways that affect proliferation, apoptosis,
migration, or senescence in an oncogenic manner (103). Indeed aberrant TFs activity has been frequently
associated with human (104; 105; 106) and mouse (107) HCC, and numerous TFs have been shown to
play central role in regulatory mechanisms of liver cancers. FOXA1/FOXA2 for example were shown
to regulate molecular mechanisms responsible for gender dimorphism in HCC (107). Activation of the
β-catenin pathway in hepatoadenoma (108; 109; 110) and in 20% to 34% of hepatocellular carcinomas
(111; 112; 113; 114) suggest important regulatory role for β-catenin in HCC.
Several intracellular pathways can modulate TFs activity including disrupted or facilitated DNA binding
efficiency through modification of chromatin status and DNA accessibility, changes in TF nuclear con-
centration, and changes in nuclear concentration of co-factors. Changes in RNA processing and splice
variants can also modulate DNA binding affinity associated with change in TFs activity (115; 116).
NGC compounds such as phenobarbital (PB) induce progressive chromatin remodeling and changes in
gene expression in target tissue of carcinogenicity (117; 118; 119; 120; 3; 121; 122; 4; 123). Furthermore
some of these changes have been shown to target key drivers of cell proliferation such as Fos and Myc
(124). All these perturbations involve TFs change in activity, and thus the identification of TFs par-
ticipating to regulation of all stages of non-genotoxic carcinogenesis is a crucial step towards assessing
carcinogenic potential of novel therapeutics and improving the understanding of their MOA. Methods to
identify dysregulated TFs are discussed in Section 2.5.
2.3.2 Hormonal perturbation in HCC development
Lower spontaneous liver tumor incidence is observed in females as compared to males in both humans
(125) and rodents (126) strongly supporting a key role of hormones in liver cancer development (127).
This gender disparity in liver cancer was shown to result in part from estrogen-mediated inhibition of
IL-6 expression in Kupffer cells that, in turn, was shown to affect hepatocyte proliferation (128). More
strikingly female mice deficient for Esr1 lost their resistance to HCC (128). Additional studies support
a liver tumor promoter role of androgens (via induction of DNA damage and oxidative stress) (129) and
a liver tumor suppressor role of estrogens (through reduction in the proinflammatory effects of MyD88-
mediated secretion of IL6) (128).
Thus hormonal perturbation is considered as a key mode of action in non-genotoxic carcinogenesis (9).
Several NGCs are indeed hormonally active agents such as the anti-epileptic phenobarbital (PB), the best
characterized NGC in rodents (please see Section 2.4.3 for detailed description of PB-mediated liver tu-
mor promotion), that has been shown to induce very quick response of the pituitary gland in both humans
(130; 131) and rodents (132). However while a sexually dimorphic regulation of phenobarbital-induced
cytochromes P450 2B1 and 2B2 has been shown in rat (133) that may be responsible for the gender-
specific regulation of xenobiotic-induced hepatocyte proliferation in mice (134), sexual dimorphism in
chemically-induced liver tumorigenesis is more controversial. Results from few studies performed in both
males and females rats or mice over long period (more than 2 years) suggest that, while PB promotional
effect is similar in males and females i.e. equal increase in tumor occurrence, female mice live longer
under PB-treatment and promotional effect in female require more time (135; 136; 137). In this thesis
we focussed on male mice, however we are aware that our results and the conclusions that we draw from
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these studies can significantly differ in female context.
2.3.3 Microenvironment in HCC development
Microenvironment plays a key role in liver tumor development (see (138) for review) and more generally
in cancer development. The liver microenvironment mainly consists in endothelial cells, Kupffer cells and
stellate cells, that are involved in immune response and fibrosis, but also in cytokines, growth factors
and several proteins. Constant communication between hepatocytes, stellate cells and Kupffer cells via
cytokines secretion contribute indeed to create a tumor-prone environment. For example, preneoplastic
hepatocytes, that have high proliferating potential, do not necessarily grow autonomously, and commu-
nication with non-parenchymal cells via paracrine factors has been shown to play key role in this process
(71). Furthermore hepatic stellate cells (Ito cells), that are activated upon liver injury, seem to play
dual role: as on one hand they produce excess extracellular matrix (ECM) and thus participate in ECM
remodelling (71), on the second hand they seem to communicate with macrophages to modulate liver
fibrosis upon liver chronic injury (139). Extracellular matrix remodeling is an additional key process in
HCC development that sustains hepatocytes proliferation by providing cells with a reservoir for a variety
of cytokines and growth factors (76).
2.4 Rodent models of HCC
In order to study the mechanistic and cellular aspects of liver tumor biology including genetics of tumor
initiation and promotion, in vivo tumor progression and spreading (metastasis), rodent experimental
models of HCC remain the standard (140). Indeed rodent models are the only available assay that allows
non-genotoxic hepatic carcinogenicity assessment of compounds in development (27; 141). Of note in
vitro cultured hepatocytes are valuable tools for hepatotoxicity testing, but their use is limited to short-
term studies due to rapid reduction in cytochrome P450 (CYP) activities caused by a decrease in CYP
transcription and an alteration in the expression of key transcription factors when cultured on plastic
(142).
During the last decades numerous experimental models of chronic or acute liver induced carcinogene-
sis have been developed as reviewed in (140). The two-stage experimental models are often used that
comprise an initiation phase, during which short-term exposure to a genotoxic compound induces genetic
alterations, followed by the tumor promotion phase, during which long-term exposure to non-genotoxic
compound accelerates the outgrowth of pre-existing mutated cells and thus the process of tumor devel-
opment.
2.4.1 Tumor initiation and genotoxic carcinogens
Rodent models of liver carcinogenesis are often initiated with carcinogenic compound that induce random
genetic mutations and therefore accelerates tumor occurrence. The most widely used experimental model
is the diethylnitrosamine (DEN)-induced liver carcinogenesis (143). A single dose of DEN at the age of
2 weeks causes DNA-damage in mice leading to HCC at approximately 8-10 months of age (140). As
reviewed in (140) the carcinogenic capacity of DEN resides in its capability of alkylating DNA structures
but also in the oxidative stress caused by DEN (144; 145). The carcinogenic potential of DEN as well as
the time needed after a DEN-injection to develop HCC does depend on the administered dose, the sex,
the age and the strain of mice (140; 146).
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2.4.2 Tumor promotion and non-genotoxic carcinogens
Tumor promotion is defined as a process through which pre-neoplastic or initiated cells evolve into a ma-
lignant neoplasm under the action of exogenous or endogenous compound that fix pre-existing mutations.
The study of the biological processes underlying tumor promotion is of great importance for both 1)
human cancer research, as several endogenous molecules have been shown to promote tumors (147; 148),
and 2) drug development process, as tumor promotion is the MOA of NGC that are difficult to identify
in early phases of drug development.
Importantly characterization of all stages of tumor promotion process is necessary as, contrarily to irre-
versible effects of genotoxic agents, tumor promotion by NGC is reversible until a certain stage (149).
However because tumor promotion develops over a long time period and involves several cellular com-
partments, the regulatory mechanisms underlying all stages of tumor promotion are poorly characterized.
Several rodent models of non-genotoxic HCC have been developed, both endogenous model of liver car-
cinogenesis such as the methyl-deficient model (150; 151), as well as exogenous models of liver carcino-
genesis, for example methapyrilene (histamine receptor antagonis), diethylstilbestrol (DES, an estrogen
receptor agonist), Wy-14643 (Wy, a peroxisome proliferator activated receptor α agonist), piperonyl-
butoxide (PBO, a pesticide synergist) (152). In the next section we focus on the best characterised
exogenous tumor promoter, the phenobarbital, that is the model used in this thesis.
2.4.3 Phenobarbital (PB)
The most widely used anticonvulsant phenobarbital (PB) is a well established rodent NGC used to in-
vestigate the promotion of non-genotoxic HCC in rodent livers (153; 154; 136). PB functions as a tumor
promoter by increasing the incidence of spontaneously and chemically induced tumors (155; 153; 154; 136;
156). As reviewed earlier, PB induces progressive chromatin remodeling and changes in gene expression
in target tissue of carcinogenicity, the liver (117; 118; 119; 120; 3; 121; 122; 4; 123). Importantly, although
liver tumors only develop after 35 weeks of chronic exposure to PB, changes in gene expression and chro-
matin modifications are detected as soon as one day after treatment initiation with PB, particularly in
genes involed in drug metabolism and xenobitic response such as Cyp2b10 (4; 121; 122; 123).
PB accomplishes its diverse effects on liver function in part by promoting nuclear translocation of the
constitutive androstane receptor (CAR) (157) which reflects both acute and chronic response to PB treat-
ment (158; 159; 160). When PB is used as a tumor promoter subsequent to DEN, more than 80% of liver
tumors harbors activating mutations in β-catenin (161) which prevents the phosphorylation of β-catenin
by the Axin/ APC/CK1/GSK3 complex (162; 163; 164), and thereby the subsequent degradation of β-
catenin by the proteosome (165). This leads to enhanced translocation to the nucleus (166) resulting in
the aberrant interaction with a variety of transcription factors and subsequent activation of target genes
(167; 168; 169). Conversely in absence of tumor-promoting agents, mouse liver tumors are frequently
mutated in Ha-ras, mutation otherwise undetectable in promoted tumors, whilst Ctnnb1 mutations are
almost absent liver tumors induced by DEN alone (161; 170; 171; 172).
Importantly PB-mediated promotion effect on DEN-initiated mice varies depending on strain, sex and
age of the mice as reviewed in (140). PB generally promotes liver tumor after DEN initiation, however a
tumor inhibiting effect has been observed in B6C3F1 male mice when exposure to DEN was performed
in the pre-weaning stage (173; 174); this effect was however absent from female B6C3F1 mice (175) and
from male Balb/c (176) and C3H (177) mice.
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Several mechanisms of PB-mediated liver tumor promotion have been proposed that include induction
of oxidative stress upon PB-mediated increased cytochrome P450 activity (178) and hypermethylation
in promoter regions of tumor suppressor genes (118). However these mechanisms remain hypotheses
and whilst a recent study identified Meg3 as an early candidate biomarker for NGC in rodents (123),
underlying regulatory mechanisms of PB-mediated tumor promotion remain elusive. In the following two
sections we present two previously identified regulators involved in PB-mediated tumor promotion.
2.4.3.1 Constitutive Androstane Receptor
PB-mediated CAR nuclear translocation is a critical process which induces both acute and chronic re-
sponse to PB treatment, and is required for gene expression changes, hepatomegaly and liver tumor
formation elicited upon prolonged PB treatment in mice (159; 160). CAR is a member of the nuclear
steroid and thyroid hormone receptor superfamily but, unlike classic nuclear hormone receptors which are
activated by their cognate ligands, CAR is a transcription factor that is indirectly activated by various
xenobiotics, and is transcriptionally active in the absence of exogenous hormone (179). CAR is involved
in several key processes of liver physiology such as drug metabolism, hepatic energy metabolism, cell
growth, and cell death (180; 181; 182; 183).
In non-induced mice, CAR is phosphorylated at Thr38 by signaling induced by epidermal growth fac-
tor (EGF) (184), and forms a complex with heat shock protein 90 (HSP90) that prevents its nuclear
translocation (157; 185). Hepatocytes exposure to PB inhibits EGFR signaling (186), leading to dephos-
phorylation of cytoplasmic CAR upon protein phosphatase 2A recruitment to the CAR:HSP90 complex,
that facilitates CAR nuclear translocation. Thus PB-induced CAR nuclear translocation is regulated
through cascade of phosphorylation-dephosphorylation (157; 185; 187).
CAR transient activation induces hepatic expression of detoxification enzymes and transporters, and
transient hepatomegaly (158; 188; 156) that augments the ability of the liver to metabolizes PB. Con-
versely chronic PB-mediated CAR activation induces complex dynamics of transcriptional response (123)
and chromatin remodeling (3; 4; 121; 122), hepatocytes hypertrophy and accelerates development of liver
tumors (158). Whilst CAR is essential for liver tumorigenesis in response to chronic treatment with PB
(189) it is not necessary for liver hepatocarcinogenesis as demonstrated by similar tumor prevalence in
non-treated CAR null and wild-type mice (189).
Please note that in addition to CAR, PB also activates the pregnane X receptor (PXR) (190), which
has overlapping functions with CAR to coregulate xenobiotic metabolism and detoxification in liver
(181; 191), and whose co-activation may enhance CAR-mediated hepatocyte proliferation (192).
2.4.3.2 β-catenin
Wnt/β-catenin pathway plays key roles in liver physiology including liver organogenesis (please see (193)
for review), metabolic zonation of adult liver (194), hepatocytes proliferation and liver regeneration,
epithelial-mesenchymal transition, and cell adhesion (by its association with epithelial cadherin and actin)
(195; 196). β-catenin is also required for metabolism of ammonia (197) and is involved in the regulation of
inducible expression of P450s and drug-metabolizing enzymes mediated by xenobiotic-sensing receptors
such as Ahr and CAR (198; 199; 200; 201).
β-catenin regulates gene expression through the growth factor-β-catenin/T-cell factor-4 (TCF4) signal-
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ing pathway. Furthermore β-catenin core domain contains 12 armadillo repeats which drive interaction
with additional nuclear TFs and target genes (202). The nuclear amount of β-catenin is regulated by
phosphorylation of its N-terminal region as reviewed in (71): cytoplasmic phosphorylation of β-catenin
by glycogen synthase kinase-3b (GSK3b) leads to rapid protein ubiquitination and subsequent degrada-
tion, that can only occur when β-catenin forms a complex with the adenomatosis polyposis coli (APC),
Axin and GSK3b. Upon Wnt binding to Frizzled, Dishevelled is phosphorylated leading to inhibition of
GSK3β and thus allowing for accumulation of β-catenin, nuclear translocation and target gene activation
such as cyclin D1, c-myc, PPARδ, Hnf1α and CD44 as reviewed in (169).
As mentioned earlier, long-term PB treatment stimulates clonal expansion of a dormant initiated cell
population mutated in β-catenin and represses clonal expansion of H-ras mutated cells that display hepa-
tocarcinogenicity in absence of PB; it is however noteworthy that in the absence of PB treatment, Ctnnb1
mutations are almost absent of mouse liver tumors induced by DEN (161; 170; 171; 172). Hepatocytes
bearing mutation in β-catenin display increase in de-phospho β-catenin and enhanced translocation to
the nucleus (161; 167; 168; 169; 203; 204). Approximately 30% of human HCC and 15% of hepatic ade-
noma have β-catenin activating mutations suggesting that the protein plays key role in HCC development
(111; 112; 113; 114; 205) in both humans and rodents. The role of β-catenin activation in HCC develop-
ment is however not clear and several studies demonstrate that β-catenin activation alone is not sufficient
for HCC development. Indeed truncated mutation in N-terminal region of the protein is not enough to
provide with proliferative advantage in absence of PB treatment (206) and Wnt pathway activation by
stabilized β-catenin was shown to be insufficient for hepatocarcinogenesis (207); the latter observation is
in line with observed low prevalence of Ctnnb1 mutated tumors after DEN-initiation in absence of PB
treatment. Moreover β-catenin has been shown to prevent tumor development in absence of PB treat-
ment by restricting oxidative stress, inflammation and fibrosis (208; 209). Thus additional (epi)-genetic
alterations must be involved in β-catenin activated HCC development.
Long-term PB treatment is apparently leading to proper (epi)-genetic alterations as it results in out-
growth of β-catenin activated hepatocytes specifically, whilst preventing outgrowth of H-ras mutated
hepatocytes. Importantly β-catenin knock-out (KO) animals are completely resistant to PB-mediated
liver tumorigenesis. Underlying regulatory mechanisms responsible for the outgrowth of Ctnnb1 mutated
hepatocytes upon long-term PB exposure remain however largely unknown. The hypothesis that PB
may select for β-catenin activated hepatocytes by interfering with β-catenin/(LEF/TCF)- dependent
transcriptional programs was rejected by Aydinilik et al, (2001) (161) due to the fact that both β-catenin
and Cyclin D1 protein levels remained equally elevated in promoted and non-promoted tumors. Fur-
thermore direct PB-mediated Wnt/β-catenin pathway activation is not supported by the absence of
liver-specific β-catenin target gene (such as glutamine synthetase) up-regulation upon PB treatment.
In conclusion while β-catenin is necessary for PB-mediated tumor promotion and its activation is a
hallmark of PB promoted liver tumors, its role in the pathogenesis remains elusive. Current studies con-
verge on the idea that β-catenin mutation is necessary but insufficient on its own for HCC and requires
cooperation with additional regulators and pathways to results in unrestricted hepatocyte proliferation
as reviewed in (39).
2.4.3.3 Remaining open question
As reviewed in precedent sections, β-catenin and CAR are two known regulators involved in PB-mediated
tumor promotion. However while crucial roles for both proteins in PB-mediated rodent liver tumor
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promotion have been demonstrated, none of them seems to be sufficient for the process. As β-catenin is
not directly activated by PB, progressive selection for β-catenin activated hepatocytes upon PB chronic
exposure is more likely to result from interaction with alternative activated cellular pathway. Finally
while CAR has been shown to be a key regulator of PB-induced gene expression, its constant activation
upon PB treatment cannot explain the complex dynamics of transcriptional response observed in the first
3 months of PB treatment (123). In conclusion additional transcription factors must be involved in this
process and their identification holds great promise in increasing understanding of PB-promoted liver
tumorigenesis. Several methods exist to identify additional transcription factors involved in this process,
especially from gene expression data; these are reviewed in Section 2.5 and Chapter 3 presents our
innovative computational approach that led to the identification of new candidate regulators of PB-
mediated tumor promotion.
2.4.4 Human relevance of rodent model of HCC
The safety assessment in experimental animals of biologically active chemicals has been very successful
in predicting toxicity in humans (8). However differences in species biochemistry, pathophysiology, or
drug pharamacology between human and rodents have raised doubts regarding the appropriateness of
extrapolating some rodent tumor findings to humans (9; 210). Indeed whilst prolonged treatment with
PB does increase liver size in humans (211), human hepatocytes are resistant to the ability of PB to in-
crease hepatocyte proliferation (212; 213) and inhibit apoptosis (213). Consequently PB-induced rodent
non-genotoxic hepatocarcinogenesis is not considered to be a relevant mechanism for humans (9) and
there is no evidence of a specific role of PB in human liver cancer risk based on epidemiological data in
epileptics (214; 215; 216).
Humanized mouse models for drug metabolizing enzymes and to a lesser extent drug transporters in
which the endogenous mouse genes have been replaced with human genes have been used in drug devel-
opment to explore the species specificity of drug toxicity and to overcome the limitation of animal models
in accurately predicting human responses (217; 218; 219; 220; 221). These include humanised mouse
models in which the endogenous mouse CAR/PXR genes have been replaced with human CAR/PXR
genes (222). However mouse genetic context largely differs from that of human (including difference
in co-factors, chromatin status, promoter of target genes, TFBS) and apart from direct drug-mediated
activation and target genes investigations in murine context, their relevance to human response is still
controversial. Alternatives to these are chimeric mice, which have human hepatocytes engrafted in their
liver and that have been used to study human drug metabolism and pharmacodynamic responses for
nearly 20 years (223).
2.5 Regulatory mechanisms investigations in biological systems
The rapid evolution of genomic-based technologies led to the emergence of toxicogenomics (224) defined
as the application of genomic science to toxicology. This approach allows to improve the understanding
of the molecular and cellular effects of chemicals in biological systems and thus complements biochemical
and phenotypic approaches in assessing the toxicology of a compound.
Gene expression data generated from DNA microarrays or RNA sequencing have been the most suc-
cessful type of data used in toxicogenomics. As many biological responses to xenobiotics are manifest at
the transcriptional level (nuclear receptor activation induced upon drug exposure is implicitly followed
by changes in gene expression (225)), gene expression data from in vivo and in vitro models have been
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used to 1) delineate mechanisms of compound toxicity and 2) identify predictive molecular markers of
toxicity by studying the function of the affected genes (24; 30; 226; 227; 228; 229; 230; 231). Furthermore
building up databases of gene expression changes associated with various toxic compound exposure can
be used to discriminate toxic from benign response (232) and to classify drugs (30).
The identification of drug-induced differentially expressed genes holds great promise for establishment
of early biomarkers of drug toxicity. Furthermore the identification of the regulators responsible for the
observed changes in gene expression -that eventually lead to perturbation of biological pathways and
cellular states- provide with a mechanistic understanding of therapeutics MOA and thus is a crucial step
towards assessing carcinogenic potential of novel therapeutics. Numerous methods - computational and
experimental - have been developed towards identifying and validating candidate regulators of biological
processes that are reviewed below.
2.5.1 Computationally-based methods to identify dysregulated TFs
Because RNA represents the direct output of TFs activity in the cells, a wealth of computational systems
biology studies are focussed on developing methods to reconstruct transcriptional regulatory networks
from gene expression data and identify TFs that regulate and determine the context-specific expression
of a gene (233).
Classic approach to predict TF activity Differentially expressed TFs identified either with gene
expression data or with Reverse Protein Arrays (RPA) are often the first approach to predict key dysreg-
ulated TFs. However because TFs activity is regulated at several level (expression, translation, PTMs,
cellular localization, interaction with co-factors and DNA binding) (234), TF activity does not necessar-
ily correlate with concentration or expression level (235) and alternative methods are required to predict
dysregulated TFs.
Cluster of co-expressed genes Classic methods for modeling transcriptional regulatory networks
from gene expression aim at collecting genes in co-expressed clusters (236). Numerous relevance scores
have been proposed to cluster genes in modules such as correlation coefficient score (237), mutual infor-
mation (238; 239; 240), and singular value decomposition. Then, assuming that co-expressed genes are
co-regulated by a common set of TFs, the corresponding regulatory regions of each genes in the cluster can
be extracted and over-representated TFBS are then considered candidate common regulatory elements for
these clusters (87; 86; 241). Numerous sequence analysis approaches have been developed which identify
potential TF binding sites in DNA sequences set (85). These methods are however prone to significant
noise as many of the predicted potential TF binding sites are not functional (242). Furthermore these
methods are limited by the need to detect motif influence from statistically aggregated expression data
rather than from individual genes and this typically restricts their application to subsets of genes with
large gene expression signals as reviewed in (243).
Combining gene expression experiments with TF-gene network topology A major challenge
in reconstructing transcriptional regulatory networks resides in the fact that as one TF may control the
expression of up to hundreds of genes, one gene is often regulated by a combination of TFs and miRNAs
as reviewed in (244). Consequently methods that model explicitly genome-wide gene expression pat-
terns in terms of condition-specific TFs post-translational activities and gene-specific regulatory network
connectivity (see (236) for review) embrace this aspect. Gene-TF connectivity can be obtained from
databases such as RegulonDB (234), using chromatin immunoprecipitation data (245; 246; 247), from
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analysis of promoter region, or by identifying which genes are differentially expressed when the TF is
deleted (248; 249). It is however important to note that the structure of the regulatory network of the
cell can change dramatically between different experimental or environmental conditions (250).
Several methods have been proposed to solve linear model that links condition-specific TFs activities
to gene expression of target genes and gene-specific regulatory network connectivity. Da et al, (2006)
propose to use line spline functions to correlate the binding strengths of motifs with the expression lev-
els (251). Gao et al, (2004) developed an algorithm that predicts TFs activities based on ChIP and
transcriptome data using multivariate regression and backward variable selection (246). Nguyen et al,
(2006) uses a deterministic mathematical strategy for deriving principles of transcription regulation at
the single-gene resolution level (243). Finally Suzuki et al, (2009) uses a bayesian framework to solve the
multivariate linear model (252). This method is further developed in the following section. Importantly
predicting TFs activities from gene expression is likely to provide with more accurate prediction than
ChIP experiments as some studies revealed that there is little overlap between the genes whose promot-
ers are bound by a TF and those whose expression changes when the TF is deleted (253). In general,
the genes whose promoters are bound by a TF according to ChIP-chip experiments and those whose
expression level responds to perturbation of the same TF show little overlap - typically 3-5% (254).
Motif Activity Response Analysis (MARA) As mentioned in previous paragraph, Suzuki et al,
(2009) uses a bayesian framework, Motif Activity Response Analysis (MARA), to solve the multivariate
linear model (252). MARA models gene expression dynamics explicitly in terms of predicted number
of functional TFBS Npm within proximal promoter regions (-300 to +100) of the genes and the post-
translational activities of their cognate transcription factors. The model assumes that the expression eps
of a promoter p in sample s is a linear function of the activities Ams of motifs m that have predicted sites
in p such as:
eps = c˜s + cp +
∑
m
NpmAms
where cp reflects the basal activity of promoters p and c˜s reflects the total expression in sample s. The
number of functional TFBS Npm are predicted using the Bayesian regulatory-site prediction algorithm
MotEvo that incorporates information from orthologous sequences in six other mammals and uses ex-
plicit models for the evolution of regulatory sites (255). As a result, MARA provides for a total of 189
TFBS motifs (that represent the DNA binding specificities of close to 350 TFs) the activity profiles of
these regulators across the samples, the significance of each motif in explaining the observed expression
variation across the samples, their target genes, and the sites on the genome through which these reg-
ulators act. The activity Ams of a motif m in a sample s represents the condition dependent nuclear
activity of positive and negative regulatory factors that bind to the sites of the motif. As motif activity
is inferred from the behavior of the predicted targets of the motif, an increasing activity is inferred when
its predicted targets show on average an increase in expression, that cannot be explained by the presence
of other motifs in their promoters. The details of the method are described elsewhere (252; 256).
Importantly instead of predicting gene expression from TFs activities and regulatory regions contained
in their promoters, this algorithm aims at predicting key regulators that drive gene expression changes
across the samples, their activities across the samples, and their genome-wide targets. Inferring regulatory
activities from the behavior of predicted targets instead of the expression profile of the TFs themselves
allows for prediction of differential activity that are not related to the expression of the TF but rather
due to post-translational modifications, changes in cellular localization, or interactions with co-factors.
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The output of MARA is a concrete set of hypotheses that are readily amenable to direct experimental
validation and follow-up.
However this method is currently limited by the TFBS data-base as in mammals sequence-specificities
are available for only about 350 of the about 1,500 TFs. Another limitation of the MARA algorithm is
that it focuses solely on predicted TFBSs in proximal promoters, ignoring the effects of distal enhancers.
Moreover motifs mode of action cannot be distinguished and therefore TFs which are both activator and
repressor under a certain condition will not be detected.
2.5.2 Experimentally-based approaches to validate predicted dysregulated
TFs
Various experimental methods intended to validate predicted dysregulated TFs have been successfully
applied that comprise knock-in (KI) (160; 220), knock-out (KO) or siRNA gene silencing experiments
(3; 129; 159; 197; 208; 257; 252; 249). In these experiments TFs coding genes are either inserted, removed
or silenced from experimental models allowing to demonstrate the causal relationship between the regu-
lator and a given phenotype; these methods do not however allow the identification of the direct target
genes. Conversely chromatin immunoprecipitation (ChIP) experiments which identify all regions bound
by a given DNA-binding regulators provide lists of direct TFs target genes together with their genomic
context (79; 80; 258; 233). Furthermore comparisons of ChIP binding results from different experimental
conditions allow to investigate differential TF activity between conditions. ChIP experiments are how-
ever limited in the number of tested hypotheses due to poor antibody quality and ChIP-based activity
prediction can yield low accuracy as TF binding does not necessarily imply a regulatory function. Im-
munohistochemistry staining experiments complement the above approaches and are often utilized to 1)
precisely identify which cell population in a tissue expresses a given TF and 2) investigate tissue hetero-
geneity in TF expression. Additional in situ hybridization of target mRNA and co-localization with TF
allows furthermore to demonstrate direct physical interaction between a TF and a target gene of interest.
2.6 IMI-MARCAR
Most gene expression data used in this thesis have been generated throughout IMI-MARCAR consortium
(http://www.imi-marcar.eu/). The MARCAR project is a 5 year project funded under the Innovative
Medicines Initiative (IMI) Joint Undertaking that aims at (i) identify early biomarkers for more reliably
predicting which compounds have a potential for later cancer development, (ii) improve the scientific basis
for assessing carcinogenic potential of non-genotoxic drugs, (iii) identify the molecular response to NGC
exposure that underpins development of early exposure biomarkers and finally (iv) improve drug safety
and the efficiency of drug development by progressing the development of alternative research methods.
Chapter 3
Computational modeling identifies
key gene regulatory interactions
underlying phenobarbital-mediated
tumor promotion
This chapter contains the main manuscript of this thesis which shows how adapting existing probabilistic
algorithm to comprehensive toxicogenomic data from in vivo experiments leads to identification of key
regulatory interactions underlying early stage of drug-induced liver tumorigenesis. The manuscript has
been published in Nucleic Acid Research in January 2014.
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ABSTRACT
Gene regulatory interactions underlying the early
stages of non-genotoxic carcinogenesis are poorly
understood. Here, we have identified key candidate
regulators of phenobarbital (PB)-mediated mouse
liver tumorigenesis, a well-characterized model of
non-genotoxic carcinogenesis, by applying a new
computational modeling approach to a comprehen-
sive collection of in vivo gene expression studies.
We have combined our previously developed motif
activity response analysis (MARA), which models
gene expression patterns in terms of computation-
ally predicted transcription factor binding sites with
singular value decomposition (SVD) of the inferred
motif activities, to disentangle the roles that
different transcriptional regulators play in specific
biological pathways of tumor promotion.
Furthermore, transgenic mouse models enabled us
to identify which of these regulatory activities was
downstream of constitutive androstane receptor
and b-catenin signaling, both crucial components
of PB-mediated liver tumorigenesis. We propose
novel roles for E2F and ZFP161 in PB-mediated hep-
atocyte proliferation and suggest that PB-mediated
suppression of ESR1 activity contributes to the de-
velopment of a tumor-prone environment. Our study
shows that combining MARA with SVD allows for
automated identification of independent transcrip-
tion regulatory programs within a complex in vivo
tissue environment and provides novel mechanistic
insights into PB-mediated hepatocarcinogenesis.
INTRODUCTION
Aberrant activity of transcription factors (TFs) is a hallmark
of both human (1–3) and mouse (4) hepatocarcinogenesis
and is considered as a key intrinsic regulatory mechanism
underlying epigenetic reprograming associated with cancer
development (5). Non-genotoxic carcinogens (NGC) are a
group of compounds that do not directly affect DNA (6),
but that produce perturbations in the gene expression and
epigenetic state of cells (7–9) which, if given in sufficient
concentration and duration, facilitate tumor formation, typ-
ically through the promotion of pre-existing neoplastic cells
into neoplasms (10,11). However, little is known about the
regulatory mechanisms that underly the tumor promotion
byNGC, particularly regarding the early regulatory changes
in response to the carcinogen.
The anticonvulsant phenobarbital (PB) is a well-estab-
lished rodent NGC that has been extensively used to in-
vestigate the promotion of liver tumors (12–14). PB
accomplishes its diverse effects on liver function, at least
in part, by promoting nuclear translocation of the consti-
tutive androstane receptor (CAR) (15) through inhibition
of Epidermal Growth Factor Receptor (EGFR) signaling
(16). CAR activation is required for the acute and the
chronic response to PB treatment and for liver tumor for-
mation elicited upon prolonged PB treatment (17–21). In
addition to this crucial role of CAR, when liver tumors are
promoted through PB treatment in combination with an
initial treatment with diethylnitrosamine (DEN), >80% of
the resulting tumors harbor activating mutations in b-
catenin (22) that stabilize b-catenin, leading to enhanced
nuclear translocation and subsequent target gene activa-
tion (23–27).
Apart from the crucial roles for CAR and b-catenin in
PB-mediated liver tumor promotion, little is known about
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additional transcriptional regulators that orchestrate the
complex and dynamic PB-mediated gene expression
programs associated with early molecular responses to
PB treatment (28) and long-term PB tumorigenic effects
(12–14).
In this study, we have elucidated gene regulatory inter-
actions underlying dynamic PB-mediated transcriptional
responses during the early stages of liver non-genotoxic
carcinogenesis by integrating multiple gene expression
datasets from independent in vivo mouse PB studies. Our
primary dataset consists of an early kinetic study (seven
time points across 91 days of PB treatment) originally
designed to investigate the temporal sequence of molecu-
lar and histopathological perturbations during the early
stages of PB-mediated liver tumor promotion in vivo
(9, 28). Several challenges are associated with the extrac-
tion of key gene regulatory interactions from gene expres-
sion time course data. First, we needed to identify the
relative contributions (activities) of specific transcriptional
regulators underlying the observed genome-wide gene ex-
pression changes. This was achieved using our recently
developed motif activity response analysis [MARA,
(29)]. MARA capitalizes on sophisticated computational
methods, developed over the last decade (30), that allow
comprehensive prediction of binding sites for hundreds of
mammalian TFs across all mammalian promoters (31).
Using such computational predictions, MARA models
observed gene expression patterns explicitly in terms of
the predicted regulatory sites and uses this to infer the
regulatory activities of TFs. A number of recent studies
(32–43) demonstrate that this approach can successfully
identify key regulators ab initio across different model
systems of interest.
A second challenge was to disentangle the complex
range of PB-mediated gene expression programs in
mouse liver tissue that are associated with distinct biolo-
gical events including xenobiotic responses, tumor promo-
tion and tumorigenesis.
Here, we show that combining MARA with singular
value decomposition (SVD) allows for automated
disentangling of independent transcription regulatory
programs within a complex in vivo tissue environment.
We were able to successfully infer key gene regulatory
proteins for xenobiotic responses, tumor promotion and
end-stage tumors as well as assess their genetic dependence
on CAR and b-catenin signaling pathways.
Collectively, our analyses provide novel mechanistic
insights into PB-mediated tumor promotion in the mouse
liver, including a proposed role of E2F and ZFP161 in
regulating PB-mediated hepatocyte proliferation at both
early and tumor stages and progressive PB-mediated sup-
pression of ESR1 activity that likely contributes to the
development of a tumor-prone environment.
MATERIALS AND METHODS
Gene expression datasets and Affymetrix
GeneChip processing
A library of 109 genome-wide messenger RNA (mRNA)
expression patterns was compiled from four different
studies (Figure 1a). In all four studies gene expression
was profiled using Affymetrix GeneChip MOE-4302
(Affymetrix, Santa Clara, CA, USA). The analysis of the
micro-array data was done with the R statistical package,
version 2.13 (2005) and Bioconductor libraries, version
1.4.7 (44).
From gene expression matrices to motif activity matrices
Matrices of activities for 189 mammalian regulatory
motifs across all samples were inferred from the
RMA-normalized expression matrices using the MARA
algorithm (29) (Figure 1b and c). MARA models
genome-wide gene expression patterns in terms of pre-
dicted functional Transcription Factor Binding Sites
(TFBSs) within proximal promoter regions (running
from !300 to+100 relative to transcription start) of the
40 300 promoters. The model assumes that the expression
eps of a promoter p in sample s is a linear function of the
predicted numbers of binding sites Npm for each motif m in
promoter p and the (unknown) activities Ams of each of
the motifs m in sample s, i.e.
eps ¼ ~cs+cp+
X
m
NpmAms
where cp reflects the basal activity of promoter p and ~cs is a
normalization constant corresponding to the total expres-
sion in sample s. The activities Ams, as well as error bars
!Ams on these activities, are thus inferred from the
measured expression data eps and the predicted binding
sites Npm. The number of functional TFBSs Npm was pre-
dicted using the Bayesian regulatory site prediction algo-
rithm MotEvo, which incorporates information from
orthologous sequences in six other mammals and uses
explicit models for the evolution of regulatory sites (30).
The 189 regulatory motifs represent binding specificities of
roughly 350 different mouse TFs. Besides the motif
activities, MARA also calculates a z-score quantifying
the significance of each motif in explaining the observed
expression variation across the samples, the target genes of
each motif, and the sites on the genome through which the
regulators act on their targets.
Formally, the activity Ams corresponds to the amount
by which the expression eps would be reduced if a binding
site for motif m in promoter p were to be removed. Thus,
an increasing activity is inferred when its targets show on
average an increase in expression, that cannot be ex-
plained by the presence of other motifs in their promoters.
The details of the method are described elsewhere (29). An
overview of the analysis strategy and an outline of the
MARA approach are depicted in Figure 1.
Detection of differential motif activity between pairs
of conditions
We quantified the differential motif activity between two
conditions using a z-statistic as
zm!c ¼
"Amc1 ! "Amc2ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
!A2mc1+!A
2
mc2
q
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where "Amc is the averaged motif activity profile over rep-
licates for condition c and motif m and !Amc is the stand-
ard error on the corresponding motif activity, which is
computed using a rigorous Bayesian procedure
(Balwierz, PJ. et al, manuscript under review). The z-
values quantify the evidence for a change in regulatory
activity of the motif between the two conditions. That is,
if zm!c is highly positive it indicates that predicted targets
of motif m are upregulated in condition c1 relative to con-
dition c2, in a way that cannot be explained by the
activities of other regulators. We consider motifs differen-
tially active if jzj # 1:5.
In order to avoid any confounding batch effects, we
only calculate differential activities across conditions
from the same dataset. Comparing activities between
treated and control samples at different timepoints of
the kinetic study allowed for the identification of PB-
mediated dysregulated TFs at the early stage of PB treat-
ment. Comparison of activities between wild-type (WT)
and CAR/b-catenin null in physiological conditions, i.e.
without treatment, identified motifs whose activities are
modulated upon KO of the respective TF (Figure 2a
and c). We consider such motifs to be downstream of
the b-catenin/CAR pathways in physiological conditions.
Similarly, comparison of activities between PB-treated
and non-treated samples allowed for the identification of
motifs that are dysregulated by PB treatment. By further
comparing the changes in motif activities upon PB treat-
ment for both WT and CAR-null samples, we can identify
motifs dysregulated by PB in a manner that is independent
of CAR signaling and motifs whose dysregulation is
downstream of CAR (Figure 2a and c). Comparison of
activities between promoted tumors and surrounding PB-
treated tissue identified motifs dysregulated in promoted
tumors; comparison of activities between non-promoted
tumors and surrounding non-treated tissue identified
motifs dysregulated in liver tumors irrespective of PB
treatment. Motifs uniquely dysregulated in promoted
tumors were classified as promoted tumor-specific regula-
tors (Figure 2b).
Characterization of PB-mediated early motif
activity profiles
SVD of the motif activities
We performed SVD of the activities of the 189 motifs
across the seven timepoints in PB- and vehicle-treated
livers, i.e. a matrix A containing 189 rows and 14
columns. SVD resulted in a decomposition, A ¼ U#V,
where # is a diagonal matrix containing the singular
values, U and V contain the orthonormal bases defined
by right and left singular vectors of A, respectively. Each
motif activity profile ~am with ð~amÞs ¼ Ams can be thought
of as a linear combination of the right singular vectors
f~vkg.
Visualization and interpretation of the SVD results
To visualize the right singular vectors f~vkg, we plotted the
activities vks on the vertical axis as a function of the time
corresponding to each sample s on the horizontal axis and
coloring all samples corresponding to PB treatment black,
and those corresponding to control-treatment gray,
e.g. Figure 1d. This visualization facilitated the biological
interpretation of the singular vectors. Biological interpret-
ation was further facilitated by identification of the regu-
latory motifs whose activity profiles correlate most
strongly (either positively or negatively) with the activity
profile of the singular vector.
Identification of representative motifs of the
singular vectors
As the right singular vectors form an orthonormal basis of
the space of activity profiles, the projection of a given
motif activity profile onto a right singular vector indicates
how strongly the motif’s activity profile overlaps with the
basis vector specified by the singular vector. The projec-
tions of the motif activity profiles ~am onto right singular
vectors ~vk are calculated as qmk ¼ ~am & ~vk and these values
are readily obtained from the SVD results as AV ¼ U#
such that qmk ¼ ðU#Þmk.
We additionally computed Pearson correlations
between the motif activity profiles ~am and the right
singular vectors ~vk. As the vectors ~vk are linear combin-
ations of the motif activity profiles ~am that are mean
centered, i.e.
P
s ams ¼ 0, these are also mean centered.
Consequently, the Pearson correlation coefficients can
also be readily obtained from the SVD results as
(a)
(b)
(c)
Figure 2. Schematic representation of contrasts applied for differential
motif activity analysis of each dataset. The color of the dot indicates
whether the sample is WT (black), b-catenin KO (green), CAR KO
(red) or tumor (blue). White boxes correspond to control samples
and gray boxes to PB-treated samples. The arrows show which pairs
of samples are compared for each contrast and point to corresponding
rows with example motif activity changes (blue corresponding to
downregulation z < !1:5, pink to upregulation z > 1:5 and white no
significant change jzj < 1:5). (a) Motif activities from the CAR KO
study are compared to identify regulators downstream of the CAR
pathway under physiological conditions and under PB treatment.
(b) Motif activities from the tumor study are compared to identify
promoted tumor-specific regulators. (c) Motif activities from
the b-catenin KO study are compared to identify downstream regula-
tors of the b-catenin pathway under physiological conditions.
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"mk ¼ qmk=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiP
k0 ðqmk0Þ2
q
. As the activity profiles of differ-
ent motifs have different overall ‘lengths’, the projections
and Pearson correlations do not carry identical informa-
tion. Motifs with large activities tend to have high
absolute projections with a given singular vector, even if
the motif activity profile is not similar to the activity
profile of the singular vector. In contrast, a motif with
small activities will tend to have low projections, but
may have a high correlation with a given singular vector.
In order to identify representative motifs for each
singular vector, motifs were ranked according to both pro-
jection and correlation scores. The highest (most positive
scores in both projection and correlation) and lowest
(most negative scores in both correlation and projection)
motifs were selected for each singular vector. As some
degree of redundancy is present among regulatory
motifs, we further refined our motifs selection in a system-
atic manner following criteria that are detailed in the
‘Results’ section.
Gene Ontology enrichment analysis
The DAVID Bioinformatics Resource (Database for
Annotation, Visualization and Integrated Discovery)
(45,46), version 6.7, sponsored by the National Institute
of Allergy and Infectious Diseases (NIAID), NIH, was
used to investigate the statistical enrichment of biological
terms and processes associated with the predicted target
genes of each motif of interest. We directly imported
official gene symbols into DAVID, exported enrichment
from biological pathways from Gene Ontology and Kyoto
Encyclopedia of Genes and Genomes (KEGG), filtered
out redundant terms and selected biological processes
with P-value of enrichment <0.05.
RESULTS
Overview of liver toxicogenomic data from
phenobarbital-treated mouse models
In order to investigate gene regulatory networks underlying
early PB-mediated liver tumor promotion, we used four
transcriptomic datasets which are illustrated in Figure 1a.
Our primary dataset is composed of transcriptome
profiling data from a PB kinetic study in B6C3F1 (livers
from vehicle, i.e. control and PB-treated male mice at+1,
+3, +7, +14, +28, +57 and +91 days of dosing). This
dataset enabled us to investigate gene expression
dynamics during the first 3 months of PB treatment.
A second CAR knock-out (KO) study composed of tran-
scriptome profiling data from livers of vehicle- and PB-
treated C3H male WT and CAR-null mice (at+161 days
of dosing) enabled us to investigate which of the responses
to PB treatment were CAR-dependent at this later time
point. A third tumor study consisting of samples from
promoted (at +35 weeks of PB treatment) and non-
promoted tumors as well as their related surrounding
tissue from C3H male mice, enabled us to identify gene
regulatory changes that were specific to promoted
tumors, as opposed to being a shared feature of tumor
tissues in general. Finally, a b-catenin KO study
composed of livers from WT and b-catenin-null C3H
male mice enabled us to investigate which of the identified
TFs were downstream of b-catenin in physiological condi-
tions. In both the CAR KO and tumor studies, mice were
DEN-initiated at 4 weeks of age.
Identifying PB-modulated activities of transcriptional
regulators using MARA
MARA is a general method for inferring the activities of a
large collection of mammalian TFs (as represented by their
DNAbinding ‘motifs’) bymodeling gene expression data in
terms of computationally predicted regulatory sites in pro-
moters. The basic approach is illustrated in Figure 1b. Note
that motif activities are inferred from the behavior of the
expression levels, typically hundreds, of predicted ‘targets’
of the motif and do not directly involve analysis of the ex-
pression levels of the regulators themselves. This is espe-
cially useful in systems where TF activities are modulated
through subcellular localization and post-translational
modifications, rather than at the transcriptional level, e.g.
such as the PB-mediated CAR nuclear translocation and
induction of downstream transcriptional responses that we
study here. Importantly, apart from inferring the motif
activities Ams, MARA also rigorously infers error bars on
these motif activities !Ams, which allow to quantify to what
extent motif activities are significantly varying across the
samples for each motif. The overall significance of each
motif m is then represented by a z-statistic (‘Materials
and Methods’ section).
TFs underlying early PB-mediated liver
transcriptional dynamics
Figure 1d shows the activities of four motifs observed
within the time course of control and PB-treated mice,
illustrating the range of different profiles that can be
observed. For example, the motif bound by the family
of E2F TFs and the motif bound by AHR, ARNT and
ARNT2 TFs both showed substantial changes in activity
across the time course that are largely the same in the
control and PB-treated animals, except for E2F’s activity
at the first timepoint. In contrast, the TATA-box motif
bound by TATA Binding Protein (TBP) exhibited almost
constant activity across time but showed a strong shift in
behavior between control and PB-treated animals. The
LMO2 motif showed no significant activity for the first
month of the time course but at later time points
(during the last 2 months) there was a marked divergence
between PB-treated and control animals.
SVD identifies four characteristic motif activity profiles
underlying early PB-mediated transcriptional changes
Although it is possible to formulate biological interpret-
ations and hypotheses for observed motif activity profiles
on a case-by-case basis, it is unclear how this could be
performed in a systematic and unbiased manner across a
large number of motifs. This is especially challenging,
because prior biological knowledge indicates that
multiple biological processes, including completion of
postnatal liver development, acute and sustained xeno-
biotic responses to PB treatment and tumor promotion,
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are occurring in parallel in our system. To address this
problem, we applied a SVD approach to decompose the
matrix of inferred motif activities Ams from the early
kinetic study into linearly independent motif activity
profiles that capture most of the variation in all motif
activities.
Over 70% of the variance in the activity matrix was
explained by the first four components of the SVD
as evidenced by the spectrum of singular values
(Figure 3b). The activity profiles of the first four right
singular vectors, ~v1 through ~v4, are shown in Figure 3c.
The first right singular vector accounted for 35% of the
variance and was characterized by an approximately
constant positive activity early in the time course that
decreased dramatically after 2 weeks. The activity profile
of this first singular vector was identical in the PB-treated
and control groups. The steep drop in activity after
2 weeks coincided with the completion of postnatal liver
development in this study, as indicated by the transcrip-
tional profile of the hepatoblast marker a-fetoprotein
(Afp) (47,48) (Supplementary Figure S4). We thus
propose that this characteristic motif activity profile is
associated with postnatal liver development. This conclu-
sion is supported by some of the motifs associated with
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this singular vector (see Supplementary Data). As this
process is presumably not relevant for the process of
non-genotoxic tumor promotion, we have not further
focused on this singular vector and a characterization of
its associated regulators is presented in the Supplementary
Data.
The second singular vector accounted for 20% of the
variance and was characterized by an activity profile that
is almost entirely constant with time, but that showed a
large difference between the PB-treated and vehicle-
treated samples. This singular vector thus corresponds to
a sustained xenobiotic response.
The third singular vector accounted for 10% of the
variance and was characterized by a difference in
activity between the control and treated group at Day 1
only; whereas activity in the control samples remained
approximately constant in the first 3 days, activity was
much higher at Day 1 and dropped significantly in PB-
treated samples over the same initial phase. Given that PB
mediates a transient mitotic response at Day 1 [also pre-
viously identified in other studies (18, 28)], we conclude
that the biological pathway corresponding to this charac-
teristic activity profile is the transient PB-mediated prolif-
erative response.
Finally, the fourth singular vector accounted for 5% of
the variance and was characterized by a divergence in the
activity of the PB-treated and control groups in the last
month of the 13-week time course. Given that this is the
most significant singular value for differences between the
PB-treated and control samples toward the end of the time
course, we infer that this characteristic adaptive xeno-
biotic response activity profile might be an important con-
tributor to the progressive creation of a tumor-prone
environment.
In summary, we have shown that the behavior of regu-
latory motifs in the early stages of PB treatment are
dominated by four characteristic activity profiles that
account for >70% of variance of the motif activities and
which correspond to the following fundamental biological
processes: (i) the completion of postnatal liver develop-
ment, (ii) a constant xenobiotic response, (iii) a PB-
mediated acute mitogenic response and (iv) an adaptive
xenobiotic response (late response to PB treatment).
Identification of representative motifs underlying the early
dysregulated biological pathways
To determine motifs underlying the four characteristic
motif activity profiles identified in the previous section,
we selected motifs which contributed and correlated the
most with each of the four singular vectors (Figure 3c, d, e
and f). In this way we obtained, for each of the four
singular vectors, two clusters of motifs with similar
activity profiles, i.e. one correlating negatively with the
singular vector and one correlating positively (Figure 3d
and f). The advantage of extracting clusters of the most
important regulatory motifs in this way, rather than
simply clustering the motif activity profiles directly, is
that many of the motif activity profiles contain compo-
nents associated with different biological processes that
are operating in parallel in our system. By first using
SVD to identify the most significant characteristic
activity profiles that are mutually ‘independent’, i.e. the
singular vectors, we disentangle the regulatory activities
associated with these different processes and cluster the
motifs by the biological process.
We further refined the selection of the motifs associated
with each singular vector as follows: (i) removing motifs
for which the overall significance was too low (z < 1:5
for motifs regulating postnatal liver development or the
constant xenobiotic response and under z < 1:0 for motifs
regulating the transient mitogenic response or the adaptive
xenobiotic response); (ii) removing motifs whose cognate
TFs were not expressed in the liver (log expression <6.0);
(iii) using z-scores for the differential activity per time
point between PB-treated and control samples, we
required z!c # 1:5 at minimum four time points out of
the seven to belong to ~v2, at Day 1 to belong to ~v3 and
at Day 91 to belong to ~v4. This lead to the identification of
eight groups of motifs, i.e. two for each characteristic
profile (Supplementary Table S1).
To further investigate the biological roles of the motifs
associated with the four singular vectors, we performed
Gene Ontology and KEGG functional enrichment
analysis of the targets of the eight groups of motifs that
are either positively or negatively associated with one
of the singular vectors (Figure 4 and Supplementary
Figure S5). Below is a brief description of most important
findings.
Constant xenobiotic response. As discussed further below,
it is well known that CAR is a crucial regulator involved
in the xenobiotic response and thus a prime candidate
for a regulator associated with a constant xenobiotic
response. Unfortunately, as there is currently no high-
quality regulatory motif available for CAR, our TFBS
predictions do not include CAR target sites and our
analysis is thus unable to infer CAR’s activity ab initio.
However, our analysis identified several additional regu-
lators that are associated with a sustained xenobiotic
response, i.e. a constant difference in activity between
the PB-treated and control samples (a full list of
associated motifs is presented in Supplementary Table S1).
Among these is TBP, whose targets are significantly
upregulated under PB treatment and enriched in oxida-
tion-reduction processes (Figure 4a), and NFE2 whose
target genes are involved in homeostatic processes
(Figure 4b) and include the proteasome complex (e.g.
Psmc3, Ufd1l and Ube2v1) and oxidative stress genes
(e.g. Ggt1, Txn1 and Adh7). These targets represent key
pathways of the liver drug-induced response that have
been recently shown to be regulated by NFE2 in hepato-
cytes (49).
Transient proliferative response. It has been observed pre-
viously that PB treatment leads to a transient mitogenic
response (18,28,20). Our analysis revealed that the process
is positively regulated by the E2F family of TFs, whose
motif activity is significantly increased at Day 1 upon
PB treatment (z ¼ 2:2). E2F family members are known
regulators of cell proliferation and the functions of their
predicted targets (Figure 4c) further confirms their specific
role in DNA replication, DNA repair and mitosis (50–53).
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Interestingly, while eight TFs are potentially binding this
motif, three of them (E2F1, E2F2 and E2F8) display a
positive correlation between their gene expression and
the motif activity in the time course (Supplementary
Figure S3a and Supplementary Table S6), suggesting
that it may be these three TFs that are involved in the
PB-mediated transient hyperplastic response.
Our analysis predicted ZFP161 as an additional regula-
tor of the transient hyperplastic response, whose targets
are downregulated upon PB treatment. Interestingly,
ZFP161’s target genes are enriched in transcriptional re-
pressors (e.g. Rb1, Bcl6, Tle2, Klf9 and Foxp1), many of
which are known to repress the cell cycle and cell growth.
Moreover, positive regulation of cell proliferation by
ZFP161 is further supported by negative regulation
of cell death genes (Figure 4d). Together, these results
suggest that PB-mediated ZFP161 activation may lead
to the downregulation of an important group of transcrip-
tional repressors and concomitant cell cycle activation.
Progressive xenobiotic response. Finally, our analysis
identified several motifs associated with a divergence
between motif activity in the PB-treated and control
samples in the last month of the time course. Among the
downregulated motifs is ESR1, whose predicted targets
regulate extracellular matrix (ECM) genes and may thus
regulate tissue remodeling (Figure 4e). NR5A1,2 is an
additional regulator whose activity was downregulated
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after 3 months of PB treatment (Figure 4e). Interestingly,
Nr5a2 (known as liver receptor homolog-1 or LRH-1) is
an established regulator of cholesterol, bile acid homeo-
stasis, glucose and lipid metabolism (54,55), as confirmed
by predicted targets functions in carbohydrate metabolism
(Figure 4f).
Regulators of PB-mediated long-term liver gene
expression changes are downstream of CAR signaling
In order to assess the importance of CAR in the livers in
physiological conditions, i.e. without PB treatment and to
identify to what extent the response to PB treatment is
downstream of CAR activation, we made use of gene
expression profiles from CAR WT and KO mice (19).
We first identified regulators that are downstream of
CAR under physiological conditions by comparing motif
activities between non-treated CAR KO and WT samples
(Figure 2a provides a schematic representation of all motif
activity contrasts that we calculated). Only five motifs
were significantly downregulated in their activity upon
CAR deletion (Supplementary Table S2 provides a full
list). To assess the CAR dependence of the regulatory
motif changes mediated by PB treatment, we compared
regulatory motifs that are perturbed in activity upon PB
treatment in WT animals, with motifs that are perturbed
upon PB treatment in CAR KO animals. Strikingly, of the
23 motifs dysregulated upon PB treatment in WT mice,
none was dysregulated in KO mice, indicating that all
regulators of PB-mediated gene expression changes
at Day 161 are downstream of CAR signaling
(Supplementary Table S2). This result is in line with
previous studies where CAR was shown to be critical for
both the acute (20) and chronic (19) transcriptional
response to PB treatment. These results are further con-
firmed by an SVD analysis (Supplementary Results and
Supplementary Figure S6), which shows that the major
source of motif activity changes in these liver samples is
the CAR-dependent liver response to PB treatment. In
summary, it is highly likely that all motif activity
changes observed in the early response time course also
depend on CAR activation.
Identification of specific regulators of promoted tumors
involved in early PB-mediated response
Our analysis above has focused on regulators that are per-
turbed during the first 3 months of PB treatment, whereas
it takes several more months for tumors to be detected at
the histopathologic level (21). We next investigated which
regulators have different activities in the end-stage
tumors that are observed after 8 months of treatment, as
compared with their surrounding tissue (Figure 2b). We
hypothesized that motifs perturbed both in the early
response as well in the end-stage tumors may likely be
involved in the process of tumor formation. Moreover,
we distinguished ‘promoted’ tumors, which are
characterized by mutations that cause constitutive activa-
tion of b-catenin, from ‘non-promoted’ tumors that are
characterized by mutations in Ha-ras activation. Motifs
that are perturbed in promoted tumors, but not in
Ha-ras tumors, are prime candidates for involvement in
the non-genotoxic tumor promotion.
We find eight motifs that are perturbed in both
promoted and non-promoted tumors (Supplementary
Table S3). Half of these were also associated with one of
the singular vectors of the early PB treatment time course.
In particular, the motif NR5A1,2 was associated with
singular vector 4, showing a downregulation in the PB-
treated animals in the third month of the time course, is
also downregulated in the end-stage tumors. Predicted
targets for NR5A1,2 are involved in several known meta-
bolic functions of the liver [oxido-reduction processes,
peroxisome proliferator-activated receptor (PPAR) signal-
ing, and energy metabolism] (55), consistent with target
functions at the early time points, indicating that
NR5A1,2 downregulation is associated with hepatocyte
loss of function (Figure 5a). Furthermore, our analysis
identifies SOX{8,9,10} as a regulator of cell proliferation
in both promoted and non-promoted tumors (Figure 5a).
As these motifs are perturbed in both promoted and non-
promoted tumors, they likely regulate genes involved in
general liver tumor biology and are presumably not
relevant for the specific process of non-genotoxic tumor
promotion.
Seven motifs were dysregulated in promoted tumors
only (Supplementary Table S4). Strikingly, all but one of
these motifs were associated with one of the singular
vectors of the early PB treatment time course. In particu-
lar, the E2F motif, which we found to be a positive regu-
lator of both the postnatal liver growth and the transient
PB-mediated mitogenic response, is here observed to be
upregulated only in promoted tumors (zpromoted tum: ¼ 2:6),
showing no significant perturbation in the non-promoted
tumors (znon!promoted tum: ¼ !0:3). Importantly, E2F1,
E2F2 and E2F8, previously identified as strong candidate
regulators of early PB-mediated transient hyperplastic
response, display similar positive correlation between
their gene expression and the motif activity in the tumor
(Supplementary Figure S3a and Supplementary Table S5).
Notably, the cellular functions regulated by SOX{8,9,10}
and E2F at tumor stage (Figure 5a and b) suggests that
these motifs have distinct regulatory effects on cell prolif-
eration; while SOX{8,9,10} regulates mitosis, E2F targets
specifically regulate DNA replication (Supplementary
Figure S2).
The ZFP161 motif, which we found to negatively
regulate transcriptional repressors of the cell cycle in
the early stages of PB treatment, also displays signifi-
cant decrease in activity in promoted tumors
(zpromoted tum: ¼ !1:6), but not in non-promoted tumors
(znon!promoted tum: ¼ 0:7) (Figure 5b). Interestingly, these
results suggest that similar regulatory mechanisms,
involving E2F and ZPF161, are responsible for the prolif-
eration that occurs transiently immediately upon PB treat-
ment as well as the proliferation in promoted tumors.
Moreover, this upregulation of proliferation, which
might involve the release of specific cell-cycle check-
points, is clearly distinct from the regulatory mechanism
responsible for upregulation of proliferation in the non-
promoted tumors.
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Another motif specifically upregulated in promoted
tumors is NFE2 (zpromoted tum: ¼ 2:5 versus
znon!promoted tum: ¼ !1:4). Furthermore targets of NFE2
that already showed upregulation at the early stage, such
as several members of the protease family and oxidative
stress response, e.g. Aox1, Acox2, Srxn1 andMocos, show
continued activation in the promoted tumors (Figure 5b).
Finally, our analysis revealed a significant decrease in
activity of the motif bound by ESR1 in promoted tumors
only (zpromoted tum: ¼ !2:9 versus znon!promoted tum: ¼ 0:5).
Moreover, our analysis shows ESR1 regulation of genes
involved in anatomical structure morphogenesis/tissue re-
modeling (genes, e.g. coding for collagen and fibronectin)
that are progressively downregulated upon PB treatment
and remain repressed at the tumor stage (Figure 5b). We
also performed an SVD analysis of the activity matrix of
this dataset (Supplementary Results and Supplementary
Figure S7). The analysis identified the most significant
singular component with regulators of promoted tumors
that largely overlap those identified by differential motif
activity analysis. The second singular component
identified a number of regulators of liver tumorigenesis.
Interestingly, these motifs were not identified by differen-
tial motif activity analysis, suggesting that SVD analysis
can identify a significant effect of a set of motifs even when
the differential activity of each motif is not significant by
itself.
Early regulators of liver tumor promotion downstream of
b-catenin signaling
It has been established that liver tumor promotion by PB
requires functional b-catenin (56) and promoted tumors
are characterized by mutations that cause constitutive ac-
tivation of b-catenin. However, it remains unclear how PB
promotes the outgrowth of pre-existing b-catenin
activated cells. The ability for b-catenin to physically
interact with various co-factors and nuclear receptors
(57,58) suggests that the predicted regulators of PB-
mediated liver tumor promotion may interact with the
b-catenin pathway.
We thus investigated which regulators are downstream
of b-catenin under physiological conditions by comparing
motif activities in non-treated WT and b-catenin KO cells
(Figure 2c). This analysis showed massive changes in regu-
latory activities upon KO of b-catenin, with as many as
33 motifs significantly perturbed in their activity
(Supplementary Table S5). Note that this analysis success-
fully retrieved known co-factors of b-catenin such as the
Tcf7-Lef1 motif, whose activity decreases strongly upon
b-catenin KO (zko!wt ¼ !3:2). Furthermore, two of the
previously identified regulators of liver tumor promotion,
i.e. E2F (zko!wt ¼ !2:0) and NFE2 (zko!wt ¼ !2:2), were
negatively modulated upon b-catenin KO, whereas ESR1
(zko!wt ¼ 2:9) was positively modulated. These findings
support the hypothesis of a positive interaction between
E2F/NFE2 and the b-catenin signaling pathway. The
strong positive correlation between ESR1 gene expression
and motif activity in both this study and the tumor study
(Supplementary Figure S3 and Supplementary Table S6)
supports a negative interaction between the b-catenin sig-
naling pathway and ESR1 in liver, potentially through
direct repression of target gene by b-catenin.
DISCUSSION
Here we describe a novel bioinformatics approach for the
automated identification of independent transcription
regulatory programs within a complex in vivo tissue envir-
onment. Using well-characterized mouse mechanistic
models for non-genotoxic hepatocarcinogeneis, we were
able to successfully infer the contributions of key
(a)
(b)
Figure 5. Regulators of liver tumorigenesis and tumor promotion.
(a) Activities of two regulators that are dysregulated in both
promoted and non-promoted tumors. (b) Activities of four regulators
that are specifically dysregulated in promoted tumors. For each regu-
lator, the activities in the tumor and surrounding normal tissue are
indicated by black and turquoise points, respectively. A z-value quan-
tifying the overall significance of the motif in tumor dataset is indicated
below each motif’s name. A selection of biological pathways and func-
tional categories (Gene Ontology or KEGG) enriched among tar-
get genes of these motifs are shown on the right of each activity
profile. The height of each bar corresponds to the significance
[! log10ðP! valueÞ] of the enrichment. Differences in activity between
the tumor and surrounding tissues that are significant are indicated by
an asterisk (jz!act:j # 1:5).
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regulators of phenobarbital-mediated xenobiotic re-
sponses, tumor promotion and end-stage tumors as well
as assess their dependence on the CAR and b-catenin
signaling pathways.
Motif activity response analysis, which models observed
gene expression patterns in terms of computationally pre-
dicted TF-binding sites, has been specifically designed to
identify the key regulators responsible for the observed
gene expression dynamics. One of its strengths is that
MARA does not rely directly on the mRNA expression
of the TFs, but instead infers the activities of regulators
from the expression of their predicted target genes.
Consequently, MARA can easily identify changes in
motif activities that are due to post-translational modifi-
cations, changes in cellular localization or interactions
with co-factors. This is specifically relevant for our
model system in which PB indirectly triggers changes
in gene expression via EGFR signaling-mediated post-
translational modification and nuclear translocation of
the TF CAR (15,16).
A major challenge in the analysis of the complicated
in vivo systems such as the one we study here, is that the
observed genome-wide expression changes result from
multiple biological pathways dynamically changing in
parallel. Consequently, even when MARA allows us to
infer the regulatory activities of key TFs across the
samples, it may be challenging to identify the independent
biological processes that these regulators contribute to
and how each regulator is contributing to each process.
To address this, we here developed a new analysis
approach based on SVD that decomposes the entire
matrix of motif activities across all samples and identifies
the major mutually independent activity profiles.
Our results show that this approach successfully
identifies the major biological pathways underlying the
response to PB treatment and it furthermore allows us
to identify how the key regulators are contributing to
each of these pathways. We identified the roles of E2F
and ZFP161 in the regulation of cell proliferation in
both the early transient mitogenic response and specific-
ally in promoted tumors. We identified ESR1 as a key
regulator of establishing a tumor-prone environment and
we identified NFE2 as a key regulator of the sustained
xenobiotic response. Figure 6 schematically summarizes
these key findings, showing both the overall picture
that emerges of the biological processes involved in PB-
mediated tumor promotion (Figure 6a) as well as the key
regulators that we identified and their role in the various
processes (Figure 6b).
In the next sections we discuss these key findings, put
them into context of relevant available literature and put
forward concrete hypotheses for the biological mechan-
isms involved in these regulatory processes. Finally,
where possible, we also discuss pieces of supporting
evidence for the hypotheses we put forward.
E2F as a positive regulator of the PB-mediated
proliferative response at both the early and tumor stages
An important aspect of PB-mediated tumor promotion is
the ability of PB to induce a transient mitogenic response
and to cause liver neoplasia upon chronic administration.
However, the exact mechanisms responsible for the exit
from the quiescent state and the re-entry into the cell
cycle remain largely unknown [see (59) for a review].
Our analysis revealed that the regulatory motif bound
(a)
(b)
(e)
(c) (d)
Figure 6. Schematical representation of PB-mediated tumor promo-
tion, as it emerges from our study. (a) Illustration of the PB-
mediated tumor promotion process and the aspects elucidated by the
four experimental studies that we analyze. KO of b-catenin identifies
regulators downstream of b-catenin in physiological conditions (yellow
arrow). This study and previous analyses suggest that all regulatory
effects of PB treatment are downstream of CAR activation (brown
arrow and black circle). This study’s motif activity and SVD analysis
of the early kinetic time course identified three key biological processes
induced by PB treatment: a transient mitogenic response, which is also
associated with a late resurgence of proliferation (I, red), a sustained
xenobiotic response (II, yellow) and a late response which is likely
involved in establishing a tumor-prone environment (III, blue).
Comparison of promoted and non-promoted tumors identifies motifs
dysregulated in all tumors and in promoted tumors only (gray arrows).
(b–d) Summary of the key regulators of liver tumor promotion
organized according to biological processes (colored boxes matching
the colors of processes I, II and III in panel a) with arrows indicating
regulatory interactions between regulators and on selected target genes.
(b) E2F and ZFP161 regulate PB-mediated hepatocyte proliferation at
the early and promoted tumor stage. E2F is downstream of b-catenin
signaling and likely induces both DNA replication, via upregulation of
E2f1,2 and aborted cytokinesis via upregulation of E2f8 and c-myc.
ZFP161 is likely involved in the G0–G1 transition via transcriptional
repression of transcriptional repressors of cell growth and cell cycle. (c)
NFE2, downstream of b-catenin as well is involved in the sustained
xenobiotic response, upregulating proteasome activity and the oxidative
stress response. (d) PB-mediated suppression of ESR1 activity underlies
development of a tumor-prone environment, most likely through re-
pression of tissue morphogenesis. b-Catenin signaling represses ESR1.
(e) Key regulators involved in tumorigenesis, i.e. dysregulated in both
promoted and non-promoted tumors. Increased SOX{8,9,10} activity
likely regulates hepatocyte mitosis and proliferation via upregulation of
cyclins. Decrease in NR5A1,2 activity is detected after 3 months of PB
treatment and maintained in tumor samples and therefore a good early
indicator of hepatocyte loss-of-function associated with tumorigenesis.
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by the E2F family of TFs is one of the key factors posi-
tively contributing to the early proliferative response upon
PB treatment. In addition, E2F is upregulated in
promoted tumors, but not in non-promoted tumors.
Importantly, the absence of E2F motif modulation in
non-promoted tumors argues against the hypothesis that
the motif is simply reflecting increased proliferative
activity. Furthermore, the fact that KO of b-catenin in
physiological conditions leads to downregulation of E2F
activity implies that b-catenin positively regulates E2F
activity (either directly or indirectly) and suggests that
PB-mediated activation of b-catenin may contribute to
the upregulation of E2F activity at the tumor stage.
The plausibility of a role for E2F TFs in PB-mediated
tumor promotion is supported by numerous studies re-
porting a central role of distinct E2F family members in
hepatocellular carcinoma (60,61). More specifically, PB-
mediated modulation of E2F gene regulation in freshly
isolated hepatocytes has been previously suggested (62).
Here we show a highly specific upregulation of E2F
activity in promoted tumors and a potential role in
tumor promotion through b-catenin-mediated activation.
The E2F family contains eight different TFs that can
bind to the E2F motif and the MARA analysis does not
directly predict which of these eight TFs is mainly respon-
sible for the activity of the E2F regulatory motif in this
system. However, measurements of motif activity correl-
ation with mRNA expression of the TFs (Supplementary
Figure S4 and Supplementary Table S6) shows that the
expression of E2F1, E2F2 and E2F8 exhibit the most sig-
nificant correlation with E2F motif activity in the time
course and tumor studies. This makes these TFs the
most likely candidates for driving the E2F motif activity,
but it should be noted that motif activity changes do not
necessarily require changes in mRNA levels of the
binding TFs, i.e. the activity change may be due to post-
translational modifications, nuclear localization, etc. E2F7
and E2F8 have been recently shown to play a key role in
positively regulating hepatocyte polyploidy (63,64).
Interestingly, Myc has been shown to be an additional
positive regulator of polyploidy in hepatocytes (65,66).
Furthermore, both E2f8 and c-myc are significantly
upregulated in promoted tumors only and both are pre-
dicted targets of E2F. Given that ligands of nuclear recep-
tors such as PB and TCPOBOP have been shown to cause
liver polyploidization (59,67,68), we propose that both
E2F1 and E2F8 are responsible for the E2F activity
modulation at the tumor stage and that they regulate
distinct cell cycle checkpoints, in particular, regulation
of entry in S-phase for E2F1 and inhibition of cytokinesis
for E2F8 together with Myc (Figure 6b).
ZFP161 as transcriptional repressor involved in the
PB-mediated proliferative response at both the early and
tumor stages
Our analysis revealed a decrease in activity of the motif
bound by ZFP161 (also known as ZF5), i.e. an overall
downregulation of its predicted targets upon PB treatment
contributing to the early transient proliferative response.
In addition, ZFP161 targets are downregulated in
promoted tumors, but not in non-promoted tumors.
Affymetrix gene expression analysis shows that while
ZFP161 is not transcriptionally regulated by PB and its
mRNA expression is not correlated with motif activity
(Supplementary Figure S3), it is clearly expressed in the
liver (log2 e ' 8:0).
Although ZFP161 has been shown to be preferentially
active in differentiated tissues with little mitotic activity
(69), where it was shown to act as a transcriptional repres-
sor of c-myc (70,71), we here show an increase in ZFP161
transcriptional repression of target genes enriched in tran-
scriptional repressors (i.e. Mxi1 and Klf10), several of
these being negative regulators of cell cycle and cell
growth. Therefore, we hypothesize that ZFP161 partici-
pates in the PB-mediated regulation of quiescent hepato-
cyte G0–G1 transition at both the early and tumor stages,
by repressing negative regulators of cell cycle and positive
regulators of apoptosis (Figure 6b).
The progressive PB-mediated downregulation of ESR1
contributes to establishing a tumor-prone environment
PB-mediated tumorigenesis involves dynamic changes in
tissue composition, and the adaptive response of the liver
to chronic stress eventually leads to the establishment of a
tumor-prone environment. The identification of key
factors that contribute to this process could provide
valuable insight into the development of PB-mediated
tumorigenesis. Our analysis identified ESR1 as a factor
progressively downregulated upon chronic PB exposure,
starting in the third month of PB treatment. In addition,
ESR1 activity is downregulated in promoted tumors, but
not in non-promoted tumors. These two observations
make ESR1 a strong candidate regulator for the process
of establishing a tumor-prone environment. Furthermore,
b-catenin KO in physiological conditions leads to
upregulation of ESR1 activity, implying that b-catenin
represses (directly or indirectly) ESR1. Further supporting
this direct link between b-catenin and ESR1 repression is
the fact that the highest correlations between ESR1
activity and mRNA expression levels are observed in the
b-catenin KO and tumor studies, i.e. precisely those ex-
periments where b-catenin activity is predicted to change
(Supplementary Figure S3). Importantly, a physical inter-
action between b-catenin/TCF-4 and ESR1 has already
been reported in other physiological contexts (72,73).
That ESR1 can have tumor suppressor activity is sup-
ported by various studies (4,74–77). However, here we
propose more specifically that the progressive suppression
of ESR1 activity from early hyperplastic tissue to cancer
(78) is mediated by PB chronic exposure and is one of the
mechanisms underlying PB-mediated liver tumor promo-
tion due to negative regulation of tissue morphogenesis
(Figure 6d).
NFE2 as a regulator of exacerbated xenobiotic response
associated with promoted tumors
Our analysis revealed that PB treatment causes a constant
upregulation of homeostatic processes via NFE2 activa-
tion of proteasome and oxidative stress biological
processes during the early phases of treatment and that
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this upregulation persists into promoted tumors
(Figure 6c). Of note, NFE2 regulatory activity in homeo-
static processes has been shown in a recent study (49).
This upregulation of NFE2 in tumors compared to the
surrounding tissue is specific to promoted tumors.
Furthermore, the fact that NFE2 activity is
downregulated upon b-catenin KO in physiological con-
ditions strongly suggests that b-catenin signaling is posi-
tively regulating NFE2 activity. As b-catenin is also
involved in the regulation of drug metabolizing enzymes
in the liver (79–82), we hypothesize that NFE2 and
b-catenin cooperate in regulating genes involved in drug
metabolism and that the xenobiotic response is partly
exacerbated in promoted samples upon constitutive acti-
vation of b-catenin, resulting in further upregulation of
NFE2.
Regulators of liver tumorigenesis
Our analysis identified several regulators of liver tumori-
genesis (Supplementary Table S3). Interestingly, NR5A1,2
downregulation is observed early in the process of tumor
promotion (after 3 months of PB treatment). Given its
apparent role in hepatocyte liver function regulation
(Supplementary Figure S1) we hypothesize that
NR5A1,2 is associated with hepatocyte loss of function
(Figure 6e). SOX{8,9,10} is an additional regulator of
liver tumorigenesis and our analysis indicates a role in
hepatocyte proliferation. Finally, comparing functional
enrichment between the target genes of SOX{8,9,10} and
E2F at tumor stage revealed that while E2F specifically
regulates DNA replication (Supplementary Figure S2),
SOX{8,9,10} preferentially targets mitotic genes
(Supplementary Figure S1). These results support our hy-
pothesis that E2F targets cell cycle check points that are
distinct from those shared with other tumors.
Future extensions of the modeling approach
In future work we will aim to address several limitations
of the current modeling approach. First and foremost,
the method is currently limited to inferring the activities
of only those TFs for which sequence specificities are
known, i.e. roughly 350 of the approximately 1500
mouse TFs. For example, we were not able to predict
CAR motif activity as there is, to our knowledge, no
high quality sequence motif available for CAR. This is
not an intrinsic limitation of the method and as regulatory
motifs for an increasing number of TFs becomes available,
they can easily be incorporated into the method.
Another major limitation of MARA is that it currently
focuses solely on predicted TFBSs in proximal promoters,
ignoring the effects of distal enhancers. Although a
number of combined experimental and computational
methods have been put forward recently that allow
genome-wide mapping of active enhancers [e.g. (83)],
these methods require considerable investment and
enhancer maps are only available for a small set of
selected model systems. As the locations of relevant en-
hancers vary highly across tissues and model systems, suc-
cessful incorporation of enhancers into MARA requires
the availability of enhancer maps for the specific system
under study.
Most importantly, all the hypotheses discussed in this
work are based on analysis of high-througput data and
future experimental studies will be required to characterize
our inferred TF activities in more detail at the biochemical
level. Such studies may include chromatin immunopre-
cipitation (ChIP) assays on liver tissue from control and
phenobarbital-treated mice.
CONCLUSION
We have demonstrated that by combining motif activity
response analysis with SVD, we are able to automatically
untangle the regulatory activities underlying the perturb-
ation of multiple biological pathways in complex in vivo
systems and derive novel hypotheses regarding the key
regulators and their role in the process. Our analyses
provide novel mechanistic insight for PB-mediated
tumor promotion in the mouse liver, including the identi-
fication of E2F and ZFP161 as regulators of PB-mediated
hepatocyte proliferation at both early and tumor stages
and progressive PB-mediated suppression of ESR1
activity that may contribute to the development of a
tumor-prone environment. These findings may also help
identify novel biomarkers for assessing the carcinogenic
potential of xenobiotics.
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1 Supplementary Material and Methods
1.1 Gene expression datasets
A library of 109 genomewide mRNA expression patterns was compiled from four different studies (Figure
1a): 70 samples from a time series of expression data from liver samples of B6C3F1 vehicle- (i.e. control) or
PB-treated mice at +1, +3, +7, +14, +28, +57 and +91 days of dosing (5 replicates) [1]; 8 mRNA expression
patterns in livers of wild-type and hepatocyte-specific β-catenin knockout C3H/N [2] animals; 13 mRNA expres-
sion patterns in livers of wild-type and CAR knock-out C3H/N animals DEN-initiated at 5 weeks of age prior
to 23 weeks of PB -or vehicle-treatment [3]. Datasets on global mRNA expression patterns (18 samples) from
liver tumors and corresponding surrounding normal tissue of C3H/N animals DEN-initiated at 4 weeks of age
prior to 35 weeks of PB- or vehicle-treatment were available to us from IMI-MARCAR partners (Unterberger
et al,(2013), manuscript submitted). Screening the tumors for mutations in Ha-ras, B-raf and Ctnnb1 (i.e.
the β-catenin coding gene) confirmed that promoted tumors (from animals exposed to PB) were mutated in
Ctnnb1 while non-promoted tumors were mutated in Ha-ras (data not shown, Unterberger et al, 2013). In all
four studies gene expression was profiled using Affymetrix GeneChip MOE-4302 (Affymetrix, Santa Clara, CA)
containing approximately 43,000 probe sets.
1.2 Affymetrix GeneChip processing
The analysis of the micro-array data was done with the R statistical package version 2.13 (2005) and Biocon-
ductor libraries version 1.4.7 [4]. The four original data-sets containing Affymetrix CEL files were normal-
ized independently using the Robust Multichip Average (RMA) implementation of the algorithm available in
R/Bioconductor [4], producing four expression matrices, and the quality of the experiments was assessed using
diverse statistics implemented in the package arrayQualityMetrics for R/Bioconductor [5].
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2 Supplementary Results
2.1 Regulators associated with termination of developmental liver growth (!v1)
To determine motifs underlying the four characteristic modes identified in this study, we selected motifs which
contributed and correlated the most with each of the four singular vectors (Figure 3c,d,e,f). In this way we
obtained, for each of the 4 singular vectors, two clusters of motifs with similar activity profiles, i.e. one correlat-
ing negatively with the singular vector, and one correlating positively (Figures 3d,f). We further refined the
selection of the motifs associated with first singular vector as follows: 1) removing motifs for which the overall
significance was lower than z < 1.5 and 2) removing motifs whose cognate TFs were not expressed in the liver
(log-expression less than 6.0) log2 e ≤ 6.0). This lead to the identification of 6 motifs motifs (Supplementary
Table S1).
As originally observed in [1], completion of the post-natal liver development process occurs during the early
PB-treatment time course, consisting in both hepatocyte proliferation at early stage, and progressive induction
of liver-specific genes [6, 7]. We here identify key regulators of these two processes: 1. we show that post-natal
liver growth (that decreases over time) is regulated by known regulators of cell proliferation such as the E2F
family of TFs [8, 9, 10], SRF [11] and Myc [12, 13]; predicted target genes of these motifs have functions related
to cell cycle and DNA replication (Supplementary Figure S6i), confirming the role of these regulators in cell
proliferation. 2. We show that post-natal liver differentiation (which increases over time) is partly regulated
by AHR, a known regulator of drug-metabolizing genes and transporters [14, 15, 16, 17] that has been shown
to play key role in liver development [18]. Thus, the main biological process associated positively with the
first singular vector is cellular proliferation associated with post-natal liver growth for the first two weeks of
the time course. Conversely, the targets of the motifs that are negatively associated with the first singular
vector, i.e. corresponding to genes that increase their expression after the first two weeks, are enriched for
functions associated with hepatocyte terminal differentiation, such as ‘liver development’, ‘drug metabolism’
and ‘transcriptional regulation’.
2.2 Singular value decomposition analysis of the activity matrix of the CAR KO
data-set
In order to identify and quantify the sources of motif activity changes in the CAR KO data-set, we performed
Singular Value Decomposition (SVD) of the activities of the 189 motifs across the four conditions (PB- and
vehicle treated livers from wild-type and CAR KO mice). Over 50% of the variance in the activity matrix was
explained by the first two components of the SVD as evidenced by the spectrum of singular values (Figure S6a).
In order to facilitate the biological interpretation of the singular vectors, we plotted the averaged activities
of the right singular vectors vks over each of the four sample groups and further identified regulatory motifs
whose activity profiles correlate most strongly (either positively or negatively) with the activity profile of the
singular vector. Visualization of the averaged activity of the first two singular vectors "v1 and "v2 in each of the
four sample groups is shown in Figure S6b and scatter plots of the correlations ρi and projections pi of all
motifs i with the first and second right singular vectors are shown in Figure S6c.
The first right singular vector accounts for 33% of the variance and is characterized by a positive activity
upon PB treatment in wild-type animals only. Given the absence of positive activity in CAR KO treated
animals, we propose that this component represents the liver response to PB that is CAR-dependent. More-
over motifs which contribute and correlate most strongly with the first singular vector (TBP, NFE2, REST,
GLI1,2,3, FOSL2, ELK1,2, and ZNF143) are all down-stream of CAR signaling under PB treatment (Table
S2) except CTCF, RXRG-dimer and STAT5{A,B}, further supporting the association of this component with
the CAR-dependent liver response to PB treatment.
The second right singular vector accounts for 18% of the variance and is characterized by 1) a lower activ-
ity in wild-type liver samples compared to CAR KO samples, and 2) by an activity further lowered upon PB
treatment in both wild-type and CAR KO samples (Figure S6b). We propose that this component represents
the basal liver activity down-stream of CAR that is further exacerbated upon PB treatment. However the
motifs that contribute and correlate most strongly with the second singular vector do not coincide with any of
the 5 motifs identified by differential motif activity analysis as down-stream of CAR signaling under physiolog-
ical condition (Table S2). Furthermore the average activities have large associated error-bars for each sample
group, indicating that the interpretation of this component must be considered with caution.
In conclusion, the SVD-based analysis of the activity matrix of the CAR KO data-set indicates that the major
2
source of motif activity changes in these liver samples is the CAR-dependent liver response to PB treatment.
This result is in line with the analysis based on differential motif activity. Importantly, prior biological knowl-
edge indicates that at least two biological processes are occurring in this system, i.e the CAR KO effect and
the xenobiotic response to PB treatment. Differential motif activity previously showed only a very minor CAR
KO effect (only 5 motifs identified as down-stream of CAR signaling under physiological condition, see Table
S2) that may explain the absence of strong association of any component with this biological process.
2.3 Singular value decomposition analysis of the activity matrix of the tumor
study data-set
In order to identify and quantify the sources of motif activity changes in the tumor data-set, we performed
Singular Value Decomposition (SVD) of the activities of the 189 motifs across the four conditions (PB- and
vehicle treated normal and tumorigenic liver samples). Over 57% of the variance in the activity matrix was
explained by the first two components of the SVD that are the two significant components of the matrix, as
evidenced by the spectrum of singular values (Figure S7a).
In order to facilitate the biological interpretation of the singular vectors, we plotted the averaged activities
of the right singular vectors vks over each of the four sample groups and further identified regulatory motifs
whose activity profiles correlate most strongly (either positively or negatively) with the activity profile of the
singular vector. Visualization of the averaged activity of the first two singular vectors "v1 and "v2 in each of the
four sample groups is shown in Figure S7b and scatter plots of the correlations ρi and projections pi of all
motifs i with the first and second right singular vectors are shown in Figure S7c.
The first right singular vector accounts for 32% of the variance (Figure S7a) and is characterized by 1) a higher
activity in PB-treated samples relative to non-treated samples, 2) an increased positive activity in promoted
tumor samples relative to all other sample groups (normal treated and non-treated samples, and non-treated
tumor samples) and 3) a slight decreased activity in non-promoted tumor samples relative to surrounding nor-
mal tissue (Figure S7b). Moreover several motifs which contribute and correlate most strongly with the first
singular vector (NFE2, E2F1-5, PBX1, and ESR1) as depicted in Figure S7c, have been identified as specific
regulators of promoted tumors by differential motif activity analysis (see Table S4). These results indicate
that motifs associated with this component are generally associated with a response to PB treatment which is
further 1) exacerbated in promoted tumor samples and 2) inhibited in non-treated tumor samples, suggesting
that the first component captures motifs associated with biological pathways underlying promoted tumors that
are already up-regulated upon PB treatment and down-regulated in non-promoted tumors.
The second right singular vector accounts for 25% of the variance (Figure S7a) and is characterized by an
overall decreased activity in tumor samples relative to normal samples, irrespective of the PB treatment (Figure
S7b); this suggests that the second component captures motifs associated with biological pathways underlying
tumorigenesis. It is however noteworthy that none of the motifs which contribute and correlate most strongly
with the second singular vector (Figure S7c) were identified as regulators of tumorigenesis by differential motif
activity analysis (Table S3). One explanation for this could be a strong variability in activity profiles leading
to low Z-value of differential activity.
In conclusion the SVD-based analysis of the activity matrix allows for the identification of 1) regulators of
promoted tumors (first component) which are consistent with those identified by differential motif activity anal-
ysis, and 2) regulators of liver tumorigenesis, which were not identified by differential motif activity analysis,
potentially due to high noise to signal ratio.
3
3 Supplementary figures
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Figure S1: Selection of representative biological terms and processes associated with the predicted target
genes of motifs which activities were significantly (a) higher or (b) lower in promoted tumors relative to
surrounding treated normal tissue, and in non-promoted tumors relative to surrounding non-treated normal
tissue (Supplementary Table S3). Bars are colored according to motif to which the target genes are asso-
ciated with. Bar height indicates significance of functional enrichment as it represents the −log10(P−Value)
of functional enrichment in the given biological term or process as obtained from the DAVID Bioinformatic
Resource (Database for Annotation, Visualization and Integrated Discovery) [19, 20] version 6.7, sponsored by
the National Institute of Allergy and Infectious Disease (NIAID), NIH.
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Figure S2: Selection of representative biological terms and processes associated with the predicted target genes
of motifs which activity was significantly (a) lower or (b) higher in promoted tumors relative to surrounding
treated normal tissue, but that did not change in non-promoted tumors relative to surrounding non-treated
normal tissue (Supplementary Table S4). Bars are colored according to motif to which the target genes are
associated with. Bar height indicates significance of functional enrichment as it represents the −log10(P−Value)
of functional enrichment in the given biological term or process as obtained from the DAVID Bioinformatic
Resource (Database for Annotation, Visualization and Integrated Discovery) [19, 20] version 6.7, sponsored by
the National Institute of Allergy and Infectious Disease (NIAID), NIH.
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Figure S3: Correlation between motif activities and mRNA expression of cognate transcription factors. (a)
Heatmap of the Pearson correlation coefficients (PCC) between the motif activities and mRNA expression
profiles of associated TFs for a selection of TFs specifically dysregulated in promoted tumors. Each column
corresponds to one of the 4 experimental data-sets (black = kinetic study, green = β-catenin KO study, red
= CAR KO study and blue = tumor study) and PCC is indicated by color running from −1 (green), to 1
(purple). PCCs close to zero are colored white. (b) Scatter plots of motif activities against mRNA expression
of associated TFs for a selection of 4 TFs. Each column of panels corresponds to one TF and each row of panels
corresponds to one of the 4 experimental data-sets.
0
2
4
6
Time [days]
1                3                   7                 14             28              57              91
lo
g
2
 e
xp
re
ss
io
n
control
phenobarbital
Figure S4: Alpha fetoprotein (Afp) gene expression in liver samples from 13 week kinetic data-sets as a surrogate
gene of post-natal liver development termination. Gene expression is given as mean ±SD (n=3-5 animals per
group). Open bars = control. Black bars = phenobarbital-treated samples.
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Figure S5: Gene Ontology and KEGG enrichment analysis of predicted targets for motifs underlying early PB-
mediated transcriptional dynamics. (a-d) Plots of the activity profiles of the first four right singular vectors.
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Figure S6: Singular Value Decomposition analysis of the activity matrix of the CARKO data-set. (a) Proportion
of the variance of the motif activity matrix. The first (blue bar) and second (green bar) components account for
33% and 18% respectively of the variance. (b) Barplot of the activity of the first two right singular vectors v1
and v2 in corresponding samples. White bars indicate activities for the control samples and black bars activities
for the PB-treated samples. (c) Scatter plot of the correlations ρi and projections pi of all motifs i with the first
and second right singular vectors respectively. Grey and black dots depict negatively and positively selected
motifs.
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Figure S7: Singular Value Decomposition analysis of the activity matrix of the tumor data-set. (a) Proportion
of the variance of the motif activity matrix captured by the first singular vectors. The first (blue bar) and second
(green bar) components account for 32% and 25% respectively of the variance. (b) Barplot of the activity of
the first two right singular vectors v1 and v2 across the corresponding samples. White bars indicate activities
for the normal samples and black bars activities for the tumor samples. (c) Scatter plot of the correlations ρi
and projections pi of all motifs i with the first and second right singular vectors respectively. Grey and black
dots depict negatively and positively selected motifs.
9
4 Abbreviations contained in Tables S1-S5
Tables S1-S5 contain motifs corresponding to specific groups that are
1. Table S1 - motifs associated with the first four singular vectors obtained from singular value decomposition
(SVD) of the inferred motifs activity matrix from early kinetic study
2. Table S2 - motifs down-stream of CAR signaling
3. Table S3 - motifs dysregulated in both promoted and non-promoted tumors
4. Table S4 - motifs specifically dysregulated in promoted tumors
5. Table S5 - motifs down-stream of β-catenin signaling.
They are all formatted in the same way and their abbreviations are described in the following:
1. Representative motifs associated with the first four singular vectors obtained from SVD of the inferred
motifs activity matrix from early kinetic study
PC1 = first singular vector associated with liver maturation
PC2 = second singular vector associated with constant xenobiotic response
PC3 = third singular vector associated with transient mitogenic response
PC4 = fourth singular vector associated with progressive xenobiotic response
+ = motifs correlating positively with corresponding singular vector
− = motifs correlating negatively with corresponding singular vector
2. Z-value of motif significance that quantifies the significance of each motif in explaining the observed gene
expression variation across the samples in the specified data-set
S1 = kinetic data-set
S2 = β-catenin KO data-set
S3 = CAR KO data-set
S4 = tumor data-set.
3. Z-values of differential motif activity that quantifies the evidence for a different regulatory activity of the
motif between the tow following conditions
di = PB-treated and control samples at corresponding time-point
KO = knock-out and wild-type samples
PB, wt = PB-treated and non-treated wild-type samples of the KO data-sets
PB, ko = PB-treated and non-treated KO samples of the KO data-sets
β-catenin = promoted tumors and treated surrounding normal tissue
H-ras = non-promoted tumors and surrounding non-treated normal tissue.
5 Supplementary Tables
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0
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7
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9
Table S1: Representative motifs of the first four singular vectors (explaining over 70% of the variance in the
activity matrix) obtained from singular value decomposition of the inferred motifs activity matrix from early
kinetic study, and underlying the early dysregulated biological pathways. Z-values of differential activity were
computed as explained in Material and Method section of the main manuscript.
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Table S2: Motifs which activities are significantly changing either 1) upon CAR KO in non-treated samples
and thus potentially down-stream of CAR signaling under physiological condition, or under PB treatment 2)
only in CAR wild-type samples and thus potentially down-stream of CAR signaling under PB treatment, or 3)
only in CAR KO samples. Z-values of differential activity were computed as explained in Material and Method
section of the main manuscript.
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Table S3: Motifs which activities are significantly changing in promoted tumors relative to surrounding treated
normal tissue, and in non-promoted tumors relative to surrounding non-treated normal tissue. These motifs are
thus candidate regulators of liver tumorigenesis. Z-values of differential activity were computed as explained in
Material and Method section of the main manuscript.
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Table S4: Motifs which activities are significantly changing in promoted tumors relative to surrounding treated
normal tissue, but not in non-promoted tumors relative to surrounding non-treated normal tissue. These motifs
are thus candidate regulators of tumor promotion. Z-values of differential activity were computed as explained
in Material and Method section of the main manuscript.
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Table S5: Motifs which activities are significantly changing upon β-catenin KO in non-treated samples and thus
potentially down-stream of β-catenin signaling under physiological condition. Z-values of differential activity
were computed as explained in Material and Method section of the main manuscript.
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Affx GS Motifs PCC P-value PCC P-value PCC P-value PCC P-value
1450695−at Ahr AHR,ARNT,ARNT2 -0.09 5.1E-01 0.73 3.87E-02 -0.43 9.3E-02 -0.45 9.2E-02
1421721−a−at Arnt ARNT,ARNT2,BHLHB2,MAX,MYC,USF1 0.20 1.1E-01 -0.45 2.62E-01 0.43 9.9E-02 0.06 8.4E-01
1434028−at Arnt2 ARNT,ARNT2,BHLHB2,MAX,MYC,USF1 0.07 5.9E-01 -0.19 6.54E-01 -0.05 8.6E-01 0.63 1.2E-02
1418025−at Bhlhe40 ARNT,ARNT2,BHLHB2,MAX,MYC,USF1 -0.41 8.1E-04 0.26 5.26E-01 0.33 2.1E-01 0.33 2.3E-01
1423501−at Max ARNT,ARNT2,BHLHB2,MAX,MYC,USF1 0.01 9.3E-01 -0.07 8.65E-01 0.04 8.8E-01 -0.06 8.3E-01
1424942−a−at Myc ARNT,ARNT2,BHLHB2,MAX,MYC,USF1 0.11 4.1E-01 -0.20 6.36E-01 -0.02 9.5E-01 -0.28 3.2E-01
1448805−at Usf1 ARNT,ARNT2,BHLHB2,MAX,MYC,USF1 0.10 4.2E-01 0.55 1.54E-01 0.25 3.4E-01 0.34 2.1E-01
1438992−x−at Atf4 ATF4 0.21 1.0E-01 -0.23 5.76E-01 0.42 1.1E-01 -0.54 3.8E-02
1425927−a−at Atf5 ATF5,CREB3 -0.40 1.1E-03 0.70 5.15E-02 0.28 2.9E-01 -0.51 5.3E-02
1419979−s−at Creb3 ATF5,CREB3 0.45 2.1E-04 0.91 1.85E-03 -0.07 7.9E-01 -0.36 1.9E-01
1456021−at Atf6 ATF6 0.26 4.5E-02 -0.46 2.56E-01 0.63 9.2E-03 0.72 2.2E-03
1449582−at Cdx1 CDX1,2,4 0.06 6.4E-01 -0.25 5.58E-01 -0.32 2.3E-01 0.22 4.3E-01
1422074−at Cdx2 CDX1,2,4 -0.01 9.3E-01 0.52 1.88E-01 -0.53 3.6E-02 -0.01 9.6E-01
1421552−at Cdx4 CDX1,2,4 0.10 4.3E-01 -0.23 5.89E-01 0.15 5.7E-01 0.27 3.4E-01
1452901−at Creb1 CREB1 0.59 4.5E-07 0.75 3.21E-02 -0.11 6.9E-01 -0.09 7.4E-01
1449042−at Ctcf CTCF 0.08 5.2E-01 0.25 5.49E-01 0.09 7.3E-01 0.30 2.7E-01
1418330−at Ctcf CTCF 0.21 1.0E-01 -0.12 7.83E-01 0.42 1.1E-01 -0.12 6.6E-01
1417878−at E2f1 E2F 0.75 2.0E-12 -0.21 6.26E-01 0.58 1.9E-02 0.59 2.1E-02
1455790−at E2f2 E2F 0.83 0.0E+00 0.80 1.83E-02 0.64 7.7E-03 0.59 2.0E-02
1434564−at E2f3 E2F 0.20 1.3E-01 -0.23 5.89E-01 0.79 2.6E-04 0.59 2.0E-02
1451480−at E2f4 E2F -0.39 1.6E-03 0.18 6.70E-01 -0.88 8.7E-06 -0.16 5.7E-01
1447625−at E2f5 E2F 0.23 6.7E-02 -0.50 2.09E-01 -0.56 2.6E-02 -0.21 4.5E-01
1448835−at E2f6 E2F 0.15 2.4E-01 0.93 7.61E-04 0.49 5.2E-02 0.65 9.1E-03
1437187−at E2f7 E2F 0.48 8.9E-05 0.45 2.66E-01 -0.06 8.3E-01 -0.53 4.0E-02
1436186−at E2f8 E2F 0.78 1.0E-13 0.43 2.93E-01 0.55 2.8E-02 0.62 1.5E-02
1439319−at Elf1 ELF1,2,4 0.18 1.7E-01 -0.40 3.26E-01 0.34 2.0E-01 0.23 4.0E-01
1428045−a−at Elf2 ELF1,2,4 0.58 8.6E-07 0.57 1.39E-01 0.30 2.6E-01 0.33 2.2E-01
1421337−at Elf4 ELF1,2,4 -0.14 2.7E-01 -0.21 6.21E-01 -0.37 1.6E-01 -0.42 1.2E-01
1446390−at Elk1 ELK1,4,GABP{A,B1} -0.02 8.7E-01 0.43 2.91E-01 -0.56 2.5E-02 -0.18 5.2E-01
1422233−at Elk4 ELK1,4,GABP{A,B1} -0.19 1.4E-01 -0.40 3.24E-01 -0.46 7.1E-02 -0.20 4.8E-01
1450665−at Gabpa ELK1,4,GABP{A,B1} 0.58 1.0E-06 0.03 9.38E-01 0.15 5.7E-01 0.05 8.7E-01
1436232−a−at Gabpb1 ELK1,4,GABP{A,B1} -0.13 3.1E-01 -0.53 1.76E-01 0.50 5.1E-02 0.17 5.5E-01
1460591−at Esr1 ESR1 0.40 1.4E-03 0.87 4.48E-03 0.51 4.5E-02 0.66 7.9E-03
1425886−at Fev FEV 0.13 3.3E-01 -0.24 5.60E-01 0.35 1.9E-01 -0.16 5.7E-01
1423100−at Fos FOS,FOS{B,L1},JUN{B,D} -0.14 2.9E-01 0.41 3.08E-01 0.55 2.9E-02 0.92 1.6E-06
1422134−at Fosb FOS,FOS{B,L1},JUN{B,D} -0.08 5.5E-01 0.05 9.14E-01 0.29 2.7E-01 -0.03 9.2E-01
1417487−at Fosl1 FOS,FOS{B,L1},JUN{B,D} 0.08 5.5E-01 -0.39 3.34E-01 0.74 9.3E-04 0.38 1.7E-01
1422931−at Fosl2 FOSL2 -0.16 2.1E-01 -0.45 2.65E-01 0.63 8.8E-03 -0.34 2.1E-01
1434939−at Foxf1 FOX{F1,F2,J1} -0.57 1.2E-06 0.19 6.52E-01 -0.60 1.4E-02 -0.10 7.3E-01
1447562−at Foxf2 FOX{F1,F2,J1} 0.38 2.2E-03 0.44 2.71E-01 0.15 5.8E-01 -0.05 8.7E-01
1425291−at Foxj1 FOX{F1,F2,J1} 0.20 1.1E-01 -0.21 6.26E-01 -0.33 2.1E-01 -0.46 8.6E-02
1449458−at Foxi1 FOX{I1,J2} -0.32 1.0E-02 -0.05 9.16E-01 -0.15 5.8E-01 0.32 2.5E-01
1420374−at Foxj2 FOX{I1,J2} -0.11 4.0E-01 0.32 4.33E-01 0.23 3.9E-01 0.06 8.2E-01
1422210−at Foxd3 FOXD3 -0.41 9.5E-04 -0.84 8.88E-03 0.26 3.2E-01 -0.35 2.1E-01
1423027−at Foxl1 FOXL1 -0.03 8.1E-01 -0.68 6.33E-02 -0.47 6.7E-02 0.64 1.1E-02
1449232−at Gata1 GATA1-3 -0.09 5.1E-01 -0.15 7.17E-01 0.20 4.5E-01 0.04 8.9E-01
1428816−a−at Gata2 GATA1-3 0.02 8.9E-01 -0.15 7.15E-01 0.43 9.3E-02 0.36 1.8E-01
1448886−at Gata3 GATA1-3 0.18 1.5E-01 -0.82 1.34E-02 0.05 8.6E-01 -0.71 2.8E-03
1425464−at Gata6 GATA6 0.06 6.7E-01 -0.49 2.20E-01 -0.50 4.8E-02 -0.24 3.9E-01
1449058−at Gli1 GLI1-3 0.11 3.9E-01 -0.19 6.56E-01 0.29 2.7E-01 0.62 1.3E-02
1446086−s−at Gli2 GLI1-3 0.23 7.0E-02 -0.40 3.20E-01 -0.25 3.5E-01 -0.06 8.3E-01
1455154−at Gli3 GLI1-3 0.18 1.5E-01 0.65 7.81E-02 0.01 9.8E-01 -0.01 9.6E-01
1450525−at Gli3 GLI1-3 0.27 3.5E-02 0.17 6.92E-01 -0.54 3.0E-02 0.44 9.7E-02
1454631−at Gtf2a1 GTF2A1-2 -0.60 2.5E-07 0.82 1.29E-02 -0.44 9.0E-02 -0.43 1.1E-01
1460367−at Hbp1 HBP1,HMGB,SSRP1,UBTF 0.46 1.7E-04 -0.75 3.24E-02 0.26 3.4E-01 0.61 1.5E-02
1438307−at Hmgb2 HBP1,HMGB,SSRP1,UBTF 0.13 3.2E-01 -0.65 7.81E-02 -0.41 1.1E-01 -0.51 5.3E-02
1416155−at Hmgb3 HBP1,HMGB,SSRP1,UBTF 0.20 1.3E-01 -0.76 2.71E-02 -0.20 4.5E-01 -0.80 3.4E-04
1426788−a−at Ssrp1 HBP1,HMGB,SSRP1,UBTF 0.09 4.9E-01 0.71 5.05E-02 -0.70 2.6E-03 -0.49 6.5E-02
1460304−a−at Ubtf HBP1.HMGB.SSRP1.UBTF 0.69 6.7E-10 -0.18 6.69E-01 -0.12 6.5E-01 0.17 5.5E-01
1434736−at Hlf HLF -0.41 1.0E-03 0.10 8.20E-01 -0.68 4.0E-03 0.35 2.0E-01
1421234−at Hnf1a HNF1A 0.07 6.1E-01 0.45 2.63E-01 0.22 4.2E-01 -0.25 3.7E-01
1427000−at Hnf4a HNF4A,NR2F1,2 -0.02 9.0E-01 -0.43 2.86E-01 -0.35 1.8E-01 -0.64 1.1E-02
1418157−at Nr2f1 HNF4A,NR2F1,2 -0.33 9.4E-03 -0.47 2.45E-01 -0.22 4.1E-01 0.40 1.4E-01
1416159−at Nr2f2 HNF4A,NR2F1,2 0.45 2.3E-04 0.10 8.10E-01 -0.41 1.2E-01 0.69 4.1E-03
1427354−at Hoxa4 HOX{A4,D4} 0.05 7.2E-01 0.16 7.12E-01 0.72 1.6E-03 0.20 4.8E-01
1450209−at Hoxd4 HOX{A4,D4} 0.04 7.7E-01 0.40 3.29E-01 0.03 9.1E-01 0.11 7.0E-01
1448436−a−at Irf1 IRF1,2,7 0.49 5.8E-05 0.10 8.17E-01 0.44 8.9E-02 0.87 2.4E-05
1418265−s−at Irf2 IRF1,2,7 -0.20 1.2E-01 0.36 3.87E-01 -0.35 1.8E-01 -0.15 5.9E-01
1417244−a−at Irf7 IRF1,2,7 0.71 1.0E-10 0.75 3.30E-02 0.61 1.2E-02 0.19 5.1E-01
1439846−at Klf12 KLF12 -0.42 7.9E-04 0.57 1.41E-01 0.55 2.7E-02 0.04 9.0E-01
1417395−at Klf4 KLF4 0.00 9.7E-01 0.75 3.36E-02 0.46 7.3E-02 -0.20 4.8E-01
Table S6: Pearson correlation coefficient (PCC) and associate P -values between motif activities and mRNA
expression of cognate transcription factors in each data-sets - part 1. Part 2 in Table S7. Affx = probe-set ID
from Affymetrix platform Mouse 430 2. GS = gene symbol. PCC = Pearson correlation coefficient.
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Affx GS Motifs PCC P-value PCC P-value PCC P-value PCC P-value
1454734−at Lef1 LEF1,TCF7,TCF7L1,2 -0.03 8.4E-01 0.30 4.73E-01 -0.25 3.5E-01 0.49 6.2E-02
1433471−at Tcf7 LEF1,TCF7,TCF7L1,2 0.22 8.2E-02 0.46 2.52E-01 -0.26 3.3E-01 0.32 2.4E-01
1450117−at Tcf7l1 LEF1,TCF7,TCF7L1,2 0.22 8.0E-02 -0.76 2.86E-02 0.25 3.5E-01 -0.43 1.1E-01
1426639−a−at Tcf7l2 LEF1,TCF7,TCF7L1,2 0.32 1.2E-02 0.38 3.53E-01 0.45 8.3E-02 0.20 4.8E-01
1454086−a−at Lmo2 LMO2 -0.01 9.7E-01 0.22 5.95E-01 -0.60 1.5E-02 -0.25 3.6E-01
1429170−a−at Mtf1 MTF1 -0.55 3.4E-06 0.54 1.70E-01 -0.34 2.0E-01 -0.09 7.4E-01
1421317−x−at Myb MYB -0.20 1.2E-01 -0.33 4.19E-01 -0.07 8.1E-01 -0.24 4.0E-01
1452001−at Nfe2 NFE2 -0.27 3.5E-02 -0.71 4.74E-02 0.76 6.0E-04 0.22 4.3E-01
1457117−at Nfe2l2 NFE2L2 -0.35 4.8E-03 -0.35 3.97E-01 -0.21 4.3E-01 0.22 4.2E-01
1418932−at Nfil3 NFIL3 -0.07 5.7E-01 -0.31 4.49E-01 -0.55 2.7E-02 -0.10 7.3E-01
1427705−a−at Nfkb1 NFKB1,REL,RELA 0.24 5.8E-02 -0.83 1.02E-02 0.48 5.8E-02 0.28 3.1E-01
1420710−at Rel NFKB1,REL,RELA -0.44 3.1E-04 0.07 8.76E-01 0.18 5.2E-01 0.02 9.3E-01
1419536−a−at Rela NFKB1,REL,RELA 0.14 2.9E-01 0.55 1.62E-01 0.19 4.9E-01 0.13 6.3E-01
1427808−at Nfya NFY{A,B,C} -0.08 5.2E-01 0.24 5.73E-01 -0.35 1.9E-01 -0.47 7.8E-02
1419266−at Nfyb NFY{A,B,C} 0.32 1.2E-02 0.58 1.36E-01 0.70 2.6E-03 0.73 2.1E-03
1448963−at Nfyc NFY{A,B,C} 0.35 4.9E-03 0.36 3.87E-01 0.17 5.3E-01 -0.28 3.1E-01
1421112−at Nkx2-2 NKX2-2,8 -0.31 1.3E-02 0.35 3.96E-01 -0.09 7.3E-01 0.09 7.4E-01
1422284−at Nkx2-9 NKX2-2,8 -0.46 1.9E-04 -0.10 8.21E-01 -0.17 5.3E-01 -0.19 4.9E-01
1421464−at Nkx3-2 NKX3-2 0.21 9.5E-02 0.18 6.78E-01 -0.11 6.9E-01 -0.01 9.8E-01
1419105−at Nr1h4 NR1H4 -0.16 2.0E-01 -0.19 6.56E-01 0.38 1.5E-01 0.66 7.0E-03
1421730−at Nr5a1 NR5A1,2 0.26 4.4E-02 -0.20 6.29E-01 0.79 3.1E-04 0.37 1.7E-01
1449707−at Nr5a2 NR5A1,2 0.07 5.8E-01 -0.29 4.79E-01 0.21 4.4E-01 -0.41 1.3E-01
1421515−at Nr6a1 NR6A1 0.24 5.9E-02 0.37 3.69E-01 0.17 5.3E-01 0.38 1.6E-01
1424787−a−at Nrf1 NRF1 0.55 4.2E-06 -0.36 3.80E-01 0.33 2.0E-01 -0.08 7.9E-01
1460044−at Onecut2 ONECUT1,2 -0.27 3.3E-02 0.77 2.50E-02 0.41 1.2E-01 -0.29 2.9E-01
1428647−at Pbx1 PBX1 0.29 2.2E-02 -0.37 3.63E-01 0.47 6.8E-02 0.10 7.4E-01
1416967−at Sox2 POU5F1,SOX2{dimer} 0.45 2.7E-04 0.08 8.46E-01 0.20 4.6E-01 -0.23 4.1E-01
1452844−at Pou6f1 POU6F1 0.51 2.6E-05 -0.68 6.22E-02 0.21 4.3E-01 0.00 1.0E+00
1420425−at Prdm1 PRDM1 0.00 9.9E-01 -0.09 8.36E-01 0.36 1.7E-01 0.48 7.1E-02
1428227−at Rest REST -0.64 2.3E-08 -0.62 9.92E-02 -0.54 3.1E-02 -0.06 8.3E-01
1436059−at Rfx1 RFX1-5,RFXANK,RFXAP -0.10 4.4E-01 0.57 1.43E-01 -0.36 1.7E-01 -0.43 1.1E-01
1442578−at Rfx2 RFX1-5,RFXANK,RFXAP 0.23 7.3E-02 0.62 1.03E-01 0.55 2.6E-02 0.09 7.5E-01
1425413−at Rfx3 RFX1-5,RFXANK,RFXAP 0.27 3.5E-02 -0.77 2.68E-02 0.49 5.4E-02 0.19 5.1E-01
1436931−at Rfx4 RFX1-5,RFXANK,RFXAP 0.00 9.8E-01 0.78 2.20E-02 -0.59 1.6E-02 -0.32 2.5E-01
1425670−at Rfxank RFX1-5,RFXANK,RFXAP 0.44 3.9E-04 -0.11 7.94E-01 0.41 1.2E-01 0.23 4.0E-01
1455303−at Rfxap RFX1-5,RFXANK,RFXAP 0.53 1.1E-05 -0.08 8.59E-01 -0.34 2.0E-01 -0.10 7.1E-01
1440878−at Runx1 RUNX1-3 0.05 6.8E-01 0.64 8.89E-02 0.15 5.7E-01 0.43 1.1E-01
1425389−a−at Runx2 RUNX1-3 0.28 2.8E-02 -0.63 9.54E-02 0.29 2.8E-01 0.35 2.0E-01
1421467−at Runx3 RUNX1-3 -0.06 6.7E-01 0.59 1.22E-01 0.65 5.9E-03 0.31 2.7E-01
1454773−at Rxra RXR{A,B,G} 0.27 3.7E-02 0.88 3.55E-03 -0.17 5.4E-01 0.43 1.1E-01
1416990−at Rxrb RXR{A,B,G} -0.26 4.3E-02 0.09 8.27E-01 -0.04 8.9E-01 0.14 6.3E-01
1418782−at Rxrg RXR{A,B,G} 0.19 1.4E-01 0.24 5.68E-01 0.59 1.5E-02 -0.36 1.8E-01
1451689−a−at Sox10 SOX{8,9,10} 0.02 8.5E-01 -0.49 2.21E-01 -0.66 5.3E-03 -0.59 2.1E-02
1435438−at Sox8 SOX{8,9,10} -0.06 6.7E-01 -0.23 5.82E-01 0.17 5.2E-01 0.40 1.4E-01
1451538−at Sox9 SOX{8,9,10} -0.24 5.5E-02 0.74 3.66E-02 -0.64 7.7E-03 -0.19 5.0E-01
1418747−at Sfpi1 SPI1 -0.06 6.4E-01 0.08 8.59E-01 0.51 4.5E-02 0.25 3.6E-01
1418256−at Srf SRF 0.26 4.4E-02 0.22 6.08E-01 -0.02 9.5E-01 0.80 3.6E-04
1426470−at Tbp TBP -0.07 6.0E-01 0.07 8.74E-01 -0.46 7.1E-02 -0.61 1.5E-02
1429556−at Tead1 TEAD1 -0.02 9.0E-01 0.72 4.59E-02 0.40 1.2E-01 -0.13 6.5E-01
1436392−s−at Tfap2c TFAP{A,C} 0.07 6.1E-01 -0.70 5.47E-02 0.26 3.3E-01 0.45 9.2E-02
1426048−s−at Tfap2a TFAP2{A,C} 0.44 3.3E-04 0.36 3.75E-01 0.27 3.1E-01 0.47 7.4E-02
1435670−at Tfap2b TFAP2B -0.36 4.6E-03 -0.02 9.67E-01 -0.61 1.1E-02 -0.05 8.5E-01
1418167−at Tfap4 TFAP4 0.15 2.6E-01 -0.75 3.24E-02 -0.13 6.2E-01 -0.18 5.3E-01
1418159−at Tfcp2 TFCP2 -0.30 1.7E-02 -0.46 2.48E-01 -0.22 4.0E-01 -0.21 4.5E-01
1455273−at Zbtb6 ZBTB6 0.69 8.0E-10 0.52 1.83E-01 -0.39 1.3E-01 -0.01 9.7E-01
1420865−at Zbtb14 ZFP161 0.40 1.2E-03 -0.52 1.86E-01 -0.52 3.8E-02 0.30 2.8E-01
1422599−s−at Zfp143 ZNF143 0.41 8.4E-04 0.65 7.98E-02 0.74 1.1E-03 -0.14 6.1E-01
1436217−at Zfp148 ZNF148 -0.73 1.7E-11 -0.46 2.56E-01 -0.28 3.0E-01 -0.72 2.3E-03
1438047−at Zfp384 ZNF384 0.08 5.2E-01 -0.43 2.85E-01 0.08 7.6E-01 -0.19 4.9E-01
Table S7: Pearson correlation coefficient (PCC) and associate P -values between motif activities and mRNA
expression of cognate transcription factors in each data-sets - part 2. Affx = probe-set ID from Affymetrix
platform Mouse 430 2. GS = gene symbol. PCC = Pearson correlation coefficient.
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Chapter 4
Phenobarbital Induces Cell Cycle
Transcriptional Responses in Mouse
Liver Humanized for Constitutive
Androstane and Pregnane X
Receptors
This chapter contains the second manuscript of this thesis which describes a study where human relevance
of rodent humanized model in drug toxicity assessment is discussed in terms of gene expression data. The
manuscript has been published in Toxicological Sciences in April 2014.
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The constitutive androstane receptor (CAR) and the pregnane
X receptor (PXR) are closely related nuclear receptors involved in
drug metabolism and play important roles in the mechanism of
phenobarbital (PB)-induced rodent nongenotoxic hepatocarcino-
genesis. Here, we have used a humanized CAR/PXRmouse model
to examine potential species differences in receptor-dependent
mechanisms underlying liver tissue molecular responses to PB.
Early and late transcriptomic responses to sustained PB exposure
were investigated in liver tissue from double knock-out CAR and
PXR (CARKO-PXRKO), double humanized CAR and PXR (CARh-
PXRh), and wild-type C57BL/6 mice. Wild-type and CARh-PXRh
mouse livers exhibited temporally and quantitatively similar tran-
scriptional responses during 91 days of PB exposure including the
sustained induction of the xenobiotic response gene Cyp2b10, the
Wnt signaling inhibitor Wisp1, and noncoding RNA biomarkers
from the Dlk1-Dio3 locus. Transient induction of DNA replication
(Hells, Mcm6, and Esco2) and mitotic genes (Ccnb2, Cdc20, and
Cdk1) and the proliferation-related nuclear antigenMki67were ob-
served with peak expression occurring between 1 and 7 days PB ex-
posure. All these transcriptional responses were absent in CARKO-
PXRKO mouse livers and largely reversible in wild-type and CARh-
PXRh mouse livers following 91 days of PB exposure and a subse-
quent 4-week recovery period. Furthermore, PB-mediated upregu-
lation of the noncoding RNAMeg3, which has recently been associ-
ated with cellular pluripotency, exhibited a similar dose response
and perivenous hepatocyte-speci!c localization in both wild-type
and CARh-PXRh mice. Thus, mouse livers coexpressing human
CAR and PXR support both the xenobiotic metabolizing and the
proliferative transcriptional responses following exposure to PB.
Key Words: nongenotoxic carcinogenesis; phenobarbital; liver;
proliferation; humanized mice; CAR; PXR; transcription; cancer
risk assessment.
Phenobarbital (PB), an anticonvulsant commonly used for
treatment of epilepsy and other seizures, promotes both sponta-
neous and chemically induced liver tumors in rodents (Becker,
1982; Whysner et al., 1996) and has been widely used as a
model compound for studying molecular mechanisms underly-
ing rodent nongenotoxic hepatocarcinogenesis (Elcombe et al.,
2014; Lempiainen et al., 2011; Phillips et al., 2009a,b; Ross
et al., 2010; Thomson et al., 2013; Yamamoto et al., 2004).
Murine liver tumor promotion by PB is dependent on the consti-
tutive androstane receptor (CAR) and !-catenin (Huang et al.,
2005; Rignall et al., 2011; Yamamoto et al., 2004), and pro-
longed PB treatment selects for Ctnnb1- (encoding !-catenin)
mutated tumors (Aydinlik et al., 2001). CAR is required for
the early PB-induced gene expression and DNA methylation
changes that accompany murine hepatocyte hypertrophy and
proliferative responses (Phillips et al., 2009a; Ross et al., 2010).
PB regulates the nuclear localization of CAR (Kawamoto et al.,
1999) through an indirect mechanism involving inhibition of
epidermal growth factor receptor (EGFR) signaling (Mutoh
et al., 2013). In addition to CAR, PB also activates the preg-
nane X receptor (PXR) (Lehmann et al., 1998), which has over-
lapping functions with CAR to regulate xenobiotic metabolism
and detoxification in liver (Tolson andWang, 2010), and whose
coactivation may enhance CAR-mediated hepatocyte prolifera-
tion (Shizu et al., 2013).
C© The Author 2014. Published by Oxford University Press on behalf of the Society of Toxicology.
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FIG. 1. (A) Experimental design of the kinetic phenobarbital study for molecular and phenotypic profiling. Male C57BL6 wild-type, CARKO-PXRKO,
and CARh-PXRh mice were given ad libitum access to PB or vehicle (drinking water). Mice were sacrificed at indicated time points, livers were sampled and
aliquots used for genome-wide gene expression (mRNA and miRNA), phenobarbital exposure, histopathology, and localization studies. (B) Effect of CAR/PXR
KO and humanization on PB liver concentration in wild-type (gray bars), CAR/PXR humanized (black bars), and CAR/PXR KO (striped bars) male mice as
obtained by LC-MS/MS. PB liver concentration (ng/g) is shown as a mean ± SD (n = 5 animals per group). Statistical significance is indicated by * (p-value <
0.05; Student’s t-test), and ** (p-value < 0.01; Student’s t-test). (C) PCA analysis performed on expression data from nontreated control samples, which cannot
discriminate CARKO-PXRKO from CARh-PXRh, whereas PC2 discriminates wild-type from humanized and knock-out animals. (D) PCA analysis performed on
expression data from treated samples allowed to discriminate the samples from the three strains: as PC1 discriminates CARKO-PXRKO treated samples from wild-
type and CARh-PXRh treated samples, PC2 discriminates CARh-PXRh treated samples from wild-type, and CARKO-PXRKO treated samples. (E–G) Effect of
phenobarbital on hypertrophy grade in wild-type, CARKO-PXRKO, and CARh-PXRh respectively over time. Severity grades were on a 1–4 scale and are expressed
as median (n= 5). (H) Liver per body weight ratios (%) following PB treatment in wild-type, CARKO-PXRKO, and CARh-PXRh over time. Liver per body weight
ratios are shown as a mean ± SD (n = 5 animals per group). (I–L) Hematoxylin and eosin (H&E) staining on liver sections from vehicle-treated WT (I) and
PB-treated WT (J), PXRKO-CARKO (K), and PXRh-CARh (L) mice at day 91. Black bar: 100 "m.
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FIG. 2. Summary of PB-mediated differential mRNA (A) and miRNA (B)
expression analysis in wild-type, CAR/PXR knock-out, and human CAR/PXR
knock-in animals over time. Black horizontal bars = significantly upregu-
lated transcripts; gray horizontal bars= significantly downregulated transcripts;
white color indicates unchanged transcripts. A transcript is considered signifi-
cantly up- or downregulated if | log2 FC| > 0.53 (corresponding to a FC> 1.5)
and B.H. corrected p-value <0.01. Genes were hierarchically clustered by (1)
computing Euclidean distance between genes from decision matrix and (2) ap-
plying Ward clustering algorithm. Only transcripts that are differentially ex-
pressed in at least one time point and in at least one mouse strain were included
in the clustering analysis. Representative transcripts from each cluster are shown
alongside the vertical color-coded cluster bars (A–L).
An increased understanding of mechanisms underlying
chemical carcinogenesis has raised doubts regarding the appro-
priateness of extrapolating some rodent tumor findings to hu-
mans (Holsapple et al., 2006). Based on epidemiological data
in epileptics, there is no evidence of a specific role of PB in
human liver cancer risk (IARC, 2001; Lamminpaa et al., 2002;
La Vecchia and Negri, 2013; Whysner et al., 1996). Although
prolonged treatment with PB does increase liver size in humans
(Pirttiaho et al., 1982), human hepatocytes are resistant to the
ability of PB to increase cell proliferation (Hasmall and Roberts,
1999; Parzefall et al., 1991) and inhibit apoptosis (Hasmall and
Roberts, 1999).
The development of humanized mouse models provides a
powerful approach for understanding pathways of human dis-
ease and to improve paradigms for the development of new
drugs (Scheer et al., 2013; Scheer and Wolf, 2013). They
also have very significant potential in drug safety testing par-
ticularly in the light of the significant species differences in
metabolism and toxicological response. Because the process of
rodent nongenotoxic carcinogenesis is often mediated by nu-
clear receptors including CAR and PXR, humanized mouse
models in which the endogenous mouse CAR/PXR genes have
been replaced with human CAR/PXR genes have been used to
explore the species specificity of PB-mediated hepatocellular
responses. Humanized C57BL/6 CAR/PXRmice displayed in-
duction of cytochrome P450’s and hepatocellular hypertrophy
but did not show hepatocyte proliferation following acute expo-
sure to PB (Ross et al., 2010). In contrast, PB-induced human
CAR activation has been suggested to be associated with hepa-
tocyte proliferation in an independent transgenic mouse model
(Huang et al., 2005). In this study, we have used a humanized
(CARh-PXRh)mousemodel to examine potential species differ-
ences in receptor-dependent mechanisms underlying both early-
and longer-term liver tissue transcriptomic responses to PB.We
find that PB induces highly similar hepatic transcriptional pro-
grams in both wild-type and humanized CAR/PXR mice. This
transcriptional response includes the upregulation of cell cycle
genes, of the proliferative marker mKi67 and of Dlk1-Dio3 lo-
cus noncoding RNAs that have recently been associated with
cellular pluripotency (Lempiainen et al., 2013; Stadtfeld et al.,
2010). These findings are discussed in the context of using hu-
manized nuclear receptor mouse models to explore the human
relevance of rodent nongenotoxic carcinogens.
MATERIALS AND METHODS
Ethics statement. The wild-type, null, and humanized
CAR/PXR mouse 13-week time course study was performed
in conformity with the Swiss Animal Welfare Law (specifi-
cally under the Animal License No. 2345 by Kantonales Vet-
erina¨ramt Basel-Stadt (Cantonal Veterinary Office, Basel). The
wild-type and humanized CAR/PXR mouse 4-week dose re-
sponse study (Figs. 3B and 3C) was performed following Uni-
versity of Tu¨bingen institutional guidelines.
Animal treatment and sample preparation. C57BL/6 male
wild-type, knock-out CARKO-PXRKO and humanized CARh-
PXRh mice (Scheer et al., 2008,2010) were obtained from
TaconicArtemis (Germany). For the 13-week time course study,
9–11 week-old mice (age selected to avoid the confounding
effect of liver maturation observed in younger animals) were
allowed to acclimatize for 5 days prior to being randomly di-
vided into two treatment groups (n = 5 per time point). Phe-
nobarbital (PB; free acid, >99.0%, Sigma, St Louis, MO, no.
04710, 0.05% (wt/vol) in drinking water) was administered
to one group through ad libitum access to drinking water, as
previously reported (Phillips et al., 2009b; Lempiainen et al.,
2013; Thomson et al., 2013). Mice were checked daily for ac-
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FIG. 3. PB mediates similar transcriptional changes in wild-type,
CAR/PXR knock-out, and human CAR/PXR knock-in animals. (A) Expres-
sion of Gstm3, Wisp1, Cyp2b10, Meg3, miR-541, and miR-379 transcripts in
control (open bars), treated (black bars) and recovery time point (red bars) male
mice as determined using microarrays. Gene expression (log2) is given as a
mean ± SD (n = 3–5 animals per group). (B) Expression and localization of
Meg3 in the liver. ISH of Meg3 transcript (blue staining) in control (28 days)
and PB-treated (28 days, and 0.05% (wt/vol)) livers fromwild-type and human-
ized mice. Black bar= 100 "m. (C) Expression of Cyp2b10 andMeg3 obtained
by RT-PCR in CARh-PXRh mice and wild type controls, exposed to different
concentrations of PB via the drinking water for 28 days. Mean ± SD (n = 4
mice per group) is shown relative to 18S rRNA expression. Statistically signif-
icant differences in PB-induced gene expression change between wild-type and
CARh-PXRh genotypes at a given dose are indicated by asterisks (p < 0.05;
Student’s t-test).
tivity and behavior and sacrificed on the indicated dates. For
pharmacokinetics analysis, animals were anesthetized by in-
halation of Isoflurane/O2 and blood was taken from the orbital
plexus in tubes containing EDTA. Blood samples were cen-
trifuged at 3000× g, plasma removed carefully from the EDTA
containing tubes, snap frozen and stored at −80◦C. For liver
histopathology, one middle section of the median lobe (∼4–
5 mm) was sampled, fixed in 10% neutral-buffered formalin
for 48 h, processed, embedded in paraffin, and stained with
hematoxylin/eosin. For molecular profiling, all remaining parts
of the liver (incl. left and caudal parts) as well as the remaining
median part of the liver were sampled. To ensure sample homo-
geneity for different molecular profiling methods, frozen liver
samples were reduced to powder with CovarisCryoprep (Co-
varis Inc., Woburn, MA) system and aliquoted on dry ice. For
the 4-week dose response study, mice (n = 4 per group) were
treated with PB starting at 8 weeks of age. PB was adminis-
tered via the drinking water (PB solution prepared freshly every
fourth day) at concentrations of 0.005, 0.01, 0.02, and 0.05%
(wt/vol). Mice were kept on a 12 h dark/light cycle and had ac-
cessed to food and water ad libitum. All animals were sacrificed
between 9 and 11 a.m. to avoid circadian influences.
Phenobarbital exposure analysis in blood and liver tis-
sue. Measurement of PB concentrations in plasma and
liver were performed by Liquid Chromatography-Mass
Spectrometry/Mass Spectometry (LC-MS/MS). At each
necropsy time point, ∼0.2 ml plasma was sampled. Each
pulverized liver sample, ca. 100 mg/tube, was diluted by
adding 900 "l saline and mixed thoroughly to generate a
homogenate. Twenty microliters of the homogenate was
subjected to protein precipitation with 200 "l of internal
standard solution (methanol) and 200 "l of 1:1 of methanol
and acetonitrile. The supernatant after centrifugation was
diluted by 20% of methanol and subjected onto LC-MS/MS
determination. The separation on C18 column (Venusil ASB
C18) was achieved by a gradient with 100% of H2O and 100%
of methanol with negative ion detection by turbo ion spray
(API4000, Applied Biosystems). Data acquisition and peak
integration were performed with software Analyst version 1.5.1
(Applied Biosystems). Student’s t-test was used for statistical
analysis of PB liver and plasma exposure. Differences were
considered significant when p-value <0.05.
RNA isolation. Frozen liver samples were homogenized in
TRIzol reagent (Invitrogen, Carlsbad, CA) and subsequently
purified on a silica-gel-based-membrane (RNeasy, Qiagen,
Venlo, Netherlands) according to the manufacturer’s instruc-
tions. RNA quality was assessed by measuring the RIN (RNA
Integrity Number) using an Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Palo Alto, CA). RNA was stored at −80◦C.
miRNA was quantified using the Rediplate Ribogreen RNA
quantitation kit (Life Technologies).
Affymetrix mRNA and microRNA GeneChip processing and
gene expression data analysis. Affymetrix GeneChip Mouse
Genome 430 2.0 arrays were used to profile mRNA expression
in liver tissue of wild-type and transgenic mice (+/− PB) ex-
posure. Affymetrix GeneChip miRNA 2.0 arrays with coverage
of miRBase version 15 were used to profile miRNA expression
in liver tissue of same samples. The array was able to detect the
expression of 722 mouse mature miRNAs and 690 mouse pre-
miRNA. Five biological replicates were used for each treatment
group. Processing of GeneChip experiments was conducted as
recommended by the manufacturer of the GeneChip system
(Affymetrix, Santa Clara, CA).
All the analyses were performed with the R statistical pack-
age version 2.13 (2005) andBioconductor libraries version 1.4.7
(R Core Team, 2013). Affymetrix CEL files were normalized
using the Robust Multichip Average (RMA) implementation
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of the algorithm available in R/Bioconductor (R Core Team,
2013). Quality metrics including scaling factors, average in-
tensities, background intensities, RNA degradation, and raw Q
values obtained from arrays prior and after normalization us-
ing Bioconductor’s array QualityMetrics package (Kauffmann
et al., 2009) were within acceptable limits except for six chips
which were removed from subsequent analyses. Affymetrix mi-
croRNA chips were preprocessed and normalized according
to the Affymetrix miRNA QCTool manual. Briefly, the back-
ground control probes of the chips were grouped into bins of
same dinucleotide Guanine-Cytosine (GC) content. The median
signal of the background bin that matches with the GC con-
tent of the probe was then subtracted from the probe signal.
The background corrected probes (for all probes on the chip in-
cluding those of other species) were quantile normalized across
chips, log2 transformed and summarized into probe sets with
the median polish method as in standard RMA (Bolstad et al.,
2003). We floored all normalized signal values to 1.0.
Principal components analysis (PCA) was performed on the
entire mRNA transcriptomic data set in order to characterize
the overall structure of the data and identify major sources of
gene expression variation. Independent PCA analyses were then
performed on expression data from PB-treated and nontreated
control samples in order to evaluate mouse genetic background
effects (wild-type, CARKO-PXRKO, and CARh-PXRh) on PB
treatment. Before statistical analysis, the transcriptomic data
was filtered to remove 30% probes with lowest variation across
samples andmiRNA data was filtered to select for mouse probe-
sets only. A two-way ANOVA model (treatment, time, and
strain) was independently fitted to mRNA and miRNA data to
assess statistical significance and linear contrasts at each time
point using the Bioconductor’s Limma package, which uses
a Bayesian approach to better estimate the variance (Gentle-
man et al., 2004). The Benjamini-Hochbergmethodwas applied
to correct for multiple comparisons (Benjamini and Hochberg,
1995). Probe sets with B.H. (Benjamini and Hochberg) cor-
rected p-values <0.01 and absolute log2 fold changes above
0.53 (fold change>1.5 or<0.69) were considered differentially
expressed. For cluster analysis, Euclidean distance was used as
a similarity measure and the Ward method for agglomerative
hierarchical clustering.
Real-time RT-PCR analyses. Total RNA was reverse tran-
scribed by avian myeloblastosis virus reverse transcriptase
(Promega). Relative RNA expression levels were analyzed
on a LightCycler system (Roche) using the Fast Start DNA
MasterPLUS SYBR Green Kit (Roche) according to the man-
ufacturer’s instructions, with the following primers: 18S
rRNA forward 5′-CGGCTACCACATCCAAGGAA-3′,
18S rRNA reverse 5′-GCTGGAATTACCGCGGCT-3′,
Cyp2b10 forward 5′-TACTCCTATTCCATGTCTCCAAA-3′,
Cyp2b10 reverse 5′-TCCAGAAGTCTCTTTTCACATGT-
3′, Meg3 forward 5′-GTCTTCCTGTGCCATTTGCT-3′,
Meg3 reverse 5′-TTCATCAGTCAGTAGGTGGGTCT-3′.
Gene expression values were calculated based on the cross-
ing point differences and PCR efficiencies using the Pfaffl
method (Pfaffl, 2001). 18S rRNA expression was used for
normalization.
In situ hybridization and immunohistochemistry. In situ hy-
bridization (ISH) and immunohistochemistry (IHC) analyses
were conducted as described in the Supplementary Materials
and Methods.
RESULTS
Similar PB Exposure and Hepatocellular Hypertrophic
Responses in Wild-Type and Humanized CAR/PXR Mice
To explore potential species differences in CAR and PXR
receptor-dependent mechanisms underlying liver tissue molec-
ular responses to PB, a kinetic study (1, 7, 14, 28, and 91 days
of treatment and a 4-week recovery group) was run in C57BL/6
wild-type, CARKO-PXRKO, and CARh-PXRh mice with ad libi-
tum PB (0.05% wt/vol in drinking water) administration (Fig.
1A). Phenobarbital concentrations in plasma and liver as deter-
mined by liquid chromatography-mass spectrometry are shown
in Figure 1B and Supplementary table 1. A significantly ele-
vated PB plasma concentration was observed in all CARKO-
PXRKO mice compared with wild-type and CARh-PXRh strains
that may reflect a deficiency of their livers to metabolize PB
(Fig. 1B). Similar PB liver concentrations that decreased af-
ter day 1 were observed in both wild-type and CARh-PXRh
mice indicating similar PB-induced metabolic activities in these
two strains. The expression of mouse CAR and PXR transcripts
was only detected in wild-type mouse livers (Supplementary
fig. 4) consistent with the distinct nuclear receptor genotypes
of CARKO-PXRKO and CARh-PXRh mice (Ross et al., 2010).
The most striking PB-induced histopathological change ob-
served in both wild-type and humanized CAR/PXR mice was
hepatocellular hypertrophy starting from 7 days of PB treatment
and increased in severity at later time points (Figs. 1E–L). Hy-
pertrophy was primarily detected at perivenous hepatocytes in
the central zone of the lobule (zone III) (Figs. 1I–L). PB did
not induce hepatocellular hypertrophy in CARKO-PXRKO mice
(Figs. 1F and 1K) nor increase in liver to body weight ratio, con-
sistent with previous reports (Huang et al., 2005; Ross et al.,
2010). Very few mitotic figures were observed in any control
or PB-treated animals. Hypertrophy evaluated by histopathol-
ogy correlated well with increase in relative liver weight (Fig.
1H). Of note, PB induced higher grade of hepatocellular hyper-
trophy as well as higher relative liver weight in CARh-PXRh
animals compared with wild-type animals.
 at CRUK London Research Institute on April 10, 2014
http://toxsci.oxfordjournals.org/
Downloaded from 
6 LUISIER ET AL.
Distinct Transcriptional Patterns are Observed in Wild-Type,
Null CAR/PXR, and Humanized CAR/PXR Mouse Livers in
the Absence of PB Exposure
In the absence of PB exposure, wild-type and CARh-PXRh
mouse livers display someminor differences in their liver global
transcriptome profiles including higher basal gene expression of
Cyp2b10 in livers from humanized CAR/PXR mice compared
with wild-type mice (Supplementary table 4). PCA analysis of
transcriptomic data from nontreated control samples discrimi-
nates wild-type from CARh-PXRh and CARKO-PXRKO mouse
livers (Fig. 1C). This was confirmed by differential gene expres-
sion analysis of genes in control wild-type, CARKO-PXRKO,
and CARh-PXRh mouse livers (Supplementary fig. 1 and Sup-
plementary table 4) and is presumably due to unique constitu-
tive hCAR and hPXR interactions with endogenous mouse gene
regulatory proteins and gene regulatory DNA sequences. Addi-
tional factors that may contribute to these observed differences
include mouse substrain genetic differences (the PXR/CAR
double knock-out line is∼61% C57Bl/6J and 39% C57Bl/6N;
the double humanized CAR/PXR line is ∼78% C57Bl/6J and
22% C57Bl/6N; the wild-type comparator control mice were
∼100% C57Bl/6J) (Scheer, TaconicArtemis, personal com-
munication) and/or transgene-mediated perturbation of mouse
hepatocyte chromatin architecture.
Mouse and Human CAR/PXR Mediate Similar and Reversible
PB-Induced Mouse Liver Transcriptional Responses
PB-exposed wild-type and CARh-PXRh mouse livers dis-
play distinct liver global transcriptome profiles compared with
CARKO-PXRKO mouse livers (Fig. 1D), consistent with PB pre-
dominantly inducing CAR- and PXR-mediated transcriptional
responses (Phillips et al., 2009a; Ueda et al., 2002). Some de-
gree of difference in PB-induced global liver transcriptional
responses between wild-type and CARh-PXRh mice was indi-
cated by principal component 2 (PC2) discrimination within the
PCA analysis (Fig. 1D). To further explore potential similar-
ities and differences between mouse and human CAR/PXR-
mediated regulation of hepatic genes upon PB-treatment, we
compared mRNA and miRNA expression levels in livers from
PB-treated wild-type, CARKO-PXRKO, and CARh-PXRh mice
with their respective time-matched control samples. The dif-
ferential expression of mRNAs and miRNAs in control wild-
type, CARKO-PXRKO and CARh-PXRh mouse livers is sum-
marized in Figures 2A and 2B and a detailed gene list for the
corresponding clusters (A–L) is provided in Supplementary ta-
ble 5. The most significantly upregulated genes in wild-type
C57BL/6 mice upon PB-treatment included Cyp2b10, Gstm3,
Wisp1,Meig1, Abcc4, Cyp2b9, Cyp2c37, Prom1, and Gadd45b
(see Fig. 3A and Supplementary table 5) consistent with pre-
vious observations in PB-treated B6C3F1 mice (Lempiainen
et al., 2011, 2013; Phillips et al., 2009a,b; Thomson et al.,
2013). Moreover, Meg3 noncoding RNA and miRNAs associ-
ated with the Dlk1-Dio3 imprinted cluster (miR-541 and miR-
379), that have recently been associated with cellular pluripo-
tency and proposed as novel candidate biomarkers for mouse
liver nongenotoxic carcinogenesis (Lempiainen et al., 2013),
were also progressively upregulated upon PB-treatment (Figs.
2B and 3A). Importantly, similar quantitative and temporal re-
sponses for these PB-mediated molecular changes were also ob-
served in humanized CAR/PXR mice whilst being absent in
CAR/PXR null mice (Figs. 2B and 3A). Humanized CAR/PXR
mice akin to wild-type mice also supported the PB-mediated
induction of Kcnk1, a male-specific CAR-dependent transcrip-
tional response to PB that has been associated with the attenua-
tion of hepatic hyperplasia Saito et al., 2013 . PB-inducedMeg3
induction in wild-type and humanized CAR/PXRmicewas also
confirmed to exhibit a very similar localization to perivenous
hepatocytes in the central zone of the lobule (Fig. 3B).
The quantitative similarity between PB-mediated hepatic in-
duction of Cyp2b10 and Meg3 in wild-type and CARh-PXRh
mice was further explored in a 4-week dose response study (Fig.
3C). Humanized CAR/PXR and wild-type mice of 8 weeks age
were given four different concentrations of PB ranging from
0.005 to 0.05% (wt/vol) in drinking water. Both Meg3 and
Cyp2b10 gene expression increased in a dose-dependent man-
ner and appeared to reach a plateau at around 0.02% suggesting
saturation (Fig. 3C).
Some differences in the magnitude and timing of liver
transcriptional responses were observed between humanized
CAR/PXR and wild-type mice. One group of PB-induced gene
expression changes was observed to be more prominent in wild-
type than CARh-PXRh mice (see Fig. 4A for examples and
Supplementary table 6 for a detailed list of genes which ex-
hibit significant differences in PB-mediated gene induction be-
tween humanized and wild-type mice in at least one time point)
and an additional distinct group of PB-induced gene expression
changes was observed to be more prominent in CARh-PXRh
than the wild-type mice (e.g., see Fig. 4B). To assess whether
PB exposure differences might contribute to the observed dif-
ferential PB-induced expression of these genes, we performed
linear modeling between gene expression and liver exposure but
did not observe any significant effects (Supplementary fig. 2).
To determine the potential reversibility of molecular re-
sponses induced by 13 weeks of PB treatment, microarray ex-
periments using liver samples from 13-week PB-treated mice
followed by 4 weeks recovery (wild-type, CARKO-PXRKO, and
CARh-PXRh) were compared with liver samples of nontreated
mice from the same strains at the 119-day time point. Differ-
ential gene expression analyses revealed that only six genes
(representing 1% of differentially expressed genes over time)
maintained a qualitatively consistent residual differential ex-
pression in humanized and/or wild-type mice (Serpinb1a,Nebl,
Cyp2b13,Gna14,Gm20265, and AI132709) after 4 weeks of re-
covery (see Supplementary table 7 for complete gene list) sug-
gesting either residual CAR/PXR activity associated with posi-
tive gene regulation after removal of PB treatment, longer-term
stability of this subset of PB-induced mRNAs in mouse liver or
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FIG. 4. Temporal and quantitative differences in PB-mediated transcrip-
tional responses in wild-type versus humanized CAR/PXR mouse livers. (A)
PB-mediated gene induction of Cyp2b13 and Kcnk1 is more prominent in wild-
type than humanized animals. (B) PB-mediated gene induction of Meig1 and
Prom1 is more prominent in humanized animals than wild-type. Expression
(log2) in control (open bars), treated (black bars), and recovery time point (red
bars) male animals is given as mean ± SD (n = 3–5 animals per group).
long-lasting epigenetic changes associated with their gene reg-
ulatory regions. Importantly, the 119-day expression levels for
all of the above residual differentially expressed genes was sig-
nificantly lower than expression levels observed following 91
days of PB treatment suggesting a slow return to normal basal
gene expression levels. A small number of genes were uniquely
differentially expressed at the recovery time point in humanized
or knock-out mice (Supplementary table 7), including a number
of inflammatory genes.
Human CAR and PXR Support Mouse Liver Transcriptional
Upregulation of DNA Replication, Cell Cycle and Mitotic
Genes upon PB Exposure
Further analysis of the different clusters associated with PB-
mediated differential expression (Fig. 2A) revealed a transient
CAR/PXR-dependent cell cycle response after 1 and 7 days of
PB treatment characterized by upregulation of genes associated
with DNA replication, cell cycle and mitosis (Supplementary
tables 2 and 3; Figs. 5A and 5B). Importantly, this PB-mediated
cell cycle transcriptional response was also observed in human-
ized CAR/PXR mice whilst being absent in CAR/PXR null
mice. Further analysis of gene functions associated with this
cluster by mapping to cell cycle phases suggests that PB sup-
ports all phases of cell cycle progression at the transcriptional
level from S-phase entry to cytokinesis (Fig. 6).
DISCUSSION
This study demonstrates for the first time that mouse liv-
ers expressing only the human versions of CAR and PXR can
support PB-induced xenobiotic and proliferative responses at
the transcriptional level. Wild-type and CARh-PXRh mouse
livers exhibited temporally and quantitatively similar tran-
scriptional responses during 91 days of PB exposure includ-
ing the sustained induction of the xenobiotic response gene
Cyp2b10, the Wnt signaling inhibitor Wisp1 and noncoding
RNA biomarkers from the Dlk1-Dio3 locus (Lempiainen et al.,
2013). Importantly, mouse livers expressing human CAR and
PXR also supported PB-mediated transient DNA replication
(Hells,Mcm6, and Esco2), cell cycle (Ccnb2,Cdc20, andCdk1)
and proliferation-related nuclear antigen Mki67 transcriptional
responses consistent with hepatocyte proliferation. Our data are
consistent with a previous report that PB (0.05%; 1 week) in-
duced human CAR activation in a transgenic mouse model as-
sociated with hepatocyte DNA replication based on increased
ploidy and PCNA protein expression (Huang et al., 2005). An-
other study in humanized C57BL/6 CAR/PXRmice concluded
that PB-induced cytochrome P450’s and hepatocellular hyper-
trophy but not hepatocyte DNA replication (based on BrdU
incorporation) following acute exposure to PB (4 days; ip 80
mg/kg) (Ross et al., 2010). However, a more recent follow-
up 7-day study using an alternate dietary route of administra-
tion to generate higher systemic exposure revealed that CARh-
PXRh mice can support PB-mediated DNA replication (based
on BrdU incorporation) although at higher systemic exposures
relative to wild-type mice (Elcombe, personal communication).
The measurement of PB-induced mouse liver proliferation is
confounded by changes in a heterogenous liver parenchymal
cell population that include both mononuclear and binucleated
cells containing multiples of the diploid component of DNA
(known as polyploidy) (Bohm and Noltemeyer, 1981; Bursch
et al., 2004; Gonzales et al., 1998) that may result from in-
complete cytokinesis, endoreplication, or a combination of both
(Gentric et al., 2012a,b; Styles, 1993). Thus, increase in ei-
ther Ki67 mRNA expression, Ki-67/PCNA IHC staining, or
BrdU incorporation may reflect the increased DNA content of
a polyploid hepatocyte rather than DNA replication associated
with complete cell division cycles and hyperplasia. However,
our observation of progressive PB-induction of genes that drive
S-phase, mitosis, and cytokinesis in wild-type and humanized
CAR/PXR mouse livers (Fig. 6) supports a proliferative re-
sponse. Furthermore, we did not observe PB-mediated changes
in the expression of genes implicated in driving polyploidization
of hepatocytes such as E2f7/8 and c-Myc (see Supplementary
fig. 3) (Pandit et al., 2012, 2013).
Species differences in CAR activation by direct ligands such
as the human CAR-selective CITCO (Auerbach et al., 2005)
and mouse CAR-selective TCPOBOP (Nims et al., 1993) are
thought to be in part due to differences in ligand-binding do-
main protein structure. Murine and human CAR and PXR lig-
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FIG. 5. PB mediates cell cycle transcriptional responses in wild-type and humanized CAR/PXR mouse livers. (A) Median expression per animal of a cluster
of genes enriched for DNA replication and cell cycle functions that were differentially expressed upon PB treatment between day 1 and day 7 (cluster C from Fig.
2A). PB-mediated entry in S-phase after one day is supported by a subset of DNA replication genes significantly upregulated from day 1 (1) whereas mitosis and
cytokinesis are supported by a subset of cell cycle regulatory genes significantly upregulated around day 7 (2). (B) Expression ofMki67, Cdc20, Ccn20, andMcm6
determined using microarrays. Expression in control (open bars), treated (black bars) and recovery time point male mice is given as mean ± SD (n = 3–5 animals
per group).
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FIG. 6. Mouse and human CAR/PXRmediate similar PB-induced upreg-
ulation of genes driving both entry into S-phase and progression to cytokinesis
in wild-type and humanized mice. (A) Schematic representation of different
cell cycle stages; a selection of genes which are both reported to regulate the
different stages and are significantly upregulated upon PB treatment between
day 1 and day 3 of PB treatment is shown. (B) Schematic representation of
DNA content along the different cell cycle stages. (C) Polyploidy or polynucle-
idy can result from incomplete cytokinesis, endocycle, or endomitosis that are
likely regulated by genes reviewed in Pandit et al. (2013). Genes in bold-italic
in panel (A) are differentially upregulated between day 1 and day 7 upon PB
treatment in wild-type animals and CARh-PXRh, but not in CARKO-PXRKO,
consistent with a PB-induced hepatic proliferative transcriptional response. No
PB-induced transcriptional responses were observed in either wild-type animals
or CARh-PXRh for genes associated with polyploidy or polynucleidy in panel
(C).
and binding domains share unusually low amino acid sequence
conservation for nuclear receptor orthologs (Moore et al., 2002)
which may account for differences in respective receptor ac-
tivities upon PB exposure, as the ligand-binding domain indi-
rectly affects other receptor functions such as dimerization, lig-
and binding, interaction with heat shock proteins, nuclear lo-
calization, and transactivation functions. Indeed, structural dif-
ferences in human CAR versus mouse CAR translated into
structure-activity differences in the ability of different ligands
to activate or deactivate CAR in comparative assays (Moore
et al., 2000). In contrast to the species differences observed for
some CAR ligands, our data suggest that the indirect activation
of both mouse and human CAR by PB leads to very similar
hepatic xenobiotic and proliferative transcriptional responses
in a C57BL/6 mouse genetic background. Although we did
not find any compelling evidence for PB-mediated transcrip-
tional responses that were specific to humanized CAR/PXR
mice, multiple genes (e.g., Meig1, Prom1, Knck1, Cyp2b13)
were observed to exhibit quantitatively distinct transcriptional
responses to PB in CARh-PXRh versus wild-typemice and these
did not appear to be driven by differences in liver PB exposure.
These quantitative differences are thus likely to reflect target
gene regulatory sequence and/or chromatin structural differ-
ences in mouse CAR- and human CAR-mediated DNA bind-
ing and recruitment of mouse liver transcriptional coregulatory
proteins. Consistent with this notion, a precedent for species-
specific transcription factor interactions with their target genes
has recently been reported (Soccio et al., 2011).
Our data have important implications for the utility of human-
ized CAR/PXRmouse models in human nongenotoxic carcino-
genesis risk assessment. Although the CARh-PXRh mice used
in our studies express human CAR splice variants 1–3 in a ratio
that closely resembles human liver CAR expression profile and
is unchanged by exposure to PB (Ross et al., 2010), one caveat
of this model is that human CAR and PXR receptors function
in the context of mouse target gene regulatory elements and
chromatin structure. Previous work has shown that PB induces
extensive changes in DNA and histone modification patterns
across the regulatory regions of CAR target genes inmouse liver
(Lempiainen et al., 2011; Phillips and Goodman, 2009; Thom-
son et al., 2012, 2013), and species-specific differences in these
epigenetic perturbations may also play an important role in de-
termining susceptibility to PB-mediated hepatocarcinogenesis.
Further species differences in CAR signaling might also be con-
ferred via the recently described PB-EGFR signaling pathway
interactions (Mutoh et al., 2013).
Based on a weight of evidence human relevance framework
concept focusing on mode of action and key events, PB-induced
rodent nongenotoxic hepatocarcinogenesis is not considered to
be a relevant mechanism for humans (Holsapple et al., 2006)
and there is no evidence of a specific role of PB in human
liver cancer risk based on epidemiological data in epileptics
(IARC, 2001; Lamminpaa et al., 2002; La Vecchia and Negri,
2013; Whysner et al., 1996). The fact that CAR activation is
a key event for PB-induced rodent liver tumor formation (El-
combe et al., 2014) suggests that the use of humanized CAR
mouse models may more closely reflect human transcriptional
responses and should be more predictive of human risk. How-
ever, our data suggest that humanized nuclear receptor mice
 at CRUK London Research Institute on April 10, 2014
http://toxsci.oxfordjournals.org/
Downloaded from 
10 LUISIER ET AL.
may not be a simple model for extrapolating the risk of rodent
tumor findings to humans. Understanding and using these mod-
els will require the careful integration of quantitative exposure-
response relationships with the temporal and spatial dynamics
of human nuclear receptor expression, mechanism of modu-
lation by coactivators and further evaluation of the relevance
of heterologous mouse-human gene regulatory protein interac-
tions.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci.
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1 Supplementary protocol
1.1 Affymetrix mRNA and microRNA GeneChip processing
Processing of GeneChip R© experiments was conducted as recommended by the manufacturer of the GeneChip R©
system (Affymetrix, Santa Clara, CA). For tissue samples, double stranded cDNA was synthesized with a
starting amount of 0.1 µg total RNA. For RNA reverse transcription, the GeneChip R© 3’ IVT Express Labeling
Assay (lot ID 0904012, Affymetrix) was used in the presence of a T7-(dT)24 DNA oligonucleotide primer
(Affymetrix). The cDNA was then transcribed in vitro in the presence of biotinylated ribonucleotides to
form biotin-labelled amplified RNA (aRNA). The labelled aRNA was then purified and quantified by UV
spectrophotometry at 260 nm and fragmented. 10 µg of fragmented biotinylated aRNA were hybridized for
approximately 16 hrs at 45 ◦C and 48 ◦C to the GeneChip R© Mouse430 2 arrays and GeneChip R© miRNA2.0
arrays respectively. The arrays were then washed and stained with the GeneChip R© Hybridization Wash and
Stain kit (Affymetrix). The washing and staining steps were performed with GeneChip R© Fluidics Workstation
450 (Affymetrix). Arrays were then scanned using a solid-state laser scanner (GeneArray R© Scanner 3000
combined with the GeneChip R© autoloader, Affymetrix). The Affymetrix GeneChip R© Operating Software
(GCOS) was used to generate the primary and secondary raw data files. The scanned images from miRNA were
converted into numerical values of the signal intensity (Signal) and into categorical expression level measurement
(Absolute Call) using the Affymetrix AGCC software.
1.2 In situ hybridization (ISH) and Immunohistochemistry (IHC)
Template for Meg3 riboprobe synthesis was generated by RT-PCR on RNA from mouse brain using self-
priming oligonucleotide primers flanked in 5’ with SP6- and T3-promoter recognition sequences (forward primer:
SP6CTCTTCTC CATCGAACGGCT, reverse primer T3-AACAATAAAGAACTTGAAGAGGTTTTGAT, am-
plicon size: 537 bp). The purified PCR product was transcribed using T3-RNA polymerase (anti-sense) and
1
SP6-RNA polymerase (sense) at 37 ◦C for 2 hrs using dNTP containing Digoxigenin-UTP according to the
manufacturer recommendations (Roche Diagnostics, Schweiz AG, Rotkreuz, Switzerland). The quality and
quantity of the riboprobe was evaluated using the 2100 Bioanalyzer. ISH was performed using the fully au-
tomated instrument Ventana Discovery Ultra R© (Roche Diagnostics). All chemicals were also provided by
Roche Diagnostics. Briefly, formalin fixed paraffin embedded sections were de-paraffinized and rehydrated un-
der solvent-free conditions (EZprep solution). Pretreatment steps were done with the RiboMapTM kit following
the manufacturers instructions followed by cell conditioning (demasking) performed by heat retrieval cycles
in RiboCC solution using option mild followed by a complementary enzymatic digestion (Protease 3 for 16
minutes at 37 ◦C). Hybridization was performed adding to each slide 200 µl of RiboHybe solution containing
10 ng of DIG-riboprobe and incubating at 70 ◦C for 6 hrs. After hybridization section were washed 3 times
at 70 ◦C for 8 min on stringency conditions (2.0 x SSC). DIG-label probe detection was performed using an
Alkaline Phosphatase-conjugated Sheep anti-Digoxigenin antibody (Roche Diagnostics) diluted 1/500 in an-
tibody diluent. Antibody incubation was carried out for 30 min at 37 ◦C followed by chromogenic detection
using BlueMapTM Kit with a substrate incubation time of 4hrs. Counterstaining using ISH nuclear fast red
was performed for 2 min. Sections were mounted in Glycerol-gelatin mounting medium (Sigma-Aldrich Chemie
GmbH, Buchs, Switzerland) and post-mounted using PertexTM. For double staining with Glutamine synthetase
(GS), the rabbit anti-GS antibody from Sigma (catalog number G2781) was used at a dilution of 1/20’000 in
antibody diluent for 3 hrs and was applied just after the alkaline phosphatase conjugated sheep anti-digoxigenin.
The detection step was immediately done using a biotin conjugated donkey anti-rabbit antibody (dilution 1/500
in antibody diluent and incubation time 16 min) followed by application of the DABmapTM kit according to
the provider recommendations. The chromogenic detection for the DIG-labeled probe using the BlueMap Kit
was done at the end. IHC for Ki67 was performed using the fully automated instrument Ventana Discovery R©
(Roche Diagnostics). All chemicals were also provided by Roche Diagnostics. Formalin fixed paraffin embedded
sections were de-paraffinized and rehydrated under solvent-free conditions (EZprep solution) followed by anti-
gen retrieval (demasking) performed by heat retrieval cycles in a Tris-EDTA based buffer (CC1 solution, option
standard). Subsequently slides were blocked using 1x Casein solution in PBS (BioFX laboratories Inc, Catalog
number PBSC-0100-5x) and endogenous avidin/biotin activity was quenched for 4 min. Some 100 µl of a rabbit
anti-Ki67 from NeoMarker (catalog number RM-9106S) diluted at 1/200 in antibody diluent were added on
slides and incubated for 3 hrs at room temperature. A short post-fixation (glutaraldehyde at 0.05%) was done
before applying a biotin conjugated donkey anti-rabbit at 1/500 for 16 min (Jackson Immunoresearch Inc.).
Detection was performed with a streptavidin-biotin peroxidase detection system DABMap R© Kit following the
manufacturer recommendations. Slides were counter stained with Hematoxylin and bluing reagent, dehydrated
and mounted using PertexTM (Biosystems Switzerland AG, Nunningen, Switzerland).
2
2 Supplementary figures
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Figure S1: Summary of differential gene expression due to strain effect: comparison of gene expression at
corresponding time-point of control CARKO-PXRKO versus control wild-type, control CARh-PXRh versus
control wild-type, and control CARKO-PXRKO versus control CARh-PXRh mouse livers. Black dots = genes
significantly up-regulated, grey dots = genes significantly down-regulated and white dots = no significant change.
A gene is considered significantly up-regulated if | log2 FC |> 0.53 (corresponding to FC>1.5 or FC<0.69) and
B.H. (Benjamini and Hochberg) corrected P-Value < 0.01. Genes are clustered hierarchically by (1) computing
Euclidean distance between genes from decision matrix and (2) applying Ward clustering algorithm. Detailed
gene list can be consulted in Supplementary material (2).
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Figure S2: Linear modeling between gene expression and PB liver exposure for the genes of interest. Results
do not support significant effect on gene induction upon changes in PB liver exposure. Whilst as for Cyp2b13,
linear modeling suggests anti-correlation between PB exposure and gene expression, this indeed results from
differential expression over time: as PB liver exposure decreases over time, Cyp2b13 gene expression increases
over time.
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(n=3-5 animals per group).
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3 Supplementary tables
Liver
Wild-type CARKO-PXRKO CARh-PXRh
Time[day] mean [ng/g] sd mean [ng/g] sd mean [ng/g] sd
1 39220 7946 58220 11362 44420 10680
7 16680 6796 50400 12400 26800 7556
14 20260 5533 48520 20617 29160 14417
28 21620 6637 57800 15399 25840 5757
91 11874 2892 36960 9567 14483 5465
Plasma
Wild-type CARKO-PXRKO CARh-PXRh
Time[day] mean [ng/mL] sd mean [ng/mL] sd mean [ng/mL] sd
1 52400 4900 58700 9370 54100 8890
7 19400 3660 71900 10900 28900 5420
14 21100 3860 75300 14500 31500 7730
28 19700 3590 82700 8860 32300 5180
91 11100 3220 52600 6250 17000 7230
Table S1: Plasma and liver PB exposure as measured using LC-MS/MS at each time-point in treated animals
(n=3-5 animals per group).
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replication. Subset of cluster C of Figure 2 and group (1) of Figure 5. Gene function obtained from STRING
9.05 - Known and Predicted Protein-Protein Interactions.
7
D
ay
1
D
ay
7
W
T
C
A
R
h
-P
X
R
h
W
T
C
A
R
h
-P
X
R
h
G
en
e
Sy
m
bo
l
G
en
e
D
es
cr
ip
ti
on
G
en
e
Fu
nc
ti
on
lo
g 2
FC
B
.H
.P
-V
al
lo
g 2
FC
B
.H
.P
-V
al
lo
g 2
FC
B
.H
.P
-V
al
lo
g 2
FC
B
.H
.P
-V
al
A
rh
ga
p1
1a
R
ho
G
T
P
as
e
ac
ti
va
ti
ng
pr
ot
ei
n
11
A
0.
2
4.
4E
-0
1
0.
2
5.
4E
-0
1
0.
6
1.
1E
-0
3
0.
5
8.
0E
-0
3
A
sp
m
A
bn
or
m
al
sp
in
dl
e-
lik
e,
m
ic
ro
ce
ph
al
y
as
so
ci
at
ed
P
ro
ba
bl
e
ro
le
in
m
it
ot
ic
sp
in
dl
e
re
gu
la
ti
on
an
d
co
or
di
na
ti
on
of
m
it
ot
ic
pr
o-
ce
ss
es
.
0.
3
2.
2E
-0
1
0.
1
7.
1E
-0
1
0.
6
2.
2E
-0
3
0.
4
6.
8E
-0
2
B
ir
c5
B
ac
ul
ov
ir
al
IA
P
re
pe
at
-c
on
ta
in
in
g
5
C
om
po
ne
nt
of
th
e
ch
ro
m
os
om
al
pa
ss
en
ge
r
co
m
pl
ex
(C
P
C
),
a
co
m
pl
ex
th
at
ac
ts
as
a
ke
y
re
gu
la
to
r
of
m
it
os
is
.
0.
4
3.
7E
-0
1
0.
4
4.
3E
-0
1
1.
4
1.
0E
-0
7
0.
9
3.
9E
-0
3
C
cn
a2
C
yc
lin
A
2
E
ss
en
ti
al
fo
r
th
e
co
nt
ro
l
of
th
e
ce
ll
cy
cl
e
at
th
e
G
1/
S
(s
ta
rt
)
an
d
th
e
G
2/
M
(m
it
os
is
)
tr
an
si
ti
on
s
0.
4
1.
0E
-0
1
0.
4
1.
1E
-0
1
1.
0
1.
5E
-0
5
0.
9
7.
2E
-0
5
C
cn
b2
C
yc
lin
B
2
E
ss
en
ti
al
fo
r
th
e
co
nt
ro
lo
ft
he
ce
ll
cy
cl
e
at
th
e
G
2/
M
(m
it
os
is
)
tr
an
si
ti
on
0.
2
8.
0E
-0
1
0.
2
7.
8E
-0
1
1.
9
2.
8E
-1
0
1.
3
6.
3E
-0
6
C
dc
20
C
el
ld
iv
is
io
n
cy
cl
e
20
ho
m
ol
og
R
eq
ui
re
d
fo
r
fu
ll
ub
iq
ui
ti
n
lig
as
e
ac
ti
vi
ty
of
th
e
an
ap
ha
se
pr
om
ot
in
g
co
m
-
pl
ex
/c
yc
lo
so
m
e
(A
P
C
/C
)
0.
3
3.
7E
-0
1
0.
4
1.
9E
-0
1
1.
6
9.
4E
-1
5
1.
0
1.
1E
-0
6
C
dc
a3
C
el
ld
iv
is
io
n
cy
cl
e
as
so
ci
at
ed
3
F
-b
ox
-li
ke
pr
ot
ei
n
w
hi
ch
is
re
qu
ir
ed
fo
r
en
tr
y
in
to
m
it
os
is
.
0.
2
7.
2E
-0
1
0.
4
1.
4E
-0
1
1.
1
2.
4E
-0
8
0.
9
2.
5E
-0
6
C
dk
1
C
yc
lin
-d
ep
en
de
nt
ki
na
se
1
R
eq
ui
re
d
in
hi
gh
er
ce
lls
fo
r
en
tr
y
in
to
S-
ph
as
e
an
d
m
it
os
is
.
p3
4
is
a
co
m
po
ne
nt
of
th
e
ki
na
se
co
m
pl
ex
th
at
ph
os
ph
or
yl
at
es
th
e
re
pe
ti
ti
ve
C
-t
er
m
in
us
of
R
N
A
po
ly
m
er
as
e
II
0.
3
3.
4E
-0
1
0.
3
3.
4E
-0
1
0.
7
5.
7E
-0
3
0.
8
9.
6E
-0
4
C
dk
n3
C
yc
lin
-d
ep
en
de
nt
ki
na
se
in
hi
bi
to
r
3
0.
2
2.
4E
-0
1
0.
2
3.
8E
-0
1
0.
7
5.
0E
-0
8
0.
4
3.
2E
-0
4
C
ka
p2
C
yt
os
ke
le
to
n
as
so
ci
at
ed
pr
ot
ei
n
2
P
os
se
ss
es
m
ic
ro
tu
bu
le
st
ab
ili
zi
ng
pr
op
er
ti
es
.
In
vo
lv
ed
in
re
gu
la
ti
ng
an
eu
pl
oi
dy
,
ce
ll
cy
cl
in
g,
an
d
ce
ll
de
at
h
in
a
p5
3-
de
pe
nd
en
t
m
an
ne
r
0.
3
1.
2E
-0
1
0.
2
6.
3E
-0
1
1.
0
2.
0E
-1
0
0.
8
7.
3E
-0
7
D
tl
D
en
ti
cl
el
es
s
ho
m
ol
og
Se
em
st
o
be
ne
ce
ss
ar
y
to
en
su
re
pr
op
er
ce
ll
cy
cl
e
re
gu
la
ti
on
of
D
N
A
re
pl
ic
at
io
n.
0.
5
2.
0E
-0
2
0.
4
3.
3E
-0
2
0.
6
3.
1E
-0
3
0.
5
7.
1E
-0
3
G
st
a2
G
lu
ta
th
io
ne
S-
tr
an
sf
er
as
e,
al
ph
a
2
C
on
ju
ga
ti
on
of
re
du
ce
d
gl
ut
at
hi
on
e
to
a
w
id
e
nu
m
be
r
of
ex
og
en
ou
s
an
d
en
-
do
ge
no
us
hy
dr
op
ho
bi
c
el
ec
tr
op
hi
le
s
0.
3
4.
6E
-0
1
0.
3
4.
3E
-0
1
0.
7
8.
8E
-0
3
0.
8
6.
2E
-0
4
G
st
t1
G
lu
ta
th
io
ne
S-
tr
an
sf
er
as
e,
th
et
a
1
C
on
ju
ga
ti
on
of
re
du
ce
d
gl
ut
at
hi
on
e
to
a
w
id
e
nu
m
be
r
of
ex
og
en
ou
s
an
d
en
-
do
ge
no
us
hy
dr
op
ho
bi
c
el
ec
tr
op
hi
le
s.
0.
4
7.
3E
-0
6
0.
2
1.
2E
-0
1
0.
6
4.
9E
-1
0
0.
2
7.
3E
-0
2
H
m
m
r
H
ya
lu
ro
na
n
m
ed
ia
te
d
m
ot
ili
ty
re
ce
pt
or
In
vo
lv
ed
in
ce
ll
m
ot
ili
ty
.
0.
3
7.
7E
-0
2
0.
3
3.
7E
-0
2
0.
8
7.
0E
-1
1
0.
7
2.
8E
-0
9
K
if2
0b
K
in
es
in
fa
m
ily
m
em
be
r
20
B
P
lu
s-
en
d-
di
re
ct
ed
m
ot
or
en
zy
m
e
th
at
is
re
qu
ir
ed
fo
r
co
m
pl
et
io
n
of
cy
to
ki
ne
si
s
0.
4
6.
6E
-0
2
0.
1
7.
9E
-0
1
0.
7
1.
1E
-0
3
0.
5
3.
7E
-0
2
N
ek
2
N
ev
er
in
m
it
os
is
ge
ne
a-
re
la
te
d
ex
pr
es
se
d
ki
na
se
2
P
ro
te
in
ki
na
se
in
vo
lv
ed
in
m
it
ot
ic
re
gu
la
ti
on
.
M
ay
ha
ve
a
ro
le
at
th
e
G
2-
M
tr
an
si
ti
on
.
0.
2
3.
5E
-0
1
0.
0
1.
0E
+
00
0.
8
1.
1E
-0
5
0.
7
1.
0E
-0
4
N
uf
2
N
U
F
2,
N
D
C
80
ki
ne
to
ch
or
e
co
m
pl
ex
co
m
po
ne
nt
A
ct
s
as
a
co
m
po
ne
nt
of
th
e
es
se
nt
ia
lk
in
et
oc
ho
re
-a
ss
oc
ia
te
d
N
D
C
80
co
m
pl
ex
,
w
hi
ch
is
re
qu
ir
ed
fo
r
ch
ro
m
os
om
e
se
gr
eg
at
io
n
an
d
sp
in
dl
e
ch
ec
kp
oi
nt
ac
ti
vi
ty
.
0.
3
2.
2E
-0
1
0.
4
1.
0E
-0
1
0.
6
1.
9E
-0
3
0.
4
1.
0E
-0
1
N
us
ap
1
N
uc
le
ol
ar
an
d
sp
in
dl
e
as
so
ci
at
ed
pr
ot
ei
n
1
M
ic
ro
tu
bu
le
-a
ss
oc
ia
te
d
pr
ot
ei
n
w
it
h
th
e
ca
pa
ci
ty
to
bu
nd
le
an
d
st
ab
ili
ze
m
i-
cr
ot
ub
ul
es
.
0.
3
2.
6E
-0
1
0.
3
3.
6E
-0
1
0.
7
8.
7E
-0
3
0.
2
5.
4E
-0
1
P
ar
d3
b
P
ar
-3
pa
rt
it
io
ni
ng
de
fe
ct
iv
e
3
ho
m
ol
og
B
P
ut
at
iv
e
ad
ap
te
r
pr
ot
ei
n
in
vo
lv
ed
in
as
ym
m
et
ri
ca
lc
el
ld
iv
is
io
n
an
d
ce
ll
po
la
r-
iz
at
io
n
pr
oc
es
se
s
0.
5
1.
5E
-0
4
0.
3
1.
7E
-0
1
0.
6
5.
1E
-0
5
0.
3
1.
3E
-0
1
R
ap
ge
f4
R
ap
gu
an
in
e
nu
cl
eo
ti
de
ex
ch
an
ge
fa
ct
or
G
ua
ni
ne
nu
cl
eo
ti
de
ex
ch
an
ge
fa
ct
or
(G
E
F
)
fo
r
R
A
P
1A
,
R
A
P
1B
an
d
R
A
P
2A
sm
al
lG
T
P
as
es
th
at
is
ac
ti
va
te
d
by
bi
nd
in
g
cA
M
P.
0.
5
3.
7E
-0
1
-0
.1
9.
4E
-0
1
1.
2
2.
5E
-0
3
0.
1
9.
4E
-0
1
St
m
n1
St
at
hm
in
1
In
vo
lv
ed
in
th
e
re
gu
la
ti
on
of
th
e
m
ic
ro
tu
bu
le
fil
am
en
t
sy
st
em
by
de
st
ab
ili
zi
ng
m
ic
ro
tu
bu
le
s.
0.
2
7.
9E
-0
1
0.
1
9.
4E
-0
1
0.
8
2.
3E
-0
3
0.
8
1.
5E
-0
3
U
be
2c
U
bi
qu
it
in
-c
on
ju
ga
ti
ng
en
zy
m
e
E
2C
A
ct
s
as
an
es
se
nt
ia
l
fa
ct
or
of
th
e
an
ap
ha
se
pr
om
ot
in
g
co
m
pl
ex
/c
yc
lo
so
m
e
(A
P
C
/C
),
a
ce
ll
cy
cl
e-
re
gu
la
te
d
ub
iq
ui
ti
n
lig
as
e
th
at
co
nt
ro
ls
pr
og
re
ss
io
n
th
ro
ug
h
m
it
os
is
.
0.
4
3.
4E
-0
1
0.
2
6.
6E
-0
1
0.
9
4.
4E
-0
4
0.
7
7.
4E
-0
3
Zw
ilc
h
Zw
ilc
h,
ki
ne
to
ch
or
e
as
so
ci
at
ed
,h
om
ol
og
E
ss
en
ti
al
co
m
po
ne
nt
of
th
e
m
it
ot
ic
ch
ec
kp
oi
nt
,w
hi
ch
pr
ev
en
ts
ce
lls
fr
om
pr
e-
m
at
ur
el
y
ex
it
in
g
m
it
os
is
.
0.
5
3.
2E
-0
2
0.
4
1.
8E
-0
1
0.
9
2.
5E
-0
5
0.
6
7.
3E
-0
3
Table S3: PB-mediated differentially expressed genes (around Day 7) functionally enriched in mitosis. Subset
of cluster C of Figure 2 and group (2) of Figure 5. Gene function obtained from STRING 9.05 - Known
and Predicted Protein-Protein Interactions.
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Chapter 5
Discussion and concluding remarks
In this research project we have applied novel bioinformatic approaches to comprehensive gene expression
data from various in vivo studies leading to (i) identification of early regulators of PB-induced liver
tumorigenesis and (ii) assessment of relevance of CARPXR humanized mouse model in testing receptor-
dependent mechanisms underlying liver tissue molecular responses to NGC. In the following we discuss
the main findings, their impact in drug safety assessment, and future direction.
5.1 New DNA-binding regulators of early PB-mediated liver
tumorigenesis
A better understanding of the regulatory mechanisms underlying long-term effects of non-genotoxic car-
cinogens and more particularly identification of the TFs that regulate PB-mediated long-term transcrip-
tional changes down-stream of CAR and β-catenin is of great importance for drug development and safety
assessment of the carcinogenic potential of compounds with similar mode of action. In this study we have
adapted a robust ab initio probabilistic algorithm that models gene expression dynamics in terms of
predicted cis-regulatory sites to comprehensive toxicogenomic data from in vivo experiments to propose
new DNA-binding regulators involved in regulation of early PB mediated liver tumor promotion.
5.1.1 Summary of major findings
Collectively these analyses propose new and testable regulatory mechanisms underlying three key aspects
PB-mediated tumor promotion that are 1) PB-mediated DNA replication in hepatocytes (Figure 5.1b),
2) PB-mediated xenobiotic response (Figure 5.1-c), and 3) PB-mediated tumor-prone environment
establishment (Figure 5.1-d). Additionally these analyses identified several candidate regulators of
1) liver tumorigenesis (Figure 5.1-e), 2) early PB-mediated kinetics of transcriptional response down-
stream of CAR signaling and 3) liver context candidate regulators down-stream of β-catenin signaling
pathway.
5.1.1.1 Regulators underlying early PB-mediated kinetics of transcriptional response
The transcriptional response mediated by long-term PB treatment has been previously reported to be
complex and non-linearly dependent on time (123). Although CAR has been shown to initiate most of
PB-mediated transcriptional response, its activity cannot be the sole regulator of this response. Using
singular value decomposition applied to motif activity matrix obtained from MARA, we quantified and
characterized TFs activity variations associated with specific biological processes i.e. constant xenobiotic
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response, transient PB-mediated mitogenic response and adaptive xenobiotic response, and identified
regulators underlying these biological pathways. Thus we propose new candidate CAR-down-stream
regulators of early PB-mediated kinetics of early transcriptional response.
5.1.1.2 New liver-specific β-catenin down-stream regulators
β-catenin has been shown to physically interact with diverse nuclear transcription factors (169). As
β-catenin role in PB-mediated liver tumor promotion is more likely to arise from co-operation with
alternative TF activated by PB rather than direct activation by the compound, a list of liver-specific β-
catenin down-stream regulators would be very informative. In this study we systematically interrogated
190 motifs for β-catenin down-stream regulation by adapting MARA algorithm to genomic data from
β-catenin KO samples and proposed 30 candidate co-factors of β-catenin in the liver. Importantly the
method successfully identified TCF/LEF cofactor binding site motif which is the best characterized co-
factor of Wnt/β-catenin signaling pathway (203; 259).
5.1.1.3 E2F as a positive regulator of the PB-mediated mitogenic response at both the
early and tumor stages
An important aspect of PB-mediated tumor promotion is the ability of PB to induce transient mitogenic
response and cause liver neoplasia on chronic administration. Previous studies suggest that different
populations of hepatocytes are sensitive to proliferative induction according to stimuli such as chemical
exposure and reduction in liver mass (39; 40; 41; 42). However the exact mechanisms responsible for the
exit from the quiescent state and the re-entry into the cell cycle remain largely unknown (see (39) for
review). We here hypothesized that motifs similarly dysregulated during early PB-mediated mitogenic
response and in promoted tumors specifically were strong candidates for HC cell proliferation culminating
in liver cancer.
Our analysis revealed an increase in E2F motif activity in PB-mediated proliferative tissues (early tran-
sient peak of proliferation and tumor stage), but none in non-promoted tumors, suggesting distinct
regulatory programs of cell proliferation between these two tumor types. Numerous studies report in-
deed central role of distinct E2Fs family members in HCC (260; 261). However we are the first to our
knowledge to show specific modulation of the motif in promoted liver tumors. Furthermore our analysis
revealed that E2F motif activity is negatively modulated upon β-catenin KO, suggesting a positive inter-
action between these two pathways. Given the constitutive activation of β-catenin in promoted tumors,
amplified interaction between these two regulators may lead to aberrant E2F activity.
Whilst from MARA result, we cannot determine which of the E2F family members is responsible for
these changes in activity, significant correlation between E2f1, E2f2 and E2f8 gene expression and motif
activity suggests that these are likely to bind E2F motif. Moreover our analysis revealed that both myc
and E2f8 are 1) predicted target genes of E2F and 2) significantly up-regulated in promoted tumors only.
Interestingly both c-Myc (262; 263) and E2F8 (56) are key regulators of hepatocyte polyploidization, a
mechanism which contributes to increase in liver metabolic load. It is therefore tempting to speculate that
PB treatment induces E2F8 and c-Myc activation, potentially through EGFR signaling inhibition, leading
to increase in polyploid cells rather that increase in cell number through incomplete cytokinesis. Indeed
the measurement of PB-induced mouse liver proliferation is confounded by changes in a heterogenous
liver parenchymal cell population that include both mononuclear and binucleated cells (264; 188). Thus,
increases in either Ki67 mRNA expression, Ki-67/PCNA IHC staining or BrdU incorporation previously
reported in PB-treated hepatocytes and described as a proliferative response may indeed reflect an in-
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creased in DNA content of a polyploidy hepatocyte rather than DNA replication associated with complete
cell division cycles and hyperplasia. Further histopathologic and flow cytometry endpoints are required
to rigorously differentiate between increased ploidy in hypertrophic hepatocytes versus hepatocellular
proliferation, and in order to assess differential activity of E2F family upon PB treatment.
5.1.1.4 ZFP161 as transcriptional repressor involved in the PB-mediated mitogenic re-
sponse at both the early and tumor stages
Our analysis revealed a negative modulation of motif bound by ZFP161 (also known as ZF5) upon PB
treatment contributing to the early transient mitogenic. In addition, ZFP161 targets are down-regulated
in promoted tumors, but not in non-promoted tumors. ZFP161 has been shown to be preferentially active
in differentiated tissues with little mitotic activity (265), where it is likely to act as a transcriptional
repressor, and it is thought to directly repress myc (266; 267). However predicted targets for ZFP161 in
this study are enriched in transcriptional repressors for cell proliferation (i.e. Mxi1 and Klf10), which are
themselves down-regulated in proliferative tissues whilstmyc is not predicted as target and is up-regulated
in these tissues. We therefore hypothesize that ZFP161 participates in the PB-mediated regulation
of quiescent hepatocytes G0-G1 transition at both the early and tumor stages by repressing negative
regulators of cell cycle and this mechanism is specific to hepatocytes. Importantly while very few studies
were done on this TF, we are the first to propose a regulatory role for ZFP161 in liver tissue that is
further supported by the relatively high expression level of ZFP161 in liver samples.
5.1.1.5 ESR1 repression and creation of a tumor prone environment
PB-mediated tumorigenesis involves dynamic changes in tissue composition that progressively create a
tumor-prone environment, resulting from the liver adaptive response to chronic stress. Our analysis
identified ESR1 as a factor progressively down-regulated upon PB chronic exposure at early stage and
specifically down-regulated in promoted tumors, making this TF a strong candidate regulator for this
process. Furthermore analysis of the motif activity changes upon β-catenin KO revealed a negative in-
teraction between ESR1 and β-catenin down-stream signaling supporting the hypothesis of progressive
inhibition of ESR1 signaling by β-catenin constitutive activation. ESR1 motif activity and TF expression
correlate significantly in β-catenin and tumor studies only, which coincides with samples where β-catenin
activity is predicted to change. These results support the hypothesis of a negative ESR1 transcrip-
tional regulation by β-catenin. Of note physical interaction between β-catenin/TCF-4 and ESR1 in other
physiological contexts was reported elsewhere (268; 269). PB-mediated inhibition of EGFR may be an
additional mechanism of ESR1 inhibition, given that estrogen-independent EGFR-dependent activation
of ESR1 was shown elsewhere (270; 271).
While ESR1 tumor suppressor activity is supported by various studies (107; 128; 272; 273; 274) we
are the first to propose a PB-mediated progressive suppression of ESR1 activity upon chronic exposure
as one of the mechanisms underlying PB-mediated liver tumor promotion. The tumor suppressor role of
ESR1 evidenced in previous studies was shown to result partly from estrogen-mediated inhibition of IL-6
expression in Kupffer cells that in turn affect hepatocyte proliferation (128) suggesting key role for ESR1
in hepatocyte communication with non-parenchymal cells. Moreover results from few studies performed
in both males and females rat over more than 2 years suggest that PB promotional effect is similar in
males and females, whereas female mice live longer under PB-treatment (135; 136; 137). We think that
the time-delay between male and female liver outcome upon PB treatment results in part by higher
basal ESR1 activity in females compared to males leading female mice to less sensitivity to PB-mediated
decrease in ESR1 activity.
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According to our predictions β-catenin negatively regulates ESR1 activity, at least in males. Direct
interaction between ESR1 and TCF4 was indeed previously shown (268) and ESR1-liver specific activ-
ity may depend on such an interaction. Upon β-catenin constitutive activation, as it is the case in the
Ctnnb1 mutated cells, β-catenin may interact with most available TCF4, leading to fewer free TCF4 and
resulting in decrease ESR1-TCF4 complex formation eventually leading to decrease in activity.
5.1.2 Future work and experimental follow-up
As all these hypotheses are the results of computational predictions, further experimental follow-up is
necessary to ascertain the relevance of these regulators in PB-mediated tumor promotion. Because the
pathogenesis of PB-mediated tumor promotion is long (35 weeks) and results also from communication
between hepatocytes and non-parenchymal cells, long-term effects of PB exposure are difficult to test
using in vitro culture of hepatocytes that rapidly differentiate on plastic and loose expression of CYPs.
However short term effects such as PB-mediated transient proliferative response can be in principle
reproduced in freshly isolated primary hepatocytes and thus regulators involved in early PB-mediated
proliferative response should in principle be testable in vitro. In the following we propose experiments to
either validate or further investigate our hypotheses, some of them having being initiated in the laboratory
of Carcinogenesis and Epigenetics (PCS, Novartis, Basel).
5.1.2.1 Characterization of proliferative index and ploidy
Given the predicted modulation of E2F activity specifically in promoted tumors, the recently demon-
strated role for E2F8 and Myc in hepatocyte ploidy, and the increase in hepatocyte ploidy upon PB
exposure, we speculate that a PB-mediated coordinated change in ploidy rather than a increase in prolif-
erative index is responsible for the predicted increase in motif activity. In order to characterize prolifera-
tive index and ploidy in both promoted and non-promoted tumors, we have initiated immunostaining of
paraffin-embedded promoted and non-promoted tumors with Ki67, a marker of proliferation, and Feulgen,
that allows to quantify ploidy (275; 276). We expect similar proliferative index between the two tumor
types but differences in ploidy.
5.1.2.2 Assessment of changes in TFs activity in promoted tumors specifically
TFs activity is regulated at various levels such as transcriptional level (these changes were already tested
by differential gene expression analysis), post-translational modification of the protein, changes in cellu-
lar localization, changes in expression of co-factors and DNA accessibility of target genes (through de-
methylation of promoters for example). Immunohistochemistry staining of promoted and non-promoted
tumors samples together with surrounding normal tissue would allow (i) to assess that the proteins are
present in tissues of interest, (ii) to identify the cells that express the TFs (please note that gene ex-
pression data are very sensitive and thus tissue contamination with other cells than hepatocytes can lead
to significant signal possibly responsible for motif activity change), and (iii) to test for differential TFs
activity as per changes in cellular localization (either nuclear accumulation, or switch from membranous
to cytoplasmic). Furthermore changes in motif activity that either result from interaction with newly
available co-factors and for changes DNA accessibility of the targets could be tested using ChIP assays
that would inspect for changes in binding of TFs between the different conditions. Please note how-
ever that these experiments necessitate highly specific antibodies. Antibody testing was initiated in our
laboratory and very few antibodies so far yielded high enough specificity.
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5.1.2.3 Assessment of PB-mediated modulation of TF activity
In order to test for PB-mediated changes in TFs activity, we propose to perform a motif-reporter activity
assay in freshly isolated hepatocytes under various conditions such as with and without PB, with and
without CAR, with and without β-catenin, in order to genetically measure PB-mediated TFs signaling
and investigate dependency on different regulators. Furthermore, in order to assess which of the E2F
family member is responsible for PB-mediated change in activity motif at early stage, combination with
siRNA treatment would allow to test each of the family members separately.
5.1.2.4 Study of biochemical protein interactions
In order to test for biochemical protein interactions between β-catenin and the various identified regulators
down-stream of β-catenin signaling, we propose a co-immunoprecipitation (Co-IP) experiment using
cellular extracts from freshly isolated mouse hepatocytes.
5.1.3 Discussion about current approach
Given that PB mediates changes in gene expression primarily through inhibition of EGFR (186), it is likely
that many predicted changes in TFs activities result from post-translational modifications rather than
changes in TFs gene expression. MARA infers regulatory activities from the behavior of predicted targets
thus this algorithm allows for prediction of differential activity which may be due to post-translational
modifications, changes in cellular localization, or interactions with co-factors. Therefore we think that the
current approach is more powerful in identifying candidate TFs for tumor promotion than classic meth-
ods such as analysis of differentially expressed genes or enrichment of motifs in differentially expressed
genes. Moreover MARA provides with a list of predicted targets for each motif allowing to interrogate
for biological pathways regulated by the TFs of interest.
However this algorithm is also limited by the TFBS data-base: in mammals, sequence-specificities are
available for only about 350 of the about 1,500 TFs. While CAR is the most important regulator of
PB-mediated tumor promotion and the most characterized, prediction for CAR would have been a good
way of validating the method. However there is to our knowledge no reliable motif for CAR/PXR neither
in JASPAR(277; 86) nor in TRANSFAC (87). An important step would therefore be the creation of
ChIP-seq data in treated liver for CAR. However until now we have not been able to find a reliable CAR
antibody.
Another limitation of the method is that MARA focuses solely on predicted TFBSs in proximal pro-
moters, ignoring the effects of distal enhancers. Expanding the region would lead to increase in false
TFBS eventually leading to noisy signal. However previous studies in liver for example have shown CYPs
gene regulation by Ahr in enhancers regions and this cannot be captured by the current model. Moreover
motifs mode of action cannot be distinguished and therefore TFs which act as much as positive as negative
regulators will generate a zero signal as per weighted average of every predicted promoter expression.
5.1.4 Relevance to safety assessment of drugs in development
As reviewed earlier, identification of NGC requires 2-years in vivo experiments in rodents. Indeed one
of the major mechanistic difference between a genotoxic and a non-genotoxic carcinogen is the time-
scale of pathogenesis. As tissue exposure to a sufficient dose of genotoxic agent results in direct DNA
mutagenesis and DNA repair response, the carcinogenic effects of NGC results from progressive changes
in tissue homeostasis and interplay between several cellular subtypes. By applying a robust ab initio
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probabilistic modeling to toxicogenomics data we here propose a new set of hypotheses that can be
readily tested. Compared to the 1,500 known TFs in rodents that could potentially be involved in PB-
mediated tumor promotion, our results are expected to significantly speed up the process of understanding
the regulatory mechanisms underlying the pathogenesis. Moreover we are confident that the identification
of early regulators of NGC can be valuable early biomarkers for NGC and improve safety assessment of
compounds with similar mode of action. Finally a better understanding of the regulatory mechanisms of
PB-mediated tumorigenesis provide insights into PB MOA that can help to understand human relevance
of these models. In conclusion although this study is mainly based on the analysis of publicly available
transcriptome that require additional experimental validations, the resulting hypotheses highlight novel
potential early mechanisms and pathways for liver tumor promotion, providing new opportunities for
early assessment of the carcinogenic potential of therapeutic compounds.
5.1.5 Remaining open questions and hypothese
Our analysis propose robust new regulators for transcriptional response underlying different biological pro-
cesses such as PB-mediated hepatocyte proliferation and the repression of regulators with demonstrated
tumor suppressor activity that are down-stream of β-catenin. However the following two important ques-
tions regarding PB-mediated tumor promotion remain unsolved: 1) how does PB promote outgrowth
of β-catenin activated cells that under physiological condition are non-tumorigenic and 2) how does PB
repress the outgrowth of H-ras activated cells that are, in absence of PB, highly tumorigenic.
As reviewed earlier, in the absence of PB treatment, 30% of DEN-initiated tumors harbors activat-
ing mutation in H-ras, leading to activation of MAPK signaling, whereas under PB-treatment 80% of
the tumors are mutated in β-catenin. Furthermore high similarity between gene expression patterns of
H-ras and β-catenin tumors with gene expression patterns from periportal and perivenous hepatocytes
respectively (278) suggests distinct and mutually exclusive regulatory programs between these two tumor
types. Interestingly while β-catenin mutation alone is insufficient for hepatocarcinogenesis and H-ras mu-
tation alone rapidly causes large cell dysplasia in the hepatocytes, simultaneous induction of H-ras and
β-catenin mutations leads to 100% HCC development supporting positive and cooperative interaction
between these two pathways (279). This cooperative interaction between H-ras and β-catenin pathway
has indeed been proposed in a recent review (280), where cooperation between the two pathways was
hypothesized to trigger midzonal proliferation after 2/3 hepatectomy as a result from an extension in
the β-catenin and the H-ras activation territories leading to overlapping activities (282). This idea is
supported by the finding that while neither H-ras mutation nor β-catenin activation led to urothelial cell
carcinoma (UCC) (within 12 months), mice carrying both mutations rapidly developed UCC (281). We
consequently propose the following mechanisms for PB-mediated selection of β-catenin mutated cells and
PB-mediated repression of H-ras mutated cells.
PB-mediated negative selection for β-catenin activated cells Because PB treatment selects for
β-catenin activated cells, it is reasonable to think that PB negatively selects for cells that are able to
escape β-catenin degradation through ubiquitination by accelerating β-catenin degradation, leading to
an overall decrease in β-catenin activity. Because glutamine synthetase is not affected by PB treatment,
we think that PB-mediated degradation of β-catenin is effective solely in regions where basal β-catenin
activity is low i.e. everywhere else than in perivenous area.
PB-mediated repression of H-ras mutated cells Given that simultaneous induction of H-ras and
β-catenin mutations leads to 100% HCC development, and considering our hypothesis for PB-mediated β-
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catenin inactivation true, the impairment for H-ras cell proliferation may be due to complete inactivation
of β-catenin in periportal cells upon PB treatment. Of note the characterization of β-catenin nuclear
content using immunohistochemistry in hepatocytes failed in demonstrating preferential nuclear amount
in pervineous relative to periportal hepatocytes.
PB-mediated outgrowth of β-catenin activated cells First it is noteworthy that PB-mediated
outgrowth of β-catenin cells is a process that requires at least 24 weeks of PB exposure although pre-
existing mutated cells are likely to be present in tissue from the beginning. This strongly suggests that
progressive changes in hepatocyte regulatory programs and/or non-parenchymal cellular compartment
are necessary to promote for β-catenin activated cells. Given that β-catenin activated cells under normal
condition is not sufficient for HCC development whereas simultaneous induction of H-ras and β-catenin
mutations leads to 100% HCC development, we hypothesize that PB mediates progressive H-ras activa-
tion. Once the level of H-ras activation is high enough in cells bearing β-catenin mutations, cells can
start to grow. Of note alternative pathway may be progressively activated by PB (or non-parenchymal
cells invading the tissue) that cooperates with β-catenin.
In conclusion we think that PB treatment leads to 1) accelerated degradation of β-catenin, prohibit-
ing H-ras cell proliferation that require basal β-catenin activity and 2) progressive up-regulation of a
complementary pathway (potentially H-ras) that cooperate with β-catenin to trigger hepatocyte prolif-
eration. As sufficient β-catenin activity is only found in mutated cells, PB eventually promotes tumors
with β-catenin mutation.
5.2 Human relevance of humanized CARPXR mouse model
Based on epidemiological data in epileptics, long-term barbiturate treatment is not associated with in-
creased incidence of liver tumors in humans (214; 215; 283). Furthermore human hepatocytes are resistant
to the ability of PB to increase cell proliferation (212; 213) and inhibit apoptosis (213) whilst prolonged
treatment with PB does increase liver size in humans (284; 211). These differences in species biochem-
istry and pathophysiology have raised doubts regarding the appropriateness of extrapolating some rodent
tumor findings to humans (9). Thus a better understanding of MOA of such compounds is believed to
help addressing the relevance of rodent assays to human risk assessment (10; 9).
As reviewed earlier CAR is as a key TF that is required for liver tumor formation elicited upon pro-
longed PB treatment in mice. Consequently an important question towards addressing translatability of
rodent model to humans is to test for distinct physiological roles and behaviors of human and murine
CAR upon PB exposure. Similar cellular mechanisms of PB-induced mouse and human CAR nuclear
translocation and activation have been demonstrated that partly arise from dephosphorylation of a thre-
onine residue in the very well conserved DNA binding domain (DBD) of the receptor (184). However
human and mouse CAR have unusual divergent ligand-binding domains (LBDs) that may explain possible
different roles of CAR in these species (285; 286). Indeed LBDs mediate ligand binding, heterodimeriza-
tion with co-factors such as RXR (285), interaction with heat shock proteins, nuclear localization, and
transactivation functions as reviewed in (287) and the LBD of CAR has been suggested to bind coac-
tivators such as SRC-1 (179) or TIF2/GRIP1 (288) in the absence of ligands to exhibit its constitutive
activity (116). Therefore, despite similar DNA binding domaines (DBD), divergent LBD between human
and mouse can lead to different physiological roles. In this study, we have used a humanized CAR/PXR
mouse model to examine potential species differences in receptor-dependent mechanisms underlying liver
tissue molecular responses to PB.
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5.2.1 Resume of major findings
First, wild-type and CARh-PXRh mouse livers exhibited temporally and quantitatively similar tran-
scriptional responses during 91 days of phenobarbital exposure including the sustained induction of the
xenobiotic response gene Cyp2b10, the Wnt signalling inhibitor Wisp1 and non-coding RNA biomarkers
from the Dlk1-Dio3 locus. Second, transient induction of DNA replication (Mcm6, Esco2, Uhrf1) and
mitotic genes (Ccnb2; Cdc20; Cdk1) and the proliferation-related nuclear antigen Mki67 were observed
with peak expression occurring between 1 and 7 days PB exposure in both wild-type and humanized mice.
All these transcriptional responses were absent in CARKO-PXRKO mouse livers and largely reversible in
wild-type and CARh-PXRh mouse livers following 91 days of PB exposure and a subsequent 4 week re-
covery period. Furthermore, PB-mediated up-regulation of the non-coding RNA Meg3, that has recently
been implicated in cellular reprogramming, exhibited a similar dose response and peri-venous hepatocyte-
specific localization in both wild-type and CARh-PXRh mice. Thus mouse livers co-expressing human
CAR and PXR can support xenobiotic and proliferative transcriptional responses following exposure to
PB in mouse context .
5.2.2 Limitations of humanized model
Despite that most transcriptional and phenotypic responses upon PB exposure were very similar in
humanized and wild-type models, some differences were observed between the two strains both under
physiological condition and under PB treatment that reminds the existence of clear species differences
between human and mouse nuclear receptors, like, for example, divergent LBDs leading to potential al-
ternative cofactors depending on species. Therefore the utility of humanized model towards addressing
species differences is questionable and conclusions have to be drawn carefully.
As reviewed earlier PB-induced mouse and human CAR nuclear translocation and activation are similar
due to similar DBD domains. However additional cellular mechanisms are required for CAR DNA binding
such as heterodimerization with a variety of cofactors depending on gene and tissue. Indeed one caveat
of this model is that human nuclear receptors function in the context of mouse gene regulatory elements
and proteins i.e. different co-factors. We can not exclude that human and mouse CAR/PXR ability to
trigger hepatocyte proliferation upon PB exposure in mouse context may result from heterodimerization
with a cofactor specific to mouse context. The absence of such cofactor from human context would be
one reason for human resistance of PB to increase cell proliferation (212; 213). Thus a co-IP experiment
that would provide with a species-specific list of CAR co-factors would help addressing this issue. Al-
ternatively ChIP experiments on human and mouse primary hepatocytes treated with PB would enable
the direct comparison of PB-induced target genes bound by CAR. Finally experiments with ”murinized”
CAR-PXR human hepatocytes treated with PB would enable to assess importance of mouse context in
PB-mediated human CAR-PXR induced mouse hepatocyte proliferation.
5.2.3 Implications for drug safety assessment
Based on a weight of evidence human relevance framework concept focusing on mode of action and
key events, PB-induced rodent non-genotoxic hepatocarcinogenesis is not considered to be a relevant
mechanism for humans (9) and there is no evidence of a specific role of PB in human liver cancer risk
based on epidemiological data in epileptics (214; 215). Our data suggest that humanized nuclear receptor
mice may not be a simple model for extrapolating the risk of rodent tumor findings to humans and
will require the careful integration of quantitative exposure-response relationships with the temporal and
spatial dynamics of human nuclear receptor expression, mechanism of modulation by coactivators and
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relevance of heterologous mouse-human gene regulatory protein interactions.
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Figure 5.1: Schematical representation of PB-mediated tumor promotion, as it emerges from the study.
(a) Illustration of the PB-mediated tumor promotion process and the aspects elucidated by the 4 exper-
imental studies that we analyze. Knock-out of β-catenin identifies regulators downstream of β-catenin
in physiological conditions (yellow arrow). Ours and previous analyses suggest that all regulatory effects
of PB-treatment are downstream of CAR activation (brown arrow and black circle). Our motif activity
and SVD analysis of the early kinetic time course identified three key biological processes induced by
PB-treatment: A transient mitogenic response, which is also associated with a late resurgence of prolifer-
ation (I, red), a sustained xenobiotic response (II, yellow), and a late response which is likely involved in
establishing a tumor prone environment (III, blue). Comparison of promoted and non-promoted tumors
identifies motifs dysregulated in all tumors, and in promoted tumors only (grey arrows). (b-d) Summary
of the key regulators of liver tumor promotion organized according to biological (colored boxes matching
the colors of processes I, II, and III in panel a) with arrows indicating regulatory interactions between
regulators and on selected target genes. (b) E2F and ZFP161 regulate PB-mediated hepatocyte prolif-
eration at the early and promoted tumor stage. E2F is down-stream of β-catenin signaling and likely
induces both DNA replication, via up-regulation of E2f1,2, and aborted cytokinesis via up-regulation
of E2f8 and c-myc. ZFP161 is likely involved in the G0-G1 transition via transcriptional repression of
transcriptional repressors of cell growth and cell cycle. (c) NFE2, downstream of β-catenin as well, is
involved in the sustained xenobiotic response, upregulating proteasome activity and the oxidative stress
response. (d) PB-mediated suppression of ESR1 activity underlies development of a tumor-prone envi-
ronment, most likely through repression of tissue morphogenesis. β-catenin signaling represses ESR1. (e)
Key regulators involved in tumorigenesis, i.e. disregulated in both promoted and non-promoted tumors.
Increased SOX{8,9,10} activity likely regulates hepatocyte mitosis and proliferation via up-regulation
of cyclins. Decrease in NR5A1,2 activity is detected after 3 months of PB treatment and maintained
in tumor samples, and therefore a good early indicator of hepatocyte loss of function associated with
tumorigenesis.
Chapter 6
Concluding remark
In the course of this research project we have brought new insights and directly testable hypotheses into
regulatory mechanisms of drug-induced non-genotoxic carcinogenesis. Furthermore human relevance of
rodent models in drug toxicity assessment was discussed in the context of humanized mouse model. We
are confident that this work provides with a good example of how applying sophisticated mathematical
modeling to toxicogenomic data can significantly speed up the process of biomarker identification and
provide with a better understanding of mechanisms and pathways underlying drug-induced toxicity.
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